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ABSTRACT OF DISSERTATION 
 
MULTIFUNCTIONAL POTENTIAL THERAPEUTICS TOWARDS OXIDATIVE 
STRESS MEDIATED NEURODEGENERATIVE DISORDERS AND MODELS 
THEREOF 
 
The studies described in this dissertation were performed with the goal of understanding 
the function of antioxidant compounds delivered in vivo to rodents and the implication of the 
results towards oxidative stress (OS)-related neurodegenerative disorders with particular 
emphasis on Alzheimer’s disease (AD). OS has been implicated in AD and is characterized by 
extensive oxidative damage to protein, lipids and DNA. A major thrust of this dissertation work 
was to gain insight into antioxidant properties of compounds used in the following studies and 
their efficacy as potential therapeutics for treatment of OS-related disorders. 
D609, a glutathione (GSH) mimetic is known to trap OH. Radicals, scavenge H2O2 and 
reduce the Aβ (1-42)-induced OS and cytotoxicity in neurons. The present dissertation study 
showed in vivo protective effect of D609 in synaptosomes and mitochondria isolated from 
gerbils against OS mediated by Fe2+/H2O2, AAPH, and Aβ (1-42). Upon intraperitonial (i.p.) 
injection of gerbils, D609 showed protection of subsequently isolated brain moieties against OS. 
In vivo administration of D609 also modulates brain GSH levels and increases the activity of key 
GSH-related enzymes, thereby likely provides a protection against OS. 
Adriamycin (ADR), a quinone-containing chemotherapeutic, is known to produce ROS in 
heart. Patients under treatment with ADR often show persistent changes in cognitive function 
(effect called as chemobrain by patients). Upon i.p. injection, ADR causes OS, increases 
expression of multidrug resistant protein-1 (MRP-1) in brain and alters GSH levels and its 
related enzyme activities. γ-Glutamyl cysteinyl ethyl ester (GCEE) is known to increase GSH 
levels in brain, in vivo. Research reported in this dissertation shows that in vivo GCEE reverses 
the ADR-mediated OS in mice brain.  
N-acetylcysteine (NAC), a GSH precursor provides the limiting substrate cysteine in 
GSH synthesis. Previously, our laboratory showed increased GSH levels post i.p. injection of 
NAC and reduces OS in synaptosomes treated with acrolein. The present study showed that 
NAC given in drinking water to APP/PS-1 mice, a model of AD can significantly reduce OS. 
These results provide a potential therapeutic intervention by antioxidants that can modulate 
GSH in OS-mediated neurodegenerative disorders.  
KEYWORDS: Oxidative stress, Free radicals, Glutathione, Antioxidants, Alzheimer’s disease. 
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Chapter 1 
Introduction 
The studies presented in this dissertation were completed with the goal of 
understanding the role of oxidative stress in various neurodegenerative condition, 
specifically focusing on Alzheimer’s disease (AD) and finding efficient therapeutic 
towards reducing oxidative stress in these neurodegenerative conditions. Oxidative stress 
plays a key role in cause or consequence of various neurodegenerative disorders 
including AD (Hensley, Hall et al., 1995; Markesbery and Lovell, 1998; Butterfield, 
Drake et al., 2001; Butterfield and Lauderback, 2002), which affects more that 4 million 
American and is one of the leading causes of death in United States. There is no efficient 
therapy towards treatment of this dreaded disease as of now. Pathologically, AD is 
characterized by presence of senile plaques comprising aggregated amyloid β-peptide 
(Aβ), neurofibrillary tangles consisting of hyperphosphorylated tau, and synapse loss 
(Katzman and Saitoh, 1991; Bosetti, Brizzi et al., 2002). Etiologically, the free radical-
mediated oxidative stress hypothesis in AD has gained considerable importance in recent 
times (Butterfield, Drake et al., 2001). In AD brain, oxidative stress leads to significant 
protein oxidation (Butterfield and Lauderback, 2002), DNA and RNA oxidation 
(Mecocci, MacGarvey et al., 1993; Lovell, Gabbita et al., 1999; Nunomura, Perry et al., 
1999; Wang, Xiong et al., 2005), lipid peroxidation (Markesbery and Lovell, 1998), and 
neuronal dysfunction or death. Increased production of ROS and RNS along with 
depletion in antioxidant capacity is observed in AD and other neurodegenerative 
disorders [reviewed in (Beckman and Ames, 1998)], and, consistent with this 
observation, α-tocopherol (vitamin E) administration in AD patients delayed its 
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progression when compared to placebo treated control (Sano, Ernesto et al., 1997), 
suggesting that oxidative stress-mediated AD pathogenesis can be altered by antioxidant 
therapy. In contrast, recent studies with mild cognitive impairment (MCI), arguably the 
earliest form of AD, do not support this view (Petersen, Thomas et al., 2005). 
Mitochondrial electron transport is a potential source of ROS production (Ide, 
Tsutsui et al., 1999). It is now well known that ROS such as superoxide radical anion (O2-
.), hydroxyl radical (OH.), hydrogen peroxide (H2O2), and peroxynitrite (ONOO-) 
contribute to neurodegeneration (Zhang, Dawson et al., 1994; Cadenas and Davies, 2000; 
Rego and Oliveira, 2003; Ansari, Ahmad et al., 2004; Tangpong, Cole et al., 2006a; 
Tangpong, Cole et al., 2006b). Mitochondrial membrane potential depolarization induces 
cytochrome-c release into the cytoplasm and elevates the activity of caspase-3, 
suggesting a role for mtDNA-derived mitochondrial dysfunction in AD degeneration 
(Bosetti, Brizzi et al., 2002). 
Protein oxidation either by ROS or lipid peroxidation products such as 4-hydroxy 
2- nonenal results in altered protein structure or loss of protein function, which may lead 
to neuronal degeneration (Stadtman and Berlett, 1997). Protein oxidation markers such as 
introduction of carbonyl functionality or nitration of tyrosine residues on proteins often 
lead to conformation changes in proteins (Subramaniam, Roediger et al., 1997)that often 
leads to protein dysfunction (Butterfield and Stadtman, 1997). As a part of this 
dissertation, we have used four different oxidants, Fe2+/H2O2 (hydroxyl radical producer) 
or 2,2- Azobis (2-amidino-propane) dihydrochloride (AAPH) (alkoxyl and peroxyl 
radical producers), Aβ (1-42) and adriamycin (ADR). All these oxidants are known to 
cause protein oxidation and lipid peroxidation. 
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Major pathological hallmarks of AD include loss of synapses and the presence of 
senile plaques and neurofibrillary tangles (Katzman and Saitoh, 1991). The major protein 
component of the core of senile plaques is Aβ. The mechanisms involved in the Aβ-
mediated neurotoxicity are unknown, but there is evidence suggesting that oxidative 
stress plays a key role (Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002; 
Canevari, Abramov et al., 2004; Butterfield and Boyd-Kimball, 2005). Increased 
production of reactive oxygen and nitrogen species such as superoxide and nitric oxide 
together with imbalance of antioxidant defenses was observed in neuronal systems after 
Aβ(1-42) treatment (Keller, Pang et al., 1997; Yatin, Varadarajan et al., 1999; 
Varadarajan, Yatin et al., 2000; Butterfield, 2002). Previous studies from our laboratory 
and others reported that Aβ(1-42) induces reactive oxygen species (ROS) production, in 
vitro and in vivo protein oxidation, DNA and RNA oxidation and lipid peroxidation 
(Keller, Lauderback et al., 2000; Butterfield, 2002; Boyd-Kimball, Castegna et al., 2005).  
ADR, a cancer chemotherapeutic drug used to treat solid tumors, is known to 
cause side effects in heart and brain (Steinherz, Steinherz et al., 1991; Joshi, Sultana et 
al., 2005b; Tangpong, Cole et al., 2006a; Tangpong, Cole et al., 2006b). Cardiomyocytes 
treated with ADR have elevated levels of protein oxidation and lipid peroxidation 
(DeAtley, Aksenov et al., 1998). Free radical scavengers are known to protect 
cardiomyocytes from this effect (DeAtley, Aksenov et al., 1999). Brain isolated from 
mice treated peripherally with ADR shows evidence of oxidative damage and 
mitochondrial dysfunction (Joshi, Sultana et al., 2005b; Tangpong, Cole et al., 2006a; 
Tangpong, Cole et al., 2006b). Patients under long-term treatment with ADR for breast 
and lung cancer have shown symptoms of cognitive dysfunction such as lack of 
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concentration, forgetfulness inability to multi-task, short term memory impairment and 
dizziness, often lasting years after cessation of therapy (Meyers, 2000; Schagen, 
Hamburger et al., 2001; Freeman and Broshek, 2002). The side effects in heart limit the 
use of ADR in chemotherapy, while the side effects in brain limit the quality of life of 
patients undergoing chemotherapy. 
Recently, proteomics along with advances in bioinformatics tools have lead to the 
identification, characterization and sequencing of proteins in various organisms, 
including humans. Using redox proteomics (Dalle-Donne, Scaloni et al., 2006) our 
laboratory has shown many key proteins that are oxidized or differentially expressed in 
various neurodegenerative conditions or models thereof, such as Alzheimer’s disease 
(AD) (Butterfield and Boyd-Kimball, 2004), ageing (Poon, Calabrese et al., 2006), 
amylotropic lateral sclerosis (ALS) (Perluigi, Fai Poon et al., 2005; Poon, Hensley et al., 
2005), Parkinson’s disease (PD) (Poon, Frasier et al., 2005), mild cognitive impairment 
(MCI) (Butterfield, Poon et al., 2006) and Huntington’s disease (Perluigi, Poon et al., 
2005). Although it is clear from the dissertation research described below that in vivo 
ADR increases protein oxidation in brain, it is not clear which specific brain proteins 
show increased oxidative damage. We used 2-dimensional gel electrophoresis (2DE) 
coupled with mass spectrometric analysis (expression proteomics) to identify proteins 
that are differentially expressed and 2DE followed by Western blot coupled with mass 
spectrometric analysis (redox proteomics) to identify proteins that are oxidized in brain 
isolated from mice injected i.p. with ADR as a part of this dissertation. 
Glutathione (GSH) is the most abundant endogenous nonenzymatic antioxidant 
present in brain and is found in millimolar concentrations. GSH is an oxyradical 
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scavenger, thereby protecting against oxidative damage by free radicals and inhibits lipid 
peroxidation and DNA damage (Meister, 1995; Darley-Usmar and Halliwell, 1996; Sies, 
1999; Schulz, Lindenau et al., 2000; Hansen, Go et al., 2006). GSH has been implicated 
in a wide range of metabolic processes, including cell division, DNA repair, regulation of 
enzyme activity, activation of transcription factors, cellular homeostasis and protection 
against oxidative damage (Meister and Anderson, 1983). The nervous system is 
particularly susceptible to oxidative insults, and dependent on its glutathione defense.  
Due to the involvement of oxidative stress-mediated toxicity in neurodegenerative 
events and neuronal cell death (Good, Werner et al., 1996; Moreira, Smith et al., 2005), 
various experimental approaches for effective protection by antioxidants have emerged. 
In addition, antioxidant therapy is being discussed for Parkinson’s disease (Ebadi, 
Srinivasan et al., 1996; Prasad, Cole et al., 1999), ischemia (Marczin, El-Habashi et al., 
2003) as well as for AD (Grundman and Delaney, 2002; Gilgun-Sherki, Melamed et al., 
2003) and other age-related disorders (Ames, 2004). Numerous potential free-radical 
scavengers have been tested in different experimental paradigms of oxidative stress-
induced cell death, such as Vitamin E (Behl, Davis et al., 1992), Vitamin C, melatonin 
(Pappolla, Sos et al., 1997), ginko biloba (Smith and Luo, 2003), steroid hormones 
(Goodman, Bruce et al., 1996; Behl, Skutella et al., 1997), N-acetylcysteine (Adair, 
Knoefel et al., 2001), etc. However, many clinical trials are still unsuccessful because 
most of the antioxidants tested are poorly active in crossing the blood brain barrier 
(BBB). 
Depletion of GSH is known to be involved in several neurodegenerative disorders 
(Benzi and Moretti, 1995b; Markesbery, 1997; Butterfield, Castegna et al., 2002a). Many 
6 
attempts have been made to develop antioxidant compounds that can act as precursor of 
GSH or mimic GSH as scavenger of reactive oxygen species (ROS) and to maintain the 
intracellular redox state. Increase in endogenous GSH levels by dietary or 
pharmacological intake of GSH precursor or GSH mimetic protects brain against 
oxidative stress (Anderson and Luo, 1998; Butterfield, Drake et al., 2001; Halliwell, 
2001). Considering the importance of developing new antioxidant compounds and the 
relevance of their application in the treatment of neurodegenerative diseases, in this 
dissertation research we focused our attention on glutathione mimetic, tricyclodecan-9-yl-
xanthogenate (D609), the glutathione precursor, N-acetylcysteine (NAC), and γ-glutamyl 
cysteine ethyl ester (GCEE).  
In summary, this dissertation research has used synaptosomes, mitochondria and 
brain homogenates to address the following hypothesis: 
1. Adriamycin-mediated oxidative stress leads to significant protein 
oxidation, lipid peroxidation and alteration in glutathione levels and GSH related enzyme 
activities. 
2. γ-Glutamyl cysteine ethyl ester (GCEE), in vivo, increases the GSH level 
and reduces the protein oxidation and lipid peroxidation in brain isolated from mice that 
were previously injected with GCEE followed by ADR injection when compared to brain 
isolated from mice that are previously injected with saline followed by ADR injection. 
3. D609 prevents oxidative stress-mediated by Fe2+/H2O2, AAPH and Aβ(1-
42) in synaptosomes and mitochondria isolated from brain of gerbils previously injected 
with D609. 
7 
4. NAC, delivered via drinking water, decreases oxidative stress, in vivo, 
mediated by Aβ(1-42) in the APP/PS-1 mouse, a model of AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Gururaj Joshi 2006 
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Chapter 2 
Background 
2.1. Oxidative Stress and Neurodegeneration 
2.1.1. Overview of oxidative stress 
Free radical-mediated oxidative stress has been implicated in numerous disorders, 
particularly in neurodegenerative disorders. However, the term “oxidative stress” is often 
misinterpreted since the processes involved are poorly understood. A free radical is a 
species that contains one or more unpaired electrons. Generally, free radicals are highly 
reactive and are known to react vigorously with other less reactive non-radical species to 
produce new free radicals in a chain reaction. It is these chain reactions that can lead to 
formation of ROS (e.g., superoxide radical O2-. or hydrogen peroxide H2O2) and RNS 
(e.g. nitric Oxide radical NO. or dinitrogen tetroxide N2O4) that can further damage 
biomolecules such as proteins and lipids (Halliwell, 2001). Reactive species are found 
both intracellularly and extracellularly. The source of free radicals could be exogenous 
environmental factors such as ionizing radiation, photochemical reactions, among others 
or endogenous biochemical and enzymatic processes. Figure 2.1 shows some of the 
reactions that lead to the formation of ROS/RNS. 
Various antioxidant systems are operational in the human body that inhibits the 
activity of ROS/RNS. Some of the examples of antioxidant systems are antioxidant 
enzymes (e.g., superoxide dismutase and glutathione peroxidase), antioxidant proteins 
(e.g., thioredoxin) and antioxidant molecules (e.g., lipoic acid, GSH, vitamin E), among 
others. During disease conditions, either the level of ROS/RNS goes up or antioxidant 
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capacity is decreased or both occur at the same time (Halliwell, 2001). This condition is 
often described as oxidative stress.  
2.1.2. Free radical theory in neurodegeneration 
Free radicals in biological systems are produced by metal catalyzed reactions 
called Fenton reaction (Hensley, Carney et al., 1994) as shown in Figure 2.1. The 
hydroxyl radicals are particularly damaging to proteins, lipids and nearby DNA, reacting 
at diffusion-limited rates. O2 is the terminal acceptor of electrons in the electron transport 
chain of oxidative phosphorylation processes in mitochondria and forms superoxide 
radicals (O2-.). O2-. is relatively stable and being a free radical itself leads to formation of 
other ROS. O2 undergoes a four electron reduction process in its conversion to water 
(Fridovich, 1978a). Approximately 2% of O2 is leaked out of mitochondria as toxic 
intermediates before its conversion to water [reviewed in (Beckman and Ames, 1998)]. 
Trace amount of iron present in cell reacts with the O2 to form highly toxic hydroxyl 
radicals. 
1. O2 + 1e-    →     O2-.    
2. O2-. + H2O2    →         OH. + O2 + H2O     (Fenton reaction, catalyzed by 
Fe2+) 
3. Fe2+ + H2O2    →        Fe3+ + OH. + OH-   (Haber-Weiss reaction) 
4. O2-. + H+      →           .OOH 
5. O2-. + NO.     →           ONOO- 
6. ONOO- + H+     →          ONOOH 
Figure 2.1: Reaction leading to formation of ROS/RNS 
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ADR is a quinone-containing anthracyclin drug (Figure 2.2) used in treating 
breast cancer and various solid tumors. ADR is known to generate superoxide radical (O2-
.) (Deres, Halmosi et al., 2005). A free radical-mediated mechanism of toxicity of ADR is 
widely accepted. The quinone in ADR undergoes one electron reduction to generate 
semiquinone, which is a free radical, and in the presence of oxygen converts back to 
quinone producing O2-., a process known as redox cycling. ADR dependent redox cycling 
is likely activated by nitric oxide synthase and cytochrome P 450 (Gutierrez, 2000; 
Deres, Halmosi et al., 2005). Toxicity mediated by ADR is known to target mitochondria, 
and NADH dehydrogenase, a mitochondrial enzyme, stimulates ADR to form 
semiquinone radical and O2-. (Doroshow and Davies, 1986).  O2-. radicals are converted to 
hydrogen peroxide (H2O2) enzymatically by superoxide dismutase (Fridovich, 1978b). 
Superoxide radical can react with H2O2 and other reactive species to generate various 
other ROS/RNS (Halliwell and Gutteridge, 1999). All these reactive species target nearby 
protein, lipids and other biomolecules leading to neurodegeneration. 
 
Figure 2.2: Adriamycin 
The free radical theory of aging proposed by Denham Harman in 1956 (Harman, 
1956) states that oxyradicals or ROS, produced during aerobic respiration results in 
cumulative damage leading to aging and eventual death. The brain is particularly 
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vulnerable to free radical damage and oxidative stress because of following reasons: the 
brain has high amount of polyunsaturated fatty acids (PUFA) that are easily oxidizable by 
ROS; there is a significant amount of trace metal ions such as iron (II) and copper (I) that 
can catalyze various redox reactions to produce ROS; the brain consumes relatively more 
oxygen when compared to the other organs; the brain has relatively low antioxidant 
levels; the terminally differentiated mature neurons in brain are incapable of dividing and 
hence, once damaged are lost leading to neurodegeneration. 
2.1.3. Targets of Oxidation 
2.1.3.1.  Proteins 
Proteins are one of the most important classes of biomolecules that are involved 
in almost all physiological and biochemical functions. The genetic message from DNA is 
expressed in the form of proteins. Twenty different amino acids form the building block 
of proteins, which are composed of amino acids linked to each other by a peptide bond. 
An amino acid sequence in the polypeptide chain provides the information of its primary 
structure. The tertiary or quaternary structure of proteins can provide important clues 
about their respective function. Among others, the important function of some proteins is 
biocatalysis as enzymes, cellular functions, such as cell signaling and ligand transport and 
as structural proteins. Being one of the most important biomolecules, it is important to 
study protein oxidation, its cause and consequences and any modification or degradation 
following oxidation. 
Proteins are highly sensitive to ROS/RNS-mediated oxidative modifications. 
Proteins can also be modified by reactive alkenals produced during ROS-mediated 
oxidation of lipids (Esterbauer, Schaur et al., 1991) and glycated proteins (Nagaraj and 
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Monnier, 1995). The site of oxidation in proteins is basically amino acid residue side 
chains that can lead to fragmentation of the polypeptide chain, and the formation of 
protein-protein cross-linked aggregates that often changes the conformation, including 
protein unfolding of functional protein and thereby render a protein inactive [Reviewed in 
(Butterfield and Stadtman, 1997; Stadtman and Berlett, 1997)]. Possible consequences of 
such changes usually increase the exposure of hydrophobic residues of proteins and thus 
modify the intrinsic capacity of protein function, such as binding to receptor or ligands, 
and interaction with membrane lipid bilayer. Among other consequences, protein 
oxidation also leads to trigger the synthesis of certain “stress proteins”, such as heat 
shock proteins (HSPs) (Welch, 1992) and/or increases in susceptibility towards 
proteolytic degradation that is often preceded by their post translational modification, 
such as ubiquitinylation (Davies, Lin et al., 1987).  
The two most important oxidative modifications of proteins are formation of 
protein carbonyls and nitration of tyrosine residues on protein to form 3-nitrotyrosine 
(3NT). The carbonyl functionality can be introduced in proteins by mechanisms, such as 
β-scission and peptide bond cleavage following reaction of OH. radical, formed by metal 
catalyzed cleavage of H2O2, with any amino acid residue on a protein [reviewed in 
(Stadtman and Berlett, 1997)].  
The metal ion-catalyzed oxidation of some amino acid residues on proteins leads 
to the formation of protein carbonyl derivatives (Levine, Williams et al., 1994). Some of 
the examples of protein carbonyl derivatives are formation of glutamic semialdehyde 
derivatives of the protein following metal-catalyzed oxidation of proline and arginine 
residues of proteins, formation of adipic semialdehyde derivatives following oxidation of 
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lysine residues (Amici, Levine et al., 1989; Daneshvar, Frandsen et al., 1997; Requena, 
Chao et al., 2001), oxohystidine, etc. Since the formation of protein carbonyl groups is 
highly pronounced when compared to other oxidative modifications, determining the 
level of protein carbonyl groups become the most important marker of protein oxidation 
during various neurodegenerative disorder conditions including Alzheimer’s disease 
(AD) (Stadtman and Berlett, 1997).  
Nitric oxide (NO.), produced in the metabolism of arginine, reacts rapidly with 
O2-. to form the highly reactive peroxynitrite (ONOO-) (Ischiropoulos, Zhu et al., 1992). 
A key oxidative stress marker of peroxynitrite (ONOO-)-mediated nitration of tyrosine 
residues on proteins is 3NT. CO2 is known to stimulate the (ONOO-)-dependent nitration 
of tyrosine residues (Denicola, Freeman et al., 1996). Nitration of tyrosine may prevent 
phophorylation of tyrosine thereby preventing various signaling pathway that can have 
profound consequences in rendering protein inactive (Ischiropoulos, Zhu et al., 1992). 
Elevated levels of 3NT have been found in various neurodegenerative disorders, such as 
AD when compared to normal subjects (Hensley, Maidt et al., 1998; Castegna, 
Thongboonkerd et al., 2003; Sultana, Poon et al., 2006a). It has also been shown that 
several key proteins in AD brain are nitrated when compared to age-matched controls 
(Castegna, Thongboonkerd et al., 2003). Nitrated tyrosine residues are also found in 
degenerating motor neurons of amyotrophic lateral sclerosis (ALS) subjects (Abe, Pan et 
al., 1995) and vulnerable neurons of Parkinson’s disease (PD) (Good, Hsu et al., 1998). 
Hence, detection of 3NT may illustrate an important role in pathogenesis of various 
neurodegenerative disorders. 
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2.1.3.2. Lipids 
Unlike proteins, lipids are non-polymeric biomolecules, which are relatively small 
when compared to proteins. Lipids consist of a hydrophilic polar “head” and a 
hydrophobic “tail” consisting of acyl chains of variable length. As amphipathic 
molecules, lipids tend to aggregate with their hydrophilic head exposed at the lipid-water 
interface and their hydrophobic tails sequestered from the aqueous medium. Lipids are 
the major component of cell membranes and arranged in a bilayer. The formation of lipid 
bilayers is spontaneous and the increased entropy of the aqueous medium serves as the 
driving force for this kind of arrangement. This kind of arrangement results in formation 
of a hydrophobic domain that limits the permeability of polar species.  
Glycerophospholipids are major the class of lipids that make the important part of 
cell membrane. These glycerophospholipids consist of glycerol backbone that is 
derivatized at the three alcohol functionalities (Figure 2.3). A1 and A2 are acyl chains 
derived from fatty acids. Fatty acids can be saturated (palmitic and stearic acid) or 
unsaturated (oleic acid, for example). An acyl chain with more than one unsaturation is 
known as a polyunsaturated fatty acid (PUFA). Lipids are more susceptible to oxidation 
if they have more unsaturation in there fatty acid β-chain and high solubility of nonpolar, 
paramagnetic oxygen in bilayer (Esterbauer and Ramos, 1996). High content of PUFA 
makes brain more vulnerable to oxidative damage.  
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Figure 2.3: Glycerophospholipids. Adapted from (Garrett and Grisham, 1995) 
with slight modification. 
Lipids undergo peroxidation upon attack by a free radical. The cascades of events 
that follow are shown below (Eqn A to D). From the unsaturated sites of lipids, hydrogen 
is abstracted that results in formation of carbon-centered lipid radical (L.). L. reacts with 
readily available paramagnetic O2 to form a lipid peroxyl radical (LOO.). These peroxyl 
radicals propagate the chain reaction by reacting with nearby lipids to form lipid 
hydroperoxide (LOOH) and another carbon-centered lipid radical. The chain reaction is 
terminated by reaction between two peroxyl radical to form a non radical species and O2.  
• LH + X.         →       L. + XH                                   (Eqn A) 
• L.   + O2      →          LOO.                                       (Eqn B) 
• LOO. + LH        →    LOOH + L.                             (Eqn C) 
• LOO. + LOO.    →     Non-radical + O2                    (Eqn D) 
Adapted from (Esterbauer and Ramos, 1996) 
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Lipid peroxidation often leads to formation of toxic reactive alkenal species, such 
as 4-hydroxy 2- nonenal (HNE), acrolein (2-propane 1-al) and malenaldehyde. These 
alkenals binds to the protein by Michael addition to form covalent adducts with cysteine, 
lysine or histidine residues (Figure 2.4) and render them inactive (Butterfield and 
Stadtman, 1997). Antioxidant defense systems involving glutathione and its dependent 
enzyme glutathione-S-transferase help in clearing these lipids peroxidation products with 
the help of a detoxification protein, the multi drug resistance protein-1 (MRP1) (Sultana 
and Butterfield, 2004). Growing number of evidences suggest increased lipid 
peroxidation in various neurodegenerative disorders, including AD. HNE and acrolein are 
known to be increased in AD brain (Markesbery and Lovell, 1998; Lovell, Xie et al., 
2001). Likewise, isoprostanes and neuroprostanes (markers of lipid peroxidation) levels 
are increased in AD brain (Montine, Neely et al., 2002). Lipid oxidation can also be 
reduced by lipid soluble antioxidants, such as α-tocopherol (Esterbauer and Ramos, 
1996).   
 
Figure 2.4: Reaction of reactive alkenals with histidine, cysteine and lysine to 
form Michael adducts. P1 refers to another protein. Figure also shows formation of cross-
linked derivatives between proteins. Adapted from (Stadtman and Berlett, 1997). 
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product 
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2.2. Alzheimer’s Disease 
2.2.1. Overview 
AD is an age-associated progressive neurodegenerative disorder characterized by 
memory loss, cognitive dysfunction and is the most common form of dementia in elderly 
population. More than 4 million Americans are affected by this disease out of which 7-10 
% fall in the age group of 65-74 and more 80% are over 85 years of age (Price, Sisodia et 
al., 1998). Pathological hallmarks of AD includes brain atrophy due to neuronal and 
synapse loss, senile plaques predominantly consisting of fibrillar amyloid β-peptide and 
neurofibrillary tangles (NFT) made up of hyperphosphorylated tau, a cytoskeletal protein 
(Van Uden, Sagara et al., 2000). Some of the major risk factors for AD are unhealthy 
aging in sporadic AD cases, the presence of ApoE-4 alleles in both sporadic and familial 
AD (FAD) (Namba, Tomonaga et al., 1991) and genetic factors, such as mutation in 
amyloid precursor protein (APP) and presenilin-1 in FAD (Lee, Borchelt et al., 1997) 
among others. Growing evidence shows that AD brain is under tremendous oxidative 
stress. There is increased protein oxidation [reviewed in (Markesbery, 1997; Butterfield, 
Drake et al., 2001)] and lipid peroxidation (Markesbery and Lovell, 1998; Lauderback, 
Hackett et al., 2001; Lovell, Xie et al., 2001) in AD brain when compared to aged 
matched control, and antioxidant therapy, known to slow progress of AD (Sano, Ernesto 
et al., 1997), may reduce this effect.  
2.2.2. Aβ(1-42)-mediated oxidative stress in AD 
The major protein component of senile plaques is amyloid β-peptide (Aβ). Aβ is 
formed upon proteolytic processing (Figure 2.5) by β- and γ-secretases (Haass and De 
Strooper, 1999) of the 695 amino acid APP, a ubiquitously expressed transmembrane 
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glycoprotein (Glenner and Wong, 1984; Glenner, Eanes et al., 1988). The 40 or 42 amino 
acid Aβ peptide is the major component of senile plaques and are toxic to neuronal cells 
in culture (Yankner, Duffy et al., 1990). Another secretase involved in APP processing is 
α-secretase, the product of which is a large soluble fragment (sAPPα), which is possibly 
involved in preventing excitotoxicity by regulating intracellular calcium levels (Mattson, 
Cheng et al., 1993). The amyloid β-cascade hypothesis, suitably updated, postulates that 
Aβ is likely central to the pathogenesis of AD (Hardy and Allsop, 1991; Smith, Chen et 
al., 1999; Selkoe, 2001). The mechanisms involved in the Aβ-mediated neurotoxicity are 
unknown, but there is evidence suggesting that oxidative stress plays a key role 
(Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002; Canevari, Abramov et 
al., 2004). Growing attention has been focused to investigate the oxidative mechanism of 
Aβ toxicity and as well in the search for novel neuroprotective agents. Previous studies 
from our laboratory and others reported that Aβ peptide induces in vitro reactive oxygen 
species production, protein oxidation, DNA and RNA oxidation and lipid peroxidation 
(Butterfield, 2002). Aβ disrupts Ca2+ homeostasis in neurons (Mattson, Barger et al., 
1993), and increased intracellular Ca2+ level can increase sphingomylinase activity to 
produce ceramide (Di Paola, Zaccagnino et al., 2004). Activation of the apoptogenic 
sphingomyelin-dependent signaling pathway is mediated by ceramide (Di Paola, 
Zaccagnino et al., 2004) during oxidative stress to play role in the pathogenesis of 
neuronal disease (Michel, Lambeng et al., 1999). Increased production of ROS/RNS, 
such as superoxide and nitric oxide together with imbalance of antioxidant defenses was 
observed in neuronal systems after Aβ(1-42) treatment (Keller, Pang et al., 1997; Yatin, 
Varadarajan et al., 1999; Varadarajan, Yatin et al., 2000; Butterfield, 2002). Recently, our 
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laboratory showed the critical role of methionine at the 35th position in Alzheimer’s 
Aβ(1-42)-mediated oxidative stress and toxicity [reviewed in (Butterfield and Boyd-
Kimball, 2005)]. In addition, Aβ(1-42) leads to oxidative stress in vivo (Yatin, 
Varadarajan et al., 1999; Drake, Link et al., 2003; Mohmmad Abdul, Sultana et al., 
2006). 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Aβ(1-42) generation by APP processing. Adapted from (Butterfield 
and Boyd-Kimball, 2005) 
 
2.2.3. APP/PS-1 human double mutant knock-in mice as an AD model 
Among the genetic risk factors for AD are included mutations in the presenilin 1 
(PS1) gene on chromosome 14 (Sherrington, Rogaev et al., 1995), the presenilin 2 (PS2) 
gene on chromosome 1 (Rogaev, Sherrington et al., 1995), or the APP gene on 
chromosome 21 (Chartier-Harlin, Crawford et al., 1991). Around 30% FAD cases have 
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mutations in PS1 (Schellenberg, 1995). PS1 is part of the γ-secretase complex that 
cleaves APP to release Aβ(1-42). Mutations in PS1 has been shown to alter APP 
processing to enhance the generation of Aβ(1–42) peptides (Jarrett, Berger et al., 1993). 
Synaptosomal proteins from PS-1 mutant mice showed increased oxidative stress and 
alteration in synaptosomal protein structure when compared to wild type (LaFontaine, 
Mattson et al., 2002). 
Several lines of evidence show that Aβ(1–42) plays a central role in AD 
pathogenesis and is well documented.  Hence, a mouse model was developed by Borchelt 
et al., which had FAD mutant human PS1-A246E and a chimeric mouse/human (Mo/Hu) 
APP695 harboring a Hu Aβ domain and mutations (K595N, M596L) linked to Swedish 
FAD (APP swe) co-expressed (APP/PS-1 human knock-in mouse) (Borchelt, Ratovitski 
et al., 1997). The APP/PS-1 mice showed increased Aβ production and accelerated 
amyloid deposition in the brain (Borchelt, Ratovitski et al., 1997). Previous studies from 
our laboratory have shown that neurons from APP/PS1 have increased basal protein 
oxidation and lipid peroxidation, and are more vulnerable to oxidation by various 
exogenous oxidants when compared to wild type (Mohmmad Abdul, Sultana et al., 
2006). All these studies suggest that APP/PS1 mice can be used as a model of FAD, 
which is characterized Aβ(1–42)-mediated oxidative stress. Indeed, recently completed 
initial redox proteomics studies demonstrated elevated oxidized protein in FAD brain 
(Butterfield, Perluigi et al., 2006). 
2.3. Synaptosomes 
Synaptosomes are membrane bound sac-like structures that contain synaptic 
vesicles and mitochondria and nerve terminals isolated from the synapse of neurons. 
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During brain tissue homogenization, the synaptosomes break away from axon terminal 
under controlled conditions. Synaptosomes were first isolated by Hebb and Whittaker in 
1957. The process of isolation of synaptosomes from detached synapses involves 
ultracentrifugation and use of a discontinuous sucrose gradient.  Synaptosomes are often 
used for studies involving synaptic transmission because they have machinery similar to a 
functional synapse. They have functional pumps and channels, synaptic protein and 
receptors, respond to depolarization, can translocate metabolite and ions and can respire 
due to the presence of mitochondria (Whittaker, 1993). 
In AD, synaptic membranes are known to show increased oxidative stress 
(Hensley, Carney et al., 1994; Hensley, Hall et al., 1995). Synaptosomes were selected 
for some of the studies discussed in this dissertation for the following reasons. Synaptic 
membranes have receptors for glutamate, which mediate increased intracellular Ca2+ and 
exitotoxicity and cause production of ROS/RNS that lead to subsequent protein oxidation 
and lipid peroxidation (Hensley, Carney et al., 1994; Mattson, 1996). Elevation in Ca2+ 
levels also causes changes in mitochondrial potential and lead to production of 
superoxide ion radicals. Due to more energy usage in the synaptic region of neuron, 
mitochondria are concentrated in these areas of cell. Hence, the synaptic region of 
neurons becomes more vulnerable to oxidative stress. Synaptosomes virtually “mimic” a 
functional neuron and are easy to isolate. 
2.4. Mitochondria 
Mitochondria, often described as the “cellular power plant” and one of the most 
important intracellular organelles, occupies up to 25% of the cellular cytoplasm. The 
main function of mitochondria is to convert organic material into energy in the form of 
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ATP by a process called oxidative phosphorylation. Mitochondria are bound by an inner 
and an outer membrane with distinct functions. The mitochondrial matrix, which is the 
space enclosed by the inner membrane, has various metabolic enzymes involved in 
electron transport and energy metabolism, mitochondrial DNA (mtDNA) among others 
(Fig 2.6). The mtDNA is non chromosomal and encodes 13 mitochondrial peptides. 
Unlike nuclear DNA, mtDNA lacks histones, hence mtDNA becomes more vulnerable to 
ROS-mediated oxidative damage (Cadenas and Davies, 2000). 
 
Figure 2.6: Diagram of human mitochondrion (Adapted from wikipedia) 
Although it is reported that heart mitochondria contain catalase (Radi, Turrens et 
al., 1991), an enzyme that converts toxic H2O2 to water, brain mitochondria lacks 
catalase. Also, mitochondria lack the enzyme to synthesize GSH; hence, mitochondrial 
GSH depends on dicarboxylate and 2-oxoglutarate carriers, which aid in uptake of GSH 
(Chen and Lash, 1998). Mitochondria not only generate energy but are also a source of 
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free radicals and ROS/RNS. This, combined with factors described above, makes 
mitochondrial protein and lipids more prone to oxidative insult.  
Apart from ATP production, the mitochondrion is also involved in variety of 
functions, such as regulation of cellular redox state, glutamate-mediated exitotoxicity and 
apoptosis. Cytochrome C release from an opened mitochondrial permeability transition 
pore upon oxidative insult or compromise in cellular redox state may initiate apoptosis or 
programmed cell death. Cytochrome C released into the cytosol forms a complex with 
caspase-9 and APAF-1 called an apoptosome, which activates caspase-3. Caspase-3 
activation leads to apoptosis (Michel, Lambeng et al., 1999; Adrain and Martin, 2001). In 
this dissertation research, mitochondria were used to study the in vivo protective effect of 
GSH mimetic, D609, from various oxidants. 
2.5. Glutathione 
2.5.1. GSH metabolism and biosynthesis 
GSH is a tripeptide, γ-glutamyl-cysteinyl-glycine (IUPAC name: 2-amino-5-[2-
[(carboxymethyl) amino]- 1-(mercaptomethyl)-2-oxoethyl]amino-5-oxopentanoic acid), 
is the most abundant low molecuar weight thiol expressed ubiquitously. Glutathione is 
widely recognized as an endogenous nonenzymatic antioxidant, an oxyradical scavenger, 
thereby useful in protecting cells against oxidative damage by free radicals and inhibiting 
lipid peroxidation and DNA damage (Meister, 1995; Darley-Usmar and Halliwell, 1996; 
Sies, 1999; Schulz, Lindenau et al., 2000; Hansen, Go et al., 2006). Glutathione has been 
implicated in a wide range of metabolic processes, including cell division, DNA repair, 
regulation of enzyme activity, activation of transcription factors, modulation of anion and 
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cation homeostasis and protection against oxidative damage (Meister and Anderson, 
1983). 
The synthesis of GSH from glutamate, cysteine, and glycine is catalyzed by two 
cytosolic enzymes, γ-glutamylcysteine ligase (GCL) and GSH synthatase (GS). It is a two 
step process and both the steps need ATP as cofactor. The first step involves ligation of 
γ-glutamate to cysteine to form γ-glutamylcysteine and the reaction is catalyzed by GCL. 
This step is the rate-limiting step. Cysteine generally is present in micromolar 
concentration in brain, while glutamate and glycine are present at millimolar levels 
(Cooper, 1997). GCL is feedback inhibited by GSH itself. GS catalyzes the addition of 
glycine to the limiting substrate γ-glutamylcysteine (Figure 2.7). 
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Figure 2.7: GSH synthesis 
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2.5.2. GSH and Oxidative stress 
GSH is present in 1-3mM concentration throughout the brain (Cooper, 1997), 
acting as a high capacity detoxification agent. GSH maintains the cellular redox balance 
depending upon the pH of the cellular compartment and is involved in various 
biosynthetic processes as well (Schulz, Lindenau et al., 2000). The level of GSH is 
reduced in specific regions of the central nervous system in various neurodegenerative 
disorders and concomitant increase in oxidized glutathione (GSSG) levels contributes to 
the oxidative stress-mediated neuronal cell dysfunction and/or loss in these disorders 
(Benzi and Moretti, 1995a; Cooper, 1997). GSH, in conjugation with glutathione 
reductase (GR), glutathione peroxidase (GPx), glutathione-S-transferase (GST) and 
NADPH provide protection against various toxic electrophiles and hydrogen peroxide 
(Watson, Chen et al., 2003) (fig 2.8). 
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Figure 2.8: The reaction catalyzed by GR and GPx in conjugation with GSH and 
GSSG 
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Usually the ratio of GSH to GSSG is maintained towards more reducing state. 
The GSH/GSSG ratio toward the oxidizing state activates several signaling pathways 
including protein kinase B, calcineurin, nuclear factor κB, and mitogen- activated protein 
kinase (Wu, Fang et al., 2004). Hence, the GSH/GSSG ratio is the important indicator of 
cellular redox state. Apart from its function as ROS scavenger, GSH reacts with various 
electrophiles, physiological metabolites and xenobiotics and helps clear the toxic 
substances. GSH conjugates with NO to form an S-nitrosoglutathione adduct, which is 
cleaved by the thioredoxin system to release GSH and NO.  
2.5.3. Glutathione Peroxidase 
GPx (EC 1.11.1.9) is the enzyme that helps in detoxification by catalyzing the 
conversion of H2O2 to H2O and O2 (Figure 2.8). Different GPx isoforms also detoxify 
lipid peroxides and alkyl peroxides. The reducing electron comes from GSH. There are 
various isoforms of GPx and is present in both cytosol and mitochondria. Since 
mitochondria lacks catalase, GPx becomes particularly important in H2O2 clearance. 
H2O2, if not cleared, can produce hydroxyl radicals in the presence of Fe2+ or Cu+.  
2.5.4. Glutathione Reductase 
GR (EC 1.6.4.2) is the enzyme that keeps the GSSG concentration low compared 
to GSH and hence helps maintain the redox balance of the cell. GR catalyzes the 
conversion of GSSG to GSH with the aid of NADPH as cofactor (Figure 2.8). NADPH 
comes from the pentose phosphate pathway. GR is localized in both brain cytosol and 
mitochondrial matrix. 
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2.5.5. Glutathione-S-Transferase 
GST (EC 2.5.1.18) is the key detoxification enzyme that catalyzes the conjugation 
of various electrophiles, reactive alkenals, such as 4-hydroxynonenal (HNE) and acrolein, 
and xenobiotics to GSH. These GSH-S-conjugates are removed from cells by the 
multidrug resistant protein-1 (MRP-1) (Figure 2.9), an ATP binding cassette (ABC) 
family protein (Renes, de Vries et al., 2000; Sultana and Butterfield, 2004). MRP-1 is an 
integral plasma membrane protein that exports glutathione-S conjugates out of the cell in 
an ATP-dependent manner (Nies, Jedlitschky et al., 2004; Conseil, Deeley et al., 2005). 
Studies have shown reduced GST activity in brain and ventricular fluids in AD (Lovell, 
Xie et al., 1998). Increased expression of GST leads to increased resistance towards 
oxidative stress in neuroblastoma cells and provides protection against HNE mediated 
toxicity in neuronal cell culture (Lovell, Xie et al., 1998). 
 
Figure 2.9: Detoxification process involving GST and MRP-1 to remove GS-
conjugates out of the cell. 
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2.6 Superoxide Dismutase 
SOD (EC 1.15.1.1) converts superoxide radicals to hydrogen peroxide and 
oxygen, the former subsequently is converted to water and oxygen by action of GPx 
and/or catalase. SOD has various isoforms depending upon their reaction center, but in 
eukaryotes, two isoforms are predominantly found, Cu/ZnSOD in cytosol and MnSOD in 
mitochondria. SOD has one of the fastest turn-over numbers among any known enzymes. 
Mutation in SOD 1 has been linked with familial ALS. Increased expression of certain 
SODs has shown to be protective against oxidative stress in many disease models (Yen, 
Oberley et al., 1999). A typical reaction of CuSOD looks like those shown in equations 1 
and 2 below: 
• Cu1+-SOD + O2-. + 2H+ → Cu2+-SOD + H2O2       (Eqn 2) 
• Cu2+-SOD + O2-. → Cu1+-SOD + O2                      (Eqn 1) 
2.7.  Proteomics 
Proteomics can be broadly defined as the large-scale study of structure, function 
and localization of proteins. This term was coined to make an analogy with genomics, 
which is study of genome by gene sequencing. While the genome is static, the proteome 
is dynamic and more complex, differing from cell to cell and through biochemical 
interaction contantly keeps changing. The proteome can be defined as an entire protein 
complement of a biological system at any given time. Protein expression of any organism 
or cell differs in different parts of body, at different stages of the life cycle and in 
different environmental conditions. With the completion of he human genome, many 
researchers are tryng to solve the problem related to biological information that cannot be 
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obtained from genenome alone and now examine gene and protein interaction to form 
other proteins.  
We now know that there are far fewer protein coding genes in the human genome 
(Approximately 20 – 30 K genes) than the actual number of protein in human proteome 
(> 400 K proteins). Due to this discrepancy, gene expression analysis alone cannot be 
used to characterize its protein complement. A major diversity in proteins is due to post-
translational modification. Proteomics plays an important role in characterizing a 
particular protein in tissue or organism. Collection of such information offers opportunity 
to study mechanisms of disease, is instrumental in discovery of biomarker, such as 
markers that indicate a particular disease and often help in elucidating the pathological 
events involved in a particular disease condition for therapeutic intervention.  
With the technological advances in seperation of complex mixture of protein and 
identification by using soft ionization techniques such as matrix assisted laser disorption 
and ionization (MALDI) and electrospray ionization (ESI) coupled mass spectrometry, 
and advances in bioinformatic tools, it has become possible today to meet proteomic 
demand. Protein expression is dynamically regulated in response to internal and external 
disturbance under various physiological, pathological, developmental and 
pharmacological conditions, thereby resulting in the formation of various post-
translational modifications. ROS/RNS-mediated oxidative stress leads to the most 
common post-translational modification, carbonylation. The branch of proteomics that 
deals with identification of specifically oxidized protein under a given oxidative stress or 
diseased condition is called “Redox Proteomics”. Oxidative stress has been implicated in 
many neurodegenerative disorders, including AD. Our laboratory has successfully used 
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redox proteomics approaches towards identifying specifically oxidized, nitrated and HNE 
bound proteins in various neurodegenerative disorder condition [reviewed in (Butterfield 
and Castegna, 2003; Butterfield, 2004; Butterfield, Perluigi et al., 2006; Butterfield, Poon 
et al., 2006)]. In this dissertation research, the redox proteomics expertise of our 
laboratory was used to identify specifically oxidized and differentially expressed proteins 
in brains isolated from mice injected i.p. with ADR. 
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Chapter 3 
Experimental Procedure 
3.1.  Synaptosome Isolation 
As previously described in Chapter 2, a series of ultracentrifugation on a 
discontinuous sucrose gradient was used for synaptosome isolation. For all the studies 
with synaptosomes, male Mongolian gerbils (2-3 months of age), approximately 60-70 g 
in size, housed in the University of Kentucky Central Animal Facility in 12-h light/dark 
conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The 
animal protocols were approved by the University of Kentucky Animal Care and Use 
Committee. 
Gerbils were decapitated during the light phase and the cortex was isolated on ice. 
The synaptosomal isolation procedure has been described elsewhere (Whittaker, 1993). 
The isolated cortex was placed in ice-cold 0.32M sucrose isolation buffer containing 
4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml aprotinin, 2mM ethylenediaminetetraacetic 
acid (EDTA), 2mM ethylene glycol-bistetraacetic acid (EGTA) and 20mM 4-(2-
hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), 20μg/ml trypsin inhibitor and 
0.2mM phenylmethanesulfonyl fluoride (PMSF), pH 7.4. The cortex was homogenized 
by 20 passes with a Wheaton tissue homogenizer. The homogenate was centrifuged at 
1500 g for 10 min. The pellet was discarded and the supernatant was retained and 
centrifuged at 20000 g for 10 min. The resulting pellet was resuspended in approximately 
1ml of 0.32M sucrose isolation buffer and layered over discontinuous sucrose gradient 
(0.85M pH 8.0, 1.0M pH8.0, 1.18M pH8.5 sucrose solutions each containing 2mM 
EDTA, 2mM EGTA and 10mM HEPES) and spun at 82500g for 1h at 4o C. The purified 
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synaptosomes were collected from the sucrose gradient interface at the 1.0/1.18M (Fig 
3.1) and washed with phosphate buffered saline containing 0.01% (w/v) sodium azide 
and 0.2% (v/v) Tween 20 (PBS), twice and centrifuged at 32000 g. 
 
Figure 3.1: Sucrose density gradient for isolation of purified synaptosome 
 
3.2.  Mitochondria Isolation 
As discussed in Chapter 2, mitochondria are major source of ROS. The brain 
mitochondria were isolated according to the procedure of Sims et al. (Sims, 1990) with 
minor modifications. Gerbils were decapitated in light phase and the whole brain was 
isolated on ice. Whole brain was homogenized in ice-cold isolation buffer (250 mM 
sucrose, 10 mM HEPES, and 1 mM potassium EDTA, pH 7.2, 4 μg/ml leupeptin, 4 
μg/ml pepstatin, 5 μg/ml aprotinin 20 μg/ml trypsin inhibitor) with 6 passes of a Wheaton 
tissue homogenizer. The homogenate was centrifuged for 3 min at 1,330× g at 4°C, and 
the resulting pellet was resuspended in isolation buffer and centrifuged at 1,330× g for 3 
min. The supernatants from both spins were combined and spun at 21,200x g for 10 min 
at 4°C. The pellet was resuspended in 15% Percoll solution (v/v in isolation buffer) and 
layered onto discontinuous Percoll gradients of 23 and 40% Percoll (v/v in isolation 
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buffer). Gradients were centrifuged at 30,700× g for 5 min at 4°C. At the 23-40% Percoll 
interface, mitochondria were isolated and resuspended in respiration buffer (250 mM 
sucrose, 2 mM magnesium chloride, 20 mM HEPES, and 2.5 mM phosphate buffer, pH 
7.2) and centrifuged at 16,700× g for 10 min at 4°C. The pellet was resuspended in 
respiration buffer, centrifuged at 6,900× g for 10 min at 4°C, and the resulting pellet was 
washed in PBS at 6,900× g for 10 min at 4°C.  
3.3.  Protein Concentration 
The subsequently isolated synaptosomes and mitochondria were assayed for 
protein concentration by Pierce BCA method (Bradford, 1976). The principle behind this 
assay is to measure the absorbance of Cu1+ complex with bicinchoninic acid (BCA) at 
562 nm in a spectrophotometer. The protein-mediated reduction of Cu2+ to Cu1+ in 
alkaline solution complexes with BCA to give bluish purple color that has strong 
absorbance at 562 nm. Bovine serum albumin (BSA) was used as standard for all the 
protein concentration determination studies as a part of this dissertation. Beers law was 
used to calculate the concentration of unknown samples. 
3.4.  DCF Fluorescence 
Oxidative stress and its implication in neurodegenerative disorders can be 
understood by studying the levels of intracellular ROS generation. The 
dichlorofluorescein (DCF) assay is useful in understanding the intracellular ROS 
generation by various oxidants and can be used to test the efficacy of an antioxidant 
compound as ROS scavenger. As a part of this dissertation research, DCF assay was used 
to study the antioxidant properties of D609 and FAEE as ROS scavenger.  
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DCF is sensitive to many oxidative stress-inducing compounds including 
hydroxyl radical, ONOO-, AAPH and Aβ (Wang and Joseph, 1999; Keller, Lauderback 
et al., 2000; Lauderback, Kanski et al., 2002). Dichlorofluorescine diacetate (DCFH-DA) 
is a membrane permeable non-fluorescent compound that crosses the membrane and is 
acted upon the intracellular esterases to form dichlorofluorescine (DCFH). DCFH then 
reacts with intracellular ROS to form a fluorescent DCF which is measured by 
spectrofluorometer (Fig 3.2). To ensure that ester cleavage or efflux of the DCFH, prior 
to the reaction with ROS, was not contributing to changes in fluorescence, the oxidation-
insensitive dye (C369) was used in similar studies and was used as control.  
In this assay, 10 μM DCFH-DA was incubated with synaptosomes (1mg/ml) for 
30 minutes at 37o C. Intracellular esterases convert DCFH-DA into anionic DCFH, which 
because of its negative charge is trapped in the synaptosomes. Upon oxidation with ROS, 
DCFH is converted to DCF, a fluorescent compound. Synaptosomes were spun at 3000 g 
in a tabletop Eppendorf centrifuge for 5 minutes at 4o C. Synaptosomes were resuspended 
in 500 μl of PBS and loaded in triplicate (100 μl per well) in a black microtiter plate and 
fluorescence was measured in a Spectramax microtiter plate reader (λex = 495nm, λem = 
530nm) and quantified using softPro max software. To verify that ester cleavage and 
efflux of the dye were not contributing to changes in fluorescence, similar studies were 
done with an oxidation-insensitive dye carboxy-DCFH-DA (C369). 
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Figure 3.2: DCF assay 
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3.5.  Protein oxidation (Slot blot) 
As discussed in Chapter 2, free radical mediated oxidative stress causes protein 
oxidation. Also discussed were the consequences of protein oxidation. The two markers 
of protein oxidation are formation of protein carbonyl and nitration of tyrosine residues 
on protein by ONOO-.  
3.5.1. Protein carbonyl 
Levels of protein carbonyl can be estimated by immunochemical method. 2, 4-
dinitrophenylhydrazine reacts with the carbonyl groups on protein to form a hydrazone 
adduct (Schiff base) (Fig 3.3). By using a specific antibody for hydrazone, the carbonyl 
level can be estimated. Briefly, sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium 
dodecyl sulfate (SDS) and 10μl of 10 times diluted 2,4-dinitrophenylhydrazine (DNPH) 
from 200mM stock were incubated at room temperature for 20 min. Samples were 
neutralized with 7.5μl neutralization solution (2M Tris in 30% glycerol). The resulting 
solution was solution was loaded in each well on nitrocellulose membrane under vacuum 
using a slot blot apparatus. 
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Figure 3.3: Derivatization of protein by DNPH 
The assembly of the slot blot apparatus is shown below (fig 3.4). The membrane 
was blocked in blocking buffer (3% bovine serum albumin) in phosphate buffered saline 
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) for 1 h and 
incubated with a 1:100 dilution of anti DNP polyclonal antibody in phosphate buffered 
saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) for 1h. The 
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membrane was washed three times in PBS and was incubated for 1 h with an anti-rabbit 
IgG alkaline phosphatase secondary antibody diluted in PBS in a 1:8000 ratio. The 
membrane was washed for three times in PBS for 5 min and developed in Sigma fast 
tablets (BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and 
quantified with Scion Image (PC version of Macintosh compatible NIH image). 
 
Figure 3.4: Slot blot apparatus assembly. 
 
3.5.2. 3-Nitrotyrosine  
As described in chapter 2, 3NT is a hallmark of ONOO- - mediated protein 
damage. The 3NT levels were measured in both synaptosomal and mitochondrial 
suspension. A slot blot technique similar to protein carbonyl was employed to 
immunochemically detect the levels of 3NT. 
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The suspended synaptosomes or mitochondria samples (5 μl) (normalized to 
4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS) and 5μl of modified Laemmli buffer 
containing 0.125 M tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) glycerol were 
incubated for 20 minutes at room temperature. Sample (250 ng) was loaded in each well 
on nitrocellulose membrane in slot blot apparatus under vacuum. The membrane was 
blocked in blocking buffer (3% bovine serum albumin) in phosphate buffered saline 
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) for 1 hr and 
incubated with a 1: 2000 dilution of anti-3-nitrotyrosine (3NT) polyclonal antibody in 
PBS for 1 h 30 min. The membrane was washed in PBS for 5 min three times after 
incubation. The membrane was incubated for 1 h, following washing, with an anti-rabbit 
IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 ratio. The 
membrane was washed for three times in PBS for 5 minutes and developed in Sigma fast 
tablets. Blots were dried, scanned with Adobe Photoshop, and quantified with Scion 
Image as above. 
3.6.  Lipid peroxidation (Slot blot) 
As discussed in chapter 2 that lipid peroxidation often leads to formation of 
byproduct, such as HNE and acrolein. These reactive alkenals bind to the protein by 
Michael addition and inactivates them. A reaction of HNE with cysteine residues on 
protein to form a Michael adduct is shown in figure 3.5. Hence, estimating the levels of 
protein bound lipid peroxidation product can gives the extent of lipid peroxidation. As a 
part of this dissertation research, protein-bound HNE levels were measured to quantify 
the extent of lipid peroxidation. The protein-bound HNE levels were measured in both 
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synaptosomal and mitochondrial suspension. A slot blot technique similar to protein 
carbonyl was employed to immunochemically detect the levels of protein bound HNE. 
Sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS) 
and 5μl of modified Laemmli buffer containing 0.125 M tris base pH 6.8, 4% (v/v) SDS, 
and 20% (v/v) glycerol were incubated for 20 minutes at room temperature. Sample (250 
ng) was loaded in each well on nitrocellulose membrane in slot blot apparatus under 
vacuum. The membrane was blocked in blocking buffer (3% bovine serum albumin) in 
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 
(PBS) for 1 hr and incubated with a 1: 5000 dilution of anti-HNE polyclonal antibody in 
PBS for 1 h 30 min. The membrane was washed in PBS for 5 min three times after 
incubation. The membrane was incubated for 1 h, following washing, with an anti-rabbit 
IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 ratio. The 
membrane was washed three times in PBS for 5 min and developed in Sigma fast tablets 
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and quantified 
with Scion Image as above. 
43 
 
Figure 3.5: Reaction of HNE with cysteine 
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3.7.  GSH and GSSG assays 
As described in Chapter 2, GSH is the most abundant antioxidant present in 
millimolar concentration in brain that helps protecting cells against oxidative stress. 
Hence, it becomes important to study the levels of GSH during neurodegenerative 
disorder conditions involving oxidative stress. As a part of this dissertation research the 
GSH and GSSG levels were measured to look for the effect of D609 or GCEE as 
modulator of GSH, either by mimicking its property or by increasing its levels.  
GSH levels were measured by procedure described by Griffith et al., 1980 
(Griffith, 1980). 5, 5’-Dithiobis (2-nitrobenzoic acid) (DTNB) is used for detecting 
sulfhydryl groups. The principle behind this assay is enzymatic recycling method, using 
GR, for quantification of GSH. GSH reacts with DTNB to form a mixed disulfide and 
produces a yellow colored 5-thio-2-nitrobenzoic acid (TNB) that has absorbance at 414 
nm in spectrophotometer. The GSTNB complex is reduced by GR to form more TNB 
(Fig 3.6). The rate of formation of TNB is directly proportional to concentration of GSH 
in the sample. A kit working on this principle was used as a part of some of the 
dissertation research. Briefly, the cytosolic fraction isolated from brain homogenates was 
precipitated with 10% (w/v) metaphosphoric acid and then centrifuged for 5 min at 
5,000g. The supernatants were neutralized with 4M triethanolamine and then analyzed 
according to manufacturer instructions. GSH concentration in the samples was calculated 
using the kinetic method by measuring the absorbance at 405 nm with a Bio-Tek 
Powerwave X Microtiter Plate Reader (Bio, Inc.). A plot of the corrected absorbance vs 
the concentration of GSH standards (μM) was utilized to calculate the average 
concentration of GSH present in the samples. 
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Figure 3.6: GSH assay 
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A fluorescence method was also used to measure the level of GSH in one of the 
part of this dissertation research. This method is dependent on measuring the floroscence 
of GSH complex with O—phthaldehyde (OPT). Determination of GSH was performed 
by the method of Hissin and Hilf (Hissin and Hilf, 1976). The reaction mixture 
containing 0.1 M sodium phosphate buffer (pH-8.0), 5.0 mM EDTA, 10 μl OPT (1.0 
mg/ml) and 10 μl of sample. After incubation for 15 min at room temperature, 
fluorescence at emission 420 nm was recorded by excitation at 350nm. For assaying 
levels of GSSG, same method was used. Briefly, the samples were incubated first with 
0.04 M N-ethyleimide (NEM) for 30 min to interact with GSH present in sample. The 
reaction mixture containing 0.1 N NaOH, 5.0 mM EDTA, 10 μl O-phthaldehyde (1.0 
mg/ml) and 10 μl of sample. After incubation for 15 min at room temperature, 
fluorescence at emission 420 nm was recorded by excitation at 350nm. 
3.8.  Enzyme Activities 
3.8.1. Glutathione peroxidase 
As described in Chapter 2, GPx is the enzyme that converts H2O2 to H2O and O2. 
It gets the reducing electrons from the GSH which is converted to GSSG. GPx (EC 
1.11.1.9) activity was measured in a 96-well plate reader at 37 °C by a coupled assay 
system (Wheeler, Salzman et al., 1990). The reaction mixture consisted of 0.2 mM H2O2, 
1.0 mM GSH, 0.14 U of GR, 1.5 mM NADPH, 1.0 mM sodium azide and 0.1M 
phosphate buffer (pH 7.4) and 10 μl PMS in a total volume of 200 μl. The enzyme 
activity was calculated as nmol NADPH oxidized min− 1 mg− 1 protein. 
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3.8.2. Glutathione reductase 
GR is the enzyme that catalyzes conversion of GSSG to GSH as described in 
Chapter 2. The cofactor for this enzymatic reaction is NADPH. The assay system to 
estimate GR (EC 1.6.4.2) activity consisted of 0.1 M phosphate buffer (pH 7.6), 0.5 mM 
EDTA, 1.0 mM oxidized glutathione, 0.1 mM NADPH and 10 μl PMS in a total volume 
of 200 μl (Carlberg and Mannervik, 1985). The enzyme activity was assayed in a 96-well 
plate reader by measuring the disappearance of NADPH at 340 nm and was calculated as 
nmol NADPH oxidized min− 1 mg− 1 protein. 
3.8.3. Glutathione-S-transferase 
GST catalyzes the conjugation of GSH to various reactive alkenals, electrophiles, 
and xenobiotics to remove them out of cell. In other word, GST is a detoxification 
enzyme and functions as described earlier in Chapter 2. GST (EC 2.5.1.18) activity was 
measured in a 96-well plate reader, with the reaction mixture consisting of 0.1 M 
phosphate buffer (pH 6.5), 1.0 mM reduced glutathione, 1.0 mM CDNB and 0.1 μl of 
PMS in a total volume of 200 μl(Habig, Pabst et al., 1974). The changes in absorbance 
were recorded at 340 nm, and the enzymatic activity was calculated as nmol CDNB 
conjugate formed min− 1 mg− 1 protein. 
3.8.4. Total superoxide dismutase 
SOD (EC 1.15.1.1) activity assay reaction consisted of 50 mmol/l glycine buffer, 
pH 10.4, and 1mg/ml supernatant protein. The reaction was initiated by the addition of 20 
mg/ml solution of (–)-epinephrine and absorbance was measured at 480 nm (Stevens, 
Obrosova et al., 2000). SOD activity was expressed as nmol of (–)-epinephrine protected 
from oxidation min− 1 mg− 1 protein. 
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3.9.  Western blot 
This method was used as a part of dissertation research to investigate the 
expression levels of various proteins involved in oxidative stress-mediated 
neurodegenerative disorders. In particular, the GSH and its related enzyme expression 
levels were looked at in brain isolated from ADR injected mice. The principle behind this 
method is to separate a mixture of protein based on there molecular weight at a specific 
voltage on a sodium dodecyl sulfate-polyacrylamid gel (SDS-PAGE). Briefly, Samples 
(100 μg) were incubated with sample loading buffer, and protein samples were denatured 
and electrophoresed on a 12.5% SDS-PAGE. Proteins were transferred to a nitrocellulose 
membrane at 90 mA/gel for 2 h. The blots were blocked for 1h in fresh wash buffer (10 
mM Tris-HCl, pH7.5), 150 mM NaCl, 0.05% Tween 20, pH 7.4, containing 3% bovine 
serum albumin) and incubated with a 1:1000 dilution of the respective monoclonal 
antibody in phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% 
(v/v) Tween 20 (PBS) for 1h. The membrane was washed three times in PBS and was 
incubated for 1 h with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted 
in PBS in 1:8000 ratio. The membrane was washed for three times in PBS for 5 min and 
developed in Sigma fast tablets (BCIP/NBT substrate). 
In all cases non-specific background labeling by secondary antibody was 
negligible. 
3.10. Proteomics 
2D-PAGE followed by 2D Western blot, coupled with mass spectrometry analysis 
of the biological sample in single detectable protein spots, has been widely used to 
identify complex protein mixtures. Recent advances in proteomics have improved result 
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in identification techniques (Dalle-Donne, Scaloni et al., 2006). As a part of this 
dissertation research, this method was used to identify specifically expressed protein and 
differentially oxidized protein in brain samples obtained from ADR-injected mice.   
3.10.1. Iso-electric focusing (First dimension) 
The first dimensional separation of proteins id based on there isoelectric point 
(IP). IP is the pH at which the net charge on a protein is zero. The protein samples are 
loaded on an immobilized pH gradient (IPG) strip and a potential is supplied. The protein 
starts moving on the strip and pH gradient allows the migration of protein to a point until 
the net negative charge is balanced by the same amount of positive charge. At this point 
the protein becomes neutral and is focused at a particular pH. Due to the neutral charge 
proteins does not respond to the applied potential. This process is called isoelectric 
focusing. In IEF, protein solubalization in the sample is very important step because the 
higher gel friction coefficient might cause protein precipitation if not solubalized. The 
sample buffer for IEF consist of urea, which is an effective chaotropic agent, dithiotreitol 
(DTT) that is a reducing agent along with non-ionic detergents, such as Triton X and 
CHAPS. The voltage applied depends on nature of sample, solubility of protein and 
number of IPG strips. Following IEF, the strips are equilibrated with DTT that reduces 
disulfide bind and iodoacetamide that derivatizes the cysteine residues. 
3.10.2. SDS-PAGE (Second dimension) 
Gel electrophoresis on polyacrylamide matrix is an analytical technique that 
provides separation of proteins according to the size under applied potential difference. 
The technique had been described earlier in this chapter. The only difference being that 
instead of protein sample, the IPG strips on which proteins that are previously separated 
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based on IP is mounted on top of the gel following equilibration. The separation occurs in 
presence of detergent, SDS, that solubalizes and denatures the proteins. Due to presence 
of SDS the protein lose their three-dimensional structure and assume a net negative 
charge. Hence, unlike IEF the separation is purely based on the molecular migration rate 
of a denatured protein on a polyacrylamide gel, which is based on size of a protein. Once 
the proteins are separated into single spot on two different dimensions, the gels are 
stained with sypro ruby. The result of 2D map provides various information, important 
one being comparison between different sample to identify difference in protein 
expression (Tilleman, Stevens et al., 2002). The 2D-PAGE can resolve thousand of 
protein at once and provide clues even on posttranslational modification. The schematic 
representation of 2D-PAGE is shown in Figure 3.7.  
The overall process of 2D-PAGE follows the method as described. Samples of the 
proteins from brain homogenate were prepared as previously described (Poon, Castegna 
et al., 2004). Briefly, for isoelectric focusing, 200μg of protein were applied to a pH 3–10 
ReadyStrip™ IPG strip (Bio-Rad), and Linear Gradient (8– 16%) Precast criterion Tris-
HCl gels (Bio-Rad) were used to separate proteins according to their molecular migration 
rate (MrW). Sypro ruby stain was used to stain the gel for ~ 1 h, after which the gels were 
placed overnight in deionized water for destaining.  
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Figure 3.7: 2-Dimensional Gel Electrophoresis 
 
3.10.3. 2D Western blots 
Redox proteomics is the branch of proteomics that is used to identify specifically 
oxidized protein in a sample mixture. Our laboratory has used the redox proteomics 
method to identify specifically carbonated, nitrated and HNE-bound protein in various 
neurodegenerative disorders, including AD [reviewed in (Butterfield, Poon et al., 2006; 
Sultana, Perluigi et al., 2006).  As described in Chapter 2, ROS/RNS-mediated oxidative 
stress leads to the most common post-translational modification, carbonylation. As a part 
of this dissertation research, redox proteomics approach was used to identify 
differentially carbonylated protein that index protein oxidation in brain protein samples 
isolated from ADR-injected mice and were compared with respective control to identify 
specifically oxidized protein. Briefly, the proteins are derivatized with DNPH and are 
separated on 2D-PAGE as described in earlier section. The proteins separated on 2D gels 
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are then transferred on a nitrocellulose membrane (western blotting) and developed 
immunochemically. Western blotting for 2D-PAGE was performed as previously 
described (Poon, Castegna et al., 2004). Briefly, 200μg of the brain protein were 
incubated with 10 mM DNPH solution in 2 N HCl at room temperature (37°C) for 20 
min. The gels were prepared in the same manner as for 2DE. The proteins from gels 
following the second dimension electrophoresis were transferred onto nitrocellulose 
paper (Bio-Rad) using a Transblot-Blot® SD semi-dry Transfer Cell (Bio-Rad) at 15V 
for 2 h. The derivatized carbonyl adduct of the brain proteins were detected 
immunochemically (Butterfield, 2004).   
3.10.4. PD-Quest analysis 
Image analysis to identify the protein on gels and blots is done by using PD-Quest 
software. The sypro ruby stained gels are scanned and saved in TIF format using a Storm 
860 Scanner (Molecular Dynamics, Sunnyvale, CA) and the Western blots developed 
using a specific antibody for DNPH derivatized proteins are scanned and saved in TIF 
format using Scanjet 3300C (Hewlett Packard, Palo Alto, CA). PD-Quest (Bio-Rad) 
software was used for matching and analyzing visualized protein spots among multiple 
gels and oxyblots. After matching all the spots, the normalized intensity of each protein 
spot from individual gels (or oxyblots) is compared between groups and a protein map is 
obtained using statistical analysis. 
3.10.5. In-gel digestion 
Individual spots that show statistically significant difference between control and 
treated sample are excised from the gels and are placed in a protease buffer that favors 
peptide extraction and gets absorbed in the gel surface to cleave the protein into several 
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peptides in a sequence specific manner. The in-gel digestion was carried out as described 
previously (Poon, Castegna et al., 2004). Briefly, the excised protein spots were washed 
with ammonium bicarbonate (NH4HCO3) followed by acetonitrile at room temperature. 
The gel pieces were digested with 20ng/μl modified trypsin and incubated at 37°C 
overnight in a shaking incubator. 
3.10.6. Mass spectrometry 
Mass spectrometry is the analytical technique that provides generation, separation 
and detection of ions formed by fragmentation of a molecule of interest. The ions formed 
are then separated according to their mass-charge ratio (m/z) and are detected by a 
detector. The m/z of each ion is collected in the form a mass spectrum that provides 
structural information of an analyte. A mass spectrometer usually consist of an ion 
source, an analyzer that separates ions based on m/z, a detector that quantifies the amount 
of ions with same m/z and a computer processor that collects mass spectrum and process 
the data generated. 
3.10.7. Ion source 
As described in Chapter 2, the two types of ion sources used in proteomics study 
are ESI and MALDI. As a part of this dissertation study, MALDI was used as ionization 
technique. MALDI produces ions by irradiation of the sample embedded in a matrix of 
suitable organic compound that mixes with the sample. Sample mixture deposited on a 
special metal plate is defined as “solid solution” once the solvent is evaporated from the 
matrix. Upon laser irradiation, the matrix sublimes and the gaseous molecule act as 
carrier of the analyte into the gas phase. In this way even labile molecules can be ionize 
without decomposition. The sample preparation and matrix selection is most important 
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part in MALDI. For our sample, 1 μl of α-cyano-4-hydroxy trans-cinnamic acid (10 
mg/ml in 0.1% TFA: ACN, 1:1, v/v) was mixed with tryptic digests (1 μl). The mixture 
(1 μl) was deposited onto the surface of a fast evaporation nitrocellulose matrix. 
3.10.8. Time-of-flight (TOF) analyzer 
Each single detectable ion is separated according to m/z following ionization by 
MALDI method. This value is measured through a scanner device, which collects the 
ions coming from ionization source and transmitted on to a time scale. There are several 
kinds of analyzer based on different principles. In brief they can be divided into two 
groups: analyzer with flight tube and quadrupole analyzer. MALDI is usually coupled 
with a time-of-flight (TOF) analyzer. The ions separation in a TOF analyzer depends on 
the fact that the ions with higher mass will reach the detector slower than the smaller 
mass ions. Each ion with specific mass will have a specific “time of flight” before 
reaching the detector. The relationship between mass of ion and time taken to reach the 
detector can be derived as follows. An ion of mass m and charge q = ez accelerated at an 
applied voltage V, flying through a distance d with a velocity v, will reach the detector 
after time t 
T = d/v (Eqn 1) 
The kinetic energy K of ion  
K = mv2/2 = zeV (Eqn 2) 
Combining the two equations we get, 
t = √ (m/z) [d2/2ev] (Eqn 3) 
It is clear from equation 3 that time to reach detector is directly proportional to 
mass of ion i.e., higher mass ions take longer time to reach the detector. As a part of this 
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dissertation study, our samples were analyzed in reflectron mode with a TofSpec 2E 
(Micromass, UK) matrix-assisted laser desorption ionization-time of flight (MALDI-
TOF) mass spectrometer. The mass axis was adjusted with trypsin autohydrolysis peaks 
(m/z 2239.14, 2211.10, or 842.51) as lock masses. 
3.10.9. Database searching 
The peptide mass fingerprints obtained from MS are characteristic of a particular 
protein. The information retrieved by the mass spectrometry, i.e., a list of peptide masses, 
is searched against an online database. The Swissprot database is the widest protein 
sequence database (Hoogland, Sanchez et al., 1999) to which it is possible to submit a 
protein identification request using special “informatics” tools that are freely accessible 
through the internet. As a part of this dissertation research, the MALDI spectra used for 
protein identification from tryptic fragments were searched against the Swissprot protein 
databases using the MASCOT search engine. Peptide mass fingerprinting used the 
assumption that peptides are oxidized at methionine residues, are monoisotopic and 
cysteine residues in peptide are carbamidomethylated (Butterfield and Castegna, 2003; 
Tangpong, Cole et al., 2006a). Up to 1 missed trypsin cleavage was allowed. Window of 
error allowed for matching the peptide mass values was set at mass tolerance of 150 ppm. 
We used the probability-based Mowse score, which indicates the probability that the 
match between the database and a spectrum is a random event to assign a level of 
confidence to the identification of specific proteins from the mass spectra. This 
probability equals 10(−Mowse score/10). Mowse scores greater than 53 were considered 
significant. 
The complete flow chart for proteomics is shown in Figure 3.8 below. 
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Figure 3.8: Diagram showing sequence of events involved in redox proteomics.  
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Chapter 4 
Free radical mediated oxidative stress and toxic side effects in brain induced by the 
anti cancer drug Adriamycin: Insight into chemobrain 
4.1. Overview of the Study 
Adriamycin (ADR) is a chemotherapeutic agent useful in treating various cancers. 
Application of this drug can have serious side effects in various tissues, including brain, 
apart from the known effects such as cardiotoxicity. These effects limit the successful use 
of this drug in treatment of cancer. ADR is quinone-containing anthracycline 
chemotherapeutic and is known to produce reactive oxygen species (ROS) in heart. 
Neurons treated with ADR demonstrate significant protein oxidation and lipid 
peroxidation.  Patients under treatment with this drug often complain of forgetfulness, 
lack of concentration, dizziness (collectively called somnolence or sometimes called 
chemobrain). In this study, we tested the hypothesis that ADR induces oxidative stress in 
brain. Accordingly, we examined the in vivo levels of brain protein oxidation and lipid 
peroxidation induced by i.p. injection of ADR. We also measured levels of the multidrug 
resistance-associated protein (MRP1) in brain isolated from ADR-injected mice. MRP1 
mediates ATP-dependent export of cytotoxic organic anions, glutathione S-conjugates 
and sulphates. The results showed a significant increase in levels of protein oxidation and 
lipid peroxidation and increased expression of MRP1 in brain isolated from mice, 72 hrs 
post i.p injection of ADR. These results are discussed with reference to potential use of 
this redox cycling chemotheraputic agent in the treatment of cancer and its side effects in 
brain. 
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4.2. Introduction 
Free radical mediated oxidative stress has been implicated in many 
neurodegenerative disorders (Butterfield and Kanski, 2001). Reactive oxygen species 
(ROS) lead to protein oxidation (Hensley, Hall et al., 1995; Stadtman and Berlett, 1997), 
lipid peroxidation (Markesbery and Lovell, 1998; Butterfield and Lauderback, 2002), 
DNA and RNA oxidation in brain (Butterfield, Drake et al., 2001) and neuronal 
dysfunction and death. Oxidation of proteins leads to loss of activity of enzymes critical 
for cell functioning, and recently our lab identified some of the critical proteins that are 
oxidized in Alzheimer’s disease (AD), by using proteomics (Castegna, Aksenov et al., 
2002a; Castegna, Aksenov et al., 2002b; Lauderback, Drake et al., 2003). ROS 
generation hence becomes imperative in understanding oxidative stress and oxidative 
stress related disorders.  
Adriamycin (ADR) is a cancer chemotherapeutic useful in treating various 
cancers with especially good potency in the treatment of patients with solid tumors 
(Weiss, Sarosy et al., 1986; Eisenhauer and Vermorken, 1998). ADR is suggested to act 
as an antitumor agent by inhibiting DNA replication and DNA synthesis (Cummings, 
Anderson et al., 1991) by intercalating into grooves of DNA. Another important 
mechanisms of action of ADR involve its interaction with topoisomerase II, which forms 
a DNA-cleavable complex (Chuang and Chuang, 1979; Cheng, Cahill et al., 1992). One 
of the most accepted mechanisms of action of ADR on tumor cells is generation of free 
radicals by enzymatic electron reduction of ADR by variety of oxidase, reductase and 
dehydrogenase (Kappus, 1987; Gutierrez, 2000). However, ADR can have serious side 
effects in various non-involved tissues, including brain, apart from its known cardiotoxic 
59 
effects (Steinherz, Steinherz et al., 1991). These latter effects limit the successful use of 
ADR in cancer treatment. A free radical-mediated mechanism has been proposed to be 
responsible for ADR-induced toxicity in heart (DeAtley, Aksenov et al., 1998). 
Cardiomyocytes treated with ADR lead to significant protein oxidation and lipid 
peroxidation (DeAtley, Aksenov et al., 1998). Free radical scavengers are known to 
reduce this effect (DeAtley, Aksenov et al., 1999). ADR also disrupts the mitochondrial 
electron transport system in heart tissues (Davies, Doroshow et al., 1983; Doroshow, 
1983; Yen, Oberley et al., 1999). Increased expression of manganese superoxide 
dismutase (MnSOD) protects complex I against ADR-induced cardiomyopathy (Yen, 
Oberley et al., 1999). ADR contains a quinone in its structure ( Chapter 2, fig 2.2), and as 
is well known, quinones undergo one-electron reduction to form semiquiones, which are 
free radicals (Handa and Sato, 1975; Gutteridge, 1984).  
4.3. Purpose of the study 
Although there are numerous reports of dizziness, confusion and dementia of 
cognitive faction (somnolence) in patients treated with ADR (Schagen, Hamburger et al., 
2001), little has been reported on oxidative stress in brain due to this drug. Therefore, in 
this study oxidative stress parameters were studied in brain. Protein carbonyl and 3-
nitrotyrosine levels (indices of protein oxidation) and 4-hydroxynonenal levels (index of 
lipid peroxidation) were determined in brain from mice treated with ADR. 
4.4. Experimentals 
4.4.1 Animals 
For the studies, male mice (2-3 months of age), approximately 30 g in size, 
housed in the University of Kentucky Central Animal Facility in 12-h light/dark 
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conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The 
animal protocols were approved by the University of Kentucky Animal Care and Use 
Committee. 
 
4.4.2 Material and Method 
4.4.2.1 Chemicals 
Doxorubicin HCl (ADR) was purchased from Bedford Laboratories.  All other 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless stated otherwise. 
The protein oxidation detection kit was purchased from Intergen (Purchase, NY) and 
primary antibody for HNE, 3NT and the multidrug resistance-associated protein (MRP1) 
was purchased from Chemicon International (Temecula, CA). 
4.4.2.2 Preparation of brain homogenate 
Brains were isolated and dissected following sacrifice by decapitation from mice 
treated i.p. with ADR (20mg/kg body weight), 72 h after injection or from saline treated 
control mice, and placed in lysing buffer containing 4μg/ml leupeptin, 4μg/ml pepstatin, 
5 μg/ml aprotinin, 2mM ethylenediaminetetraacetic acid (EDTA), 2mM ethylene glycol-
bistetraacetic acid (EGTA) and 10mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic 
acid (HEPES), pH 7.4. The dosage and time were chosen based on prior studies (Yen, 
Oberley et al., 1999). The brain was homogenized by 20 passes of a Wheaton tissue 
homogenizer, and the resulting homogenate was centrifuged at 1500g for 10 minutes. The 
pellet (nuclear fraction) was suspended in 1ml PBS. The supernatant was retained and 
centrifuged at 20000g for 10 minutes. The pellet (membrane fraction) was suspended in 
1ml phosphate buffered saline (PBS) containing 0.01% (w/v) sodium azide and 0.2% 
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(v/v) Tween 20 (PBS) and the supernatant (cytosolic fraction) was retained for 
fluorescence studies. All the fractions suspended in PBS were washed twice with PBS at 
32000g for 10 min. The resulting fractions were assayed for protein concentration by the 
Pierce BCA method (Bradford, 1976).  
4.4.2.3. Protein Carbonyls  
As described earlier in chapter 3, protein carbonyls are markers of protein 
oxidation. The method described in section 3.5.1 was used to measure the levels of 
protein carbonyl. Briefly, Samples (5μl) of brain homogenate (membrane fraction), 12% 
sodium dodecyl sulfate (SDS) (5μl), and 10μl of 10 times diluted 2,4-
dinitrophenylhydrazine (DNPH) from 200mM stock were incubated at room temperature 
for 20 min, followed by neutralization with 7.5μl neutralization solution (2M Tris in 30% 
glycerol). This neutralized solution (250ng) was loaded in each well on a nitrocellulose 
membrane under vacuum using a slot blot apparatus. The membrane was blocked in 
blocking buffer (3% bovine serum albumin) in PBS 0.01% (w/v) sodium azide and 0.2% 
(v/v) Tween 20 for 1h and incubated with a 1:100 dilution of anti-DNP polyclonal 
antibody in PBS containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 for 1h. 
The membrane was washed in PBS following primary antibody incubation three times at 
intervals of 5 min each. The membrane was incubated following washing with an anti-
rabbit IgG alkaline phosphatase secondary antibody diluted in PBS in a 1:8000 ratio for 
1h. The membrane was washed for three times in PBS for 5 min and developed in 
Sigmafast tablets, [5-bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium 
substrate (BCIP/NBT substrate)]. Blots were dried, scanned with Adobe Photoshop, and 
quantified with Scion Image (PC version of Macintosh compatible NIH image). 
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4.4.2.4. 3NT 
As described in chapter 2, 3NT are maker of peroxynitrite-mediated tyrosine 
nitration. The method described in chapter 3 section 3.5.2 was used. Briefly, Samples 
(5μl) of brain homogenate (membrane fraction), 12% SDS (5μl), and 5μl of modified 
Laemmli buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) 
glycerol were incubated for 20 min at room temperature and were loaded (250ng) in each 
well on a nitrocellulose membrane in slot blot apparatus under vacuum. The membrane 
was blocked in blocking buffer (3% bovine serum albumin) in PBS containing 0.01% 
(w/v) sodium azide and 0.2% (v/v) Tween 20 for 1h and incubated with a 1: 2000 
dilution of anti-3-nitrotyrosine (3NT) polyclonal antibody in PBS for 1h 30min. The 
membrane was washed in PBS for 5 min three times after incubation. The membrane was 
incubated, following washing with an anti-rabbit IgG alkaline phosphatase secondary 
antibody diluted in PBS in 1:8000 ratios for 1h. The membrane was washed for three 
times in PBS for 5 min and developed in Sigmafast tablets. Blots were dried, scanned 
with Adobe Photoshop, and quantified with Scion Image. 
4.4.2.5. Protein-bound HNE 
As described in chapter 2, HNE are lipid peroxidation products that bind to 
protein by Michael addition and deactivate the protein. Method described in chapter 3 
section 3.6 was used to measure the levels of protein-bound HNE. Briefly, Sample (5μl) 
of brain homogenate (membrane fraction), 12% SDS (5μl), and 5μl of modified Laemmli 
buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) glycerol were 
incubated for 20 min at room temperature and were loaded (250ng) in each well on a 
nitrocellulose membrane in a slot blot apparatus under vacuum. The membrane was 
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blocked in blocking buffer (3% bovine serum albumin) in PBS containing 0.01% (w/v) 
sodium azide and 0.2% (v/v) Tween 20 for 1h and incubated with a 1: 5000 dilution of 
anti-HNE polyclonal antibody in PBS for 1h 30min. The membrane was washed in PBS 
for 5min, three times after incubation. The membrane was incubated, following washing 
with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 
ratios for 1h. The membrane was washed for three times in PBS for 5 min and developed 
in Sigmafast tablets. Blots were dried, scanned with Adobe Photoshop, and quantified 
with Scion Image. 
The specificity was checked for both 3NT and HNE primary antibodies as 
described elsewhere (Sultana, Newman et al., 2004). The sample were treated with 
primary antibody reacted with free HNE and free 3NT. HNE blot showed very faint, non-
specific binding, which was accounted for background. 3NT blot showed no staining on 
blot suggesting that there was no protein bound 3NT (data not shown) signifying the 
specificity of primary antibody. 
4.4.2.6. Western Blot  
As described in chapter 3, section 3.9, western blot is the technique used to 
separate protein based on their molecular weight and identification of expression of 
protein of interest by immunochemical methods. Briefly, samples (100 μg) were 
incubated with sample loading buffer, and protein samples were denatured and 
electrophoresed on a 10% SDS-polyacrylamide gel. Proteins were transferred to a 
nitrocellulose membrane at 90 mA/gel for 2 h. The blots were blocked for 1h in fresh 
wash buffer (10 mM Tris-HCl, pH7.5), 150 mM NaCl, 0.05% Tween 20, pH 7.4, 
containing 3% bovine serum albumin) and incubated with a 1:1000 dilution of anti MRP1 
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monoclonal antibody in phosphate buffered saline containing 0.01% (w/v) sodium azide 
and 0.2% (v/v) Tween 20 (PBS) for 1h. The membrane was washed three times in PBS 
and was incubated for 1 h with an anti-rabbit IgG alkaline phosphatase secondary 
antibody diluted in PBS in a 1:8000 ratio. The membrane was washed for three times in 
PBS for 5 min and developed in Sigma fast tablets (BCIP/NBT substrate). 
In all cases non-specific background labeling by secondary antibody was 
negligible. 
4.4.2.7. Statistical analysis 
A two-tailed Student’s t-test was used to assess statistical significance. P values 
<0.05 were considered significant for comparison between control and experimental data 
sets. 
4.5. Results 
4.5.1. Protein carbonyls 
Protein carbonyls are the most often employed index of protein oxidation 
(Stadtman and Berlett, 1997). Treatment of mice with ADR (i.p.) revealed an increase in 
protein carbonyls in brain. Figure 4.1 shows the protein carbonyl levels in brain 
homogenate extracted from saline-injected mice (control) and brain homogenate 
extracted from mice injected with ADR. There was a significant increase in protein 
carbonyl levels in brain homogenates from ADR-injected mice when compared to control 
(p< 0.001, n=5). 
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Figure 4.1: Increased in vivo protein oxidation in brain isolated from mice 
previously treated with adriamycin (20mg/kg body weight) 72 hours post i.p injection 
compared to brain isolated from saline injected mice. *P< 0. 001, n=5. (434.5 arbitrary 
unit was taken as 100% for control) 
 
4.5.2. 3NT 
Nitration of tyrosine residue is the marker of attack by RNS, such as 
peroxynitrites that may have been formed by free radical mediated oxidative stress (van 
der Vliet, Eiserich et al., 1996; Castegna, Aksenov et al., 2002a; Castegna, Aksenov et 
al., 2002b). Figure 4.2 shows 3-NT levels in brain homogenate from saline-injected mice 
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pr
ot
ei
n 
ca
rb
on
yl
 (%
 C
on
tr
ol
)
0
20
40
60
80
100
120
140
160
180
200
Control
Adriamycin
*
Brain homogenate
66 
significant increase in 3-NT levels in brain homogenate from ADR-injected mice when 
compared to control (p< 0.001, n=5). 
4.5.3. HNE 
Arachidonic acid from phospholipids, on attack of free radicals, produces reactive 
alkenals such as HNE (Lauderback, Hackett et al., 2001). HNE binds to protein and 
inactivates them by changing their conformation (Subramaniam, Roediger et al., 1997; 
Markesbery and Lovell, 1998; Lauderback, Hackett et al., 2001). Figure 4.3 shows the 
protein bound HNE levels in brain homogenate extracted from saline injected mice 
(control) and brain homogenate extracted from mice injected with ADR. There was a 
significant increase in protein bound HNE levels in brain homogenate from ADR-
injected mice when compared to control (p< 0.001, n=5). 
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Figure 4.2: Increased in vivo 3-Nitrotyrosine levels in brain isolated from mice 
previously treated with adriamycin (20mg/kg body weight) 72 hours post i.p.  injection, 
compared to brain isolated from saline injected mice. *P< 0. 001, n=5. (151.67 arbitrary 
unit was taken as 100% for control) 
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Figure 4.3: Increased in vivo protein bound HNE in brain isolated from mice 
previously treated with adriamycin (20mg/kg body weight) 72 hours post i.p. injection, 
compared to brain isolated from saline injected mice. * P<0.001, n=5. (526 arbitrary unit 
was taken as 100% for control) 
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4.5.4. MRP-1 expression 
Glutathione conjugates of ADR are exported from cells via the multi drug 
resistance-associated proein-1 (MRP-1) (Hipfner, Deeley et al., 1999). Oxidative 
modification of MRP-1 would likely lead to accumulation of HNE (Sultana and 
Butterfield, 2004), and in AD brain that is under oxidative stress (Butterfield, Drake et 
al., 2001; Butterfield and Kanski, 2001; Butterfield and Lauderback, 2002), increased 
expression of MRP-1 was observed. Consistent with results in AD brain (Sultana and 
Butterfield, 2004), Figure 4.4 shows that MRP-1 expression is significantly elevated in 
brain from ADR-injected mice (p< 0.05, n=3). 
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Figure 4.4: Plot showing significant increase in MRP1 levels in brain isolated 
from mice injected i.p with adriamycin compared to saline injected control mice. *P< 
0.05, n=3. (272 arbitrary unit was taken as 100% for control). Also shown in the figure is 
a representative western blot showing increased MRP1 expression in brain isolated from 
mice injected with adriamycin. (Data Collected in collaboration with Dr. Rukhsana 
Sultana) 
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4.6. Discussion 
ADR is a commonly used cancer chemotherapeutic agent for various solid 
tumors. This agent is known to cause serious side effects in heart. However, ADR also 
shows side effects in other organs including brain, which has not been studied 
extensively. ADR causes cardiomyopathy or congestive heart failure. Due to the presence 
of quinone in its structure, a free radical hypothesis for ADR-mediated oxidative stress 
and cytotoxicity is widely accepted. In the presence of Fe2+ free radical production 
increases (DeAtley, Aksenov et al., 1998). Fe2+ acts as a catalyst for oxidative stress in 
neurodegenerative disorders (Stadtman and Berlett, 1997; Kienzl, Jellinger et al., 1999). 
An elevated level of iron is seen in several neurodegenerative disorders, including 
Alzheimer’s disease (AD). Others showed that there is accumulation of iron in ADR-
treated myocardial and neoplastic cells, which leads to increase in oxidative stress (Kwok 
and Richardson, 2003). In the presence of an iron chelator the ADR induced oxidative 
stress is reduced in cardiomyocytes (Kalyanaraman, Morehouse et al., 1991; Dorr, 1996).  
Nitric oxide synthase and cytochrome P450 reductase are some of the 
flavoprotein reductases that reportedly activate ADR-dependent redox cycling (Vasquez-
Vivar, Martasek et al., 1997). Since mitochondria are target organelles for ADR-induced 
cytotoxicity in cardiomyocytes (Sarvazyan, 1996; Konorev, Kennedy et al., 1999; Yen, 
Oberley et al., 1999), NADH dehydrogenase, a mitochondrial enzyme, stimulates ADR to 
form semiquinone radical and superoxide anion (Davies and Doroshow, 1986). 
ADR was shown to induce depletion of glutathione (GSH) in heart tissue (Abd 
El-Gawad and El-Sawalhi, 2004). GSH is an endogenous antioxidant that is widely 
present in various tissues (Kotamraju, Konorev et al., 2000). The level of glutathione 
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peroxidase was also known to be reduced by ADR, and ebselen, a glutathione peroxidase 
mimetic, significantly inhibits ADR-induced oxidative stress and apoptosis (Kotamraju, 
Konorev et al., 2000). All these studies provide evidence for a free radical mechanism 
involved in ADR induced cytotoxicity. 
Brain is particularly vulnerable to oxidative stress due to the presence of high 
levels of polyunsaturated fatty acids, relatively low antioxidant capacity, the presence of 
redox metal ions, and high oxygen utilization (Stadtman and Berlett, 1997). The free 
radicals generated in the brain cause damage to proteins, lipids and DNA and 
subsequently lead to cellular dysfunction or cell death (Yu, 1994; Butterfield, Drake et 
al., 2001; Butterfield and Lauderback, 2002; Castegna, Aksenov et al., 2002a; Castegna, 
Aksenov et al., 2002b). Oxidative stress induced by ADR in brain could lead to damage 
to proteins critical for cell functioning and may also lead to cell death. Involvement of the 
central nervous system in patients treated with ADR was previously shown (Abali and 
Celik, 2002). These authors found that patients under treatment with ADR often complain 
of forgetfulness, lack of concentration and dizziness (collectively called somnolence). We 
demonstrated that ADR increases oxidative stress and causes cell death in neuronal cell 
culture (Vide infra). The data presented in this paper shows that ADR in vivo causes 
oxidative damage to brain tissue. 
Previously we reported oxidized proteins in AD are critical for some vital 
functions (Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002; Castegna, 
Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; Lauderback, Drake et al., 2003). 
The results shown in our in vivo study are consistent with our in vitro results, showing 
that ADR acts as an oxidant. In the present study there was a significant increase in 
73 
protein carbonyl formation and 3-NT levels, markers of protein oxidation and RNS attack 
on tyrosine residues of protein, and in HNE, a marker of lipid peroxidation, in brain 
homogenates isolated from ADR-injected mice.    
ADR increases superoxide production and enhances formation of nitric oxide 
(Vasquez-Vivar, Hogg et al., 1999). As a consequence, the balance between superoxide 
and nitric oxide shifts and could lead to formation of peroxynitrite (van der Vliet, 
Eiserich et al., 1996; Vasquez-Vivar, Hogg et al., 1999), from which 3-NT can arise 
(Lauderback, Drake et al., 2003). We have seen a significant increase in 3-NT levels in 
brain homogenate from ADR-treated mice when compared to those from control mice. 
This could be due to reaction of peroxynitrite with tyrosine residues on polypeptide 
chains. The resulting nitration changes protein conformation (Koppal, Drake et al., 
1999b) and, consequently, alters their function (Lauderback, Drake et al., 2003).  
Lipid peroxidation products such as HNE and acrolein are known to be elevated 
in brain under oxidative stress in various diseased conditions, including AD (Sayre, 
Zelasko et al., 1997; Markesbery and Lovell, 1998; Butterfield, Drake et al., 2001; 
Lauderback, Hackett et al., 2001; Butterfield and Lauderback, 2002). These alkenals react 
with GSH (Lovell, Xie et al., 1998; Xie, Lovell et al., 1998), and are also known to be 
involved in apoptosis, which is correlated with GSH depletion (Mark, Lovell et al., 
1997). In the current study there was a significant increase in protein bound HNE levels 
in brain homogenate isolated from ADR-injected mice. 
MRP1 is one of the 9-multidrug resistance proteins belonging to the ATP-binding 
cassette (ABC) transporter family (Nies, Jedlitschky et al., 2004). MRP1 is an integral 
plasma membrane protein, which mediates ATP-dependent export of cytotoxic organic 
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anions, glutathione S-conjugates and sulphates (Jedlitschky, Leier et al., 1994; 
Jedlitschky and Keppler, 2002). MRP1 is expressed in various human tumors. Oxidized 
glutathione (GSSG) has been recognized as a co-substrate for MRP1 (Loe, Almquist et 
al., 1996; Loe, Deeley et al., 2000). Translocation of therapeutic drugs into and out of the 
CNS mediated by MRP1 has been shown (Huai-Yun, Secrest et al., 1998; Rao, 
Dahlheimer et al., 1999), and others have reported expression of MRP1 in cultured 
astroglial cells (Decleves, Regina et al., 2000). Involvement of MRP1 in the release of 
GSSG from brain astrocytes under oxidative stress has also been reported (Hirrlinger, 
Konig et al., 2001). These studies suggest that MRP1 expression is altered during 
oxidative stress conditions. Consistent with this suggestion, we reported increased 
expression of MRP-1 in AD brain (Sultana and Butterfield, 2004), which is under 
oxidative stress (Stadtman and Berlett, 1997; Markesbery and Lovell, 1998; Butterfield, 
Drake et al., 2001; Butterfield and Kanski, 2001; Butterfield and Lauderback, 2002; 
Castegna, Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b). 
Studies have shown that MRP1 does not directly transport chemotherapeutic 
agents such as ADR (Hipfner, Deeley et al., 1999). However, its not clear whether 
glutathione is either co-transported as a GS-conjugate with ADR or activates MRP1 for 
ADR transport (Priebe, Krawczyk et al., 1998; Hipfner, Deeley et al., 1999).  
In the current study, we observed a significant increase in the levels of MRP1 in 
brain isolated from ADR-injected mice compared to the level of MRP1 in brain isolated 
from saline injected control mice. The increased expression could be due to increase in 
GSSG because of oxidative stress caused by ADR. Since the mechanism of action of 
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MRP1 is not clear yet, the increased expression could also be result of increased GS-
conjugate of ADR, which is transported out of brain with the help of MRP1. 
Patients under prolonged treatment with ADR show symptoms of forgetfulness, 
dizziness and loss of memory, a phenomenon commonly called chemobrain (Abali and 
Celik, 2002). ADR leads to post-chemotherapeutics problems in children. Often, the 
symptoms are noticed approximately 10 yrs after treatment. Our current in vivo studies 
show that ADR acts as an oxidant in brain. Our data suggest that ADR or its metabolites 
likely enter the brain and cause oxidative stress, which may contribute to chemobrain. 
Further studies are necessary to find the oxidative stress mechanism induced by ADR, 
which will help in designing therapeutics to reduce the side effects of such anti-cancer 
drugs in tissues, including chemobrain. 
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Chapter 5 
Alteration in glutathione level and glutathione-related enzyme expression and 
activity in brain induced by the anti-cancer drug Adriamycin: Implications for 
oxidative stress-mediated CNS toxicity 
5.1. Overview of study: 
Adriamycin (ADR), a chemotherapeutic agent useful in treating solid cancers, has 
side effects in various tissues, including brain, apart from its known effects in heart. 
These side effects limit the successful use of this drug in treatment of cancer. This 
quinone-containing anthracycline chemotherapeutic is known to produce reactive oxygen 
species (ROS) in heart. One of the common observations in patients under long-term 
treatment with ADR is somnolence, often termed as chemobrain by patients. Previously 
our laboratory has shown significant ADR-induced protein oxidation and lipid 
peroxidation in cultured neurons and brain, in vitro and in vivo, respectively. ADR-
injected mice also showed an increase in MRP-1 levels, a protein that mediates export of 
cytotoxic organic anions, glutathione S-conjugates and sulphates. Although, ADR doesn’t 
cross blood brain barrier, we recently showed that the toxicity in the central nervous 
system (CNS) induced by ADR is mediated by tumor necrosis factor α (TNF- α). Given 
the oxidative stress in brain induced in vivo by ADR, in the current study we measured 
the levels of brain glutathione (GSH), a major thiol antioxidant, in ADR-injected mice 
brain. Accordingly, we examined the in vivo levels of GSH-related enzyme expression 
and activity induced by i.p. injection of ADR. The results showed a significantly 
decreased total GSH levels, increased levels of glutathione peroxidase (GPx), 
glutathione-S-transferase (GST) and glutathione reductase (GR) and an increased activity 
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of GPx and GST, but a significant reduction in GR activity in brain isolated from mice, 
72 hrs post i.p injection of ADR (20 mg/kg). These results are consistent with brain-
resident oxidative stress observed in ADR treated mice and consistent with the hypothesis 
that in vivo administration of ADR causes alterations in antioxidant capacity in brain. 
Sequelae of ADR may be the cause of chemobrain observed in the patients treated with 
this redox cycling chemotherapeutic agent. The results suggest that a potential therapeutic 
intervention towards increasing the antioxidant capacity in brain might alleviate the side 
effects in brain. 
5.2. Introduction 
Free radical-mediated oxidative stress has been implicated in many 
neurodegenerative disorders (Hensley, Hall et al., 1995; Stadtman and Berlett, 1997; 
Markesbery and Lovell, 1998; Butterfield, Drake et al., 2001; Butterfield and 
Lauderback, 2002). Reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
produced as a consequence to oxidative stress leads to a significant protein oxidation 
(Hensley, Hall et al., 1995; Stadtman and Berlett, 1997), lipid peroxidation (Markesbery 
and Lovell, 1998; Butterfield and Lauderback, 2002) and DNA and RNA oxidation 
(Butterfield, Drake et al., 2001).  
Glutathione (GSH) is a major tripeptide intracellular antioxidant present 
ubiquitously in the range of 1-3mM throughout the brain (Cooper, 1997), acting as a high 
capacity detoxification agent. GSH maintains the cellular redox balance and is involved 
in various biosynthetic processes as well (Schulz, Lindenau et al., 2000). The level of 
GSH is reduced in specific regions of the central nervous system in various 
neurodegenerative disorders and concomitant increase in oxidized glutathione (GSSG) 
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levels contributes to the oxidative stress-mediated neuronal cell dysfunction and/or loss 
in these disorders (Benzi and Moretti, 1995a; Cooper, 1997). GSH, in conjugation with 
glutathione reductase (GR), glutathione peroxidase (GPx), glutathione-S-transferase 
(GST) and NADPH provide protection against various toxic electrophiles and hydrogen 
peroxide (Watson, Chen et al., 2003). GST-mediated glutathione-S conjugates are further 
acted upon by multi drug resistant protein-1 (MRP-1), an ATP-binding cassette (ABC) 
transporter family protein (Nies, Jedlitschky et al., 2004), for their export out of the cell 
in an ATP-dependent manner (Sultana and Butterfield, 2004). 
Adriamycin (ADR) is a quinone containing cancer chemotherapeutic agent used 
to treat various solid tumors. ADR intercalates itself into the grooves of DNA and 
inhibits its replication and synthesis (Cummings, Anderson et al., 1991). Although there 
are various other mechanism of action of this drug described in literature, enzymatic free 
radical generation by action of a variety of oxidases, reductases and dehydrogenases on 
ADR is widely accepted (Kappus, 1987; Gutierrez, 2000) and could be contributing 
factor towards its toxicity. The quinone in ADR undergoes one electron reduction to 
produce a semiquinone, which is a free radical itself, and in the presence of oxygen it 
generates superoxide radical and converts itself back to quinone, a process called redox 
cycling (Handa and Sato, 1975; Gutteridge, 1984). This property of ADR may be 
responsible for its serious side effects in heart. A free radical mediated protein oxidation 
and lipid peroxidation has been reported in cardiomyocytes treated with ADR (DeAtley, 
Aksenov et al., 1998). Apart from cardiomyopathy, patients under long term treatment 
with ADR have complained of dizziness, forgetfulness and lack of concentration 
(somnolence) (Meyers, 2000; Schagen, Hamburger et al., 2001; Freeman and Broshek, 
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2002). Recently, we showed that systemic administration of ADR induces brain TNF 
accumulation, causes neuronal mitochondrial dysfunction and may be responsible for 
consequent CNS injury (Tangpong, Cole et al., 2006b). Although the biochemical basis 
for ADR-mediated cognitive imbalance is not very well established, ADR is known to 
cause increased protein oxidation and lipid peroxidation along with increased MRP-1 
expression in brain isolated from ADR-injected mice (Joshi, Sultana et al., 2005b). ADR 
cannot cross the blood brain barrier (Bigotte, Arvidson et al., 1982a; Bigotte, Arvidson et 
al., 1982b; Tangpong, Cole et al., 2006b) hence, the side effects could be due to ADR-
mediated TNF-α production via activation of glia, which can further lead to increased 
ROS and RNS.  
In recent years, GSH and other cellular antioxidant enzyme systems have been 
studied with reference to redox signaling mechanisms that function in cell regulation and 
growth control. Among others, one such antioxidant enzyme system is superoxide 
dismutase (SOD). The primary function of SOD is to convert superoxide radicals to 
hydrogen peroxide, which is subsequently converted to water and oxygen by action of 
GPx and/or catalase. Increased expression of certain SOD has shown to be protective 
against oxidative stress in many disease models (Yen, Oberley et al., 1999). Based on 
these studies we tested the hypothesis that in vivo administration of ADR modulates the 
GSH antioxidant defense mechanism. 
The present study was designed to look at the effect of in vivo administration of 
ADR on certain antioxidant enzyme systems with prime focus on modulation of GSH and 
its related enzyme expression and activities. The results shown here are discussed with 
reference to chemobrain induced by free radical-mediated oxidative stress by ADR. 
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5.3. Experimentals 
5.3.1. Animals 
For the studies, male B6C3 mice (2-3 months of age), approximately 30 g in size, 
housed in the University of Kentucky Central Animal Facility in 12-h light/dark 
conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The 
animal protocols were approved by the University of Kentucky Animal Care and Use 
Committee.  
5.3.2. Chemicals 
Doxorubicin HCl (ADR) was purchased from Bedford Laboratories.  All other 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless stated otherwise. 
The primary antibody for GST and GPx were purchased from Chemicon International 
(Temecula, CA). The primary antibody for GR was purchased from Abcam, Inc 
(Cambridge, MA). Sodium dodecyl sulfate (SDS) polyacrylamide gels (12.5%) and 
transfer membranes were purchased from Biorad (Hercules, CA). The GSH assay kit was 
purchased from Cayman chemicals (Ann Arbor, MI). 
5.3.3 Preparation of brain homogenate 
Brains were isolated and dissected following sacrifice by decapitation from mice 
injected intraperitoneally (i.p.) with ADR (20mg/kg body weight), 72 h post i.p. injection, 
or from saline treated control mice, and placed in ice cold lysing buffer containing 
4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml aprotinin, 2mM ethylenediaminetetraacetic 
acid (EDTA), 2mM ethylene glycol-bistetraacetic acid (EGTA) and 10mM 4-(2-
hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), pH 7.4. The dosage of ADR 
and time used were chosen based on prior studies (Joshi, Sultana et al., 2005b). The brain 
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was homogenized by 20 passes of a Wheaton tissue homogenizer, and the resulting 
homogenate was centrifuged at 1500g for 10 minutes. The pellet (nuclear fraction) was 
suspended in 1ml phosphate buffered saline (PBS) containing 0.01% (w/v) sodium azide 
and 0.2% (v/v) Tween 20. The supernatant was retained and centrifuged at 20000g for 10 
minutes. The pellet (membrane fraction) was suspended in 1ml PBS and the supernatant 
(cytosolic fraction) was retained for fluorescence studies, GSH measurement and enzyme 
activities. All the fractions suspended in PBS were washed twice with PBS at 32000g for 
10 min. The resulting fractions were assayed for protein concentration by the Pierce BCA 
method (Bradford, 1976). 
5.3.4. GSH assay 
The supernatant obtained from homogenate was deproteinated with 10% meta 
phosphoric acid. The subsequent deproteinated supernatant was treated with 4M 
triethanolmalamine (TEAM) solution. Following TEAM treatment, the GSH assay kit 
was used according to the manufacturer’s direction to assay total GSH. 
5.3.5. Western blots 
Samples (100 μg) were incubated with sample loading buffer, and protein 
samples were denatured and electrophoresed on a 12.5% SDS-polyacrylamide gel. 
Proteins were transferred to a nitrocellulose membrane at 90 mA/gel for 2 h. The blots 
were blocked for 1h in fresh wash buffer (10 mM Tris-HCl, pH7.5), 150 mM NaCl, 
0.05% Tween 20, pH 7.4, containing 3% bovine serum albumin) and incubated with a 
1:1000 dilution of the respective anti GST, GPx and GR monoclonal antibody in 
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 
(PBS) for 1h. The membrane was washed three times in PBS and was incubated for 1 h 
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with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 
ratio. The membrane was washed for three times in PBS for 5 min and developed in 
Sigma fast tablets (BCIP/NBT substrate). 
In all cases non-specific background labeling by secondary antibody was 
negligible. 
5.3.6. Enzyme activity assays 
5.3.6.1. Estimation of glutathione-S-transferase activity 
GST (EC 2.5.1.18) activity was measured using a reaction mixture consisting of 
0.1 M phosphate buffer (pH 6.5), 1.0 mM reduced glutathione, 1.0 mM CDNB and 
1mg/ml of supernatant protein (Habig, Pabst et al., 1974). The changes in absorbance 
were recorded at 340 nm in a 96 well microtiter plate, and the enzymatic activity was 
calculated as nmol of CDNB conjugate formed min− 1 mg− 1 protein. 
5.3.6.2. Estimation of glutathione peroxidase activity 
GPx (EC 1.11.1.9) was measured using a reaction mixture consisting of 0.2 mM 
H2O2, 1.0 mM GSH, 0.14 U of glutathione reductase (GR), 1.5 mM NADPH, 1.0 mM 
sodium azide and 0.1M phosphate buffer (pH 7.4) and 1mg/ml of supernatant protein 
(Wheeler, Salzman et al., 1990). The changes in absorbance were recorded at 340 nm in a 
96 well microtiter plate and enzyme activity was calculated as nmol of NADPH oxidized 
min− 1 mg− 1 protein.  
5.3.6.3. Estimation of glutathione reductase activity 
The GR (EC 1.6.4.2) activity assay reaction mixture consisted of 0.1 M phosphate 
buffer (pH 7.6), 0.5 mM EDTA, 1.0 mM oxidized glutathione, 0.1 mM NADPH and 
1mg/ml of supernatant protein in a total volume of 200 μl (Carlberg and Mannervik, 
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1985). The enzyme activity was assayed in a 96-well plate reader by measuring the 
disappearance of NADPH at 340 nm and was calculated as nmol of NADPH oxidized 
min− 1 mg− 1 protein. 
5.3.6.4. Estimation of total SOD activity 
SOD (EC 1.15.1.1) activity assay reaction consisted of 50 mmol/l glycine buffer, 
pH 10.4, and 1mg/ml supernatant protein. The reaction was initiated by the addition of 20 
mg/ml solution of (–)-epinephrine and absorbance was measured at 480 nm (Stevens, 
Obrosova et al., 2000). SOD activity was expressed as nmol of (–)-epinephrine protected 
from oxidation min− 1 mg− 1 protein. 
5.4. Statistical analysis 
A two-tailed Student’s t-test was used to assess statistical significance. P values 
<0.05 were considered significant for comparison between control and experimental data 
sets. 
5.5. Results 
5.5.1. GSH assay 
GSH levels in a system are an indication of its cellular redox balance. A more 
reduced to oxidized ratio is indication of healthy state, whereas a reduction in total GSH 
levels may be an indication of redox imbalance or oxidative stress (Watson, Chen et al., 
2003).  Figure 5.1 shows a significantly reduced GSH level in brain isolated from ADR-
injected mice when compared to saline-injected control (p < 0.05, n = 5). 
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Figure 5.1: Brain total GSH level in saline-injected and ADR-injected mice, 72 h 
post i.p. injections. A significant reduction in GSH level is seen in brain isolated from 
ADR-injected mice when compared to control. * p < 0.05, n = 5. The data are presented 
as mean ± SEM expressed as percentage of control. 
 
5.5.2. Western blot analysis 
Figure 5.2 shows the western blots and representative plots of GST, GPx and GR 
in brain isolated from mice injected i.p. with saline or ADR. GAPDH is used as a loading 
control. Plots of normalized entity of each enzyme are shown in figure 5.3. As evident 
from the figures, a significant increased expression of GST, GPx and GR in brain isolated 
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from ADR-injected mice when compared to saline-injected control is observed (p < 0.05, 
n = 5).  
 
 
GPx 
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GR 
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Control                                     ADR 
Figure 5.2: Representative Western blots of brain GPx, GST and GR 72 h post 
i.p. injection of saline or ADR in mice. GAPDH is used as a loading control. 
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Figure 5.3: Representative plot of GST, GPx and GR levels in saline-injected and 
ADR-injected mice brain, 72 h post i.p. injections. A significant increase in GST, GPx 
and GR level is seen in ADR-injected mice brain when compared to control. * p < 0.05, n 
= 5. The data are presented as mean ± SEM expressed as percentage of control. 
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5.5.3. Enzyme activities 
Table 5.1 shows the activity of GSH related enzymes GST, GPx and GR along 
with the activity of total SOD. There was a significant increase in activity of GPx, 
whereas a significantly reduced activities of GST, GR and SOD in brain isolated from 
ADR-injected mice when compared to saline-injected control (p < 0.05, n = 5 in each 
case). 
 
Enzyme Brain from saline-
injected Group 
Brain from ADR-
injected Group 
GST (nmol CDNB 
conjugate formed 
min−1 mg−1 protein) 
15.6 ± 0.3 
 
12.1 ± 0.3 * 
GPx (nmol NADPH 
oxidized min−1 mg−1 
protein) 
83.7 ± 0.8 
 
 96.9 ± 0.7 * 
GR (nmol NADPH 
oxidized min−1 mg−1 
protein) 
34.9 ± 1.6 
 
27.16 ± 2.0 * 
SOD (nmol of (–)-
epinephrine protected from 
oxidation min− 1 mg− 1 
protein. 
9.4 ± 1.6 
 
7.1 ± 3.1 *  
 
 
Table 5.1: GSH-related enzymes and SOD activity in brain homogenate obtained 
from mice, 72 h post i.p. injection of saline (control) or ADR. The data are presented as 
mean ± SEM (n=5), * p < 0.05. 
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5.6. Discussion 
GSH is the major non-protein thiol antioxidant used in the redox balance of cells 
and cellular environments. Any kind of imbalance in the ratio of reduced to oxidized 
GSH may both index and cause oxidative stress that leads to significant protein oxidation 
and lipid peroxidation. GSH is known to protect against cellular free radical-mediated 
oxidative damage by functioning as an oxyradical scavenger thereby reducing lipid 
peroxidation (Meister, 1995; Darley-Usmar and Halliwell, 1996; Sies, 1999; Schulz, 
Lindenau et al., 2000; Hansen, Go et al., 2006). GSH, apart from its endogenous 
antioxidant activity, also has role in wide range of metabolic processes such as activation 
of transcription factors, DNA repair, enzyme activity regulation and biosynthetic 
processes (Meister and Anderson, 1983).  
The nervous system is particularly susceptible to oxidative insults because of high 
level of polyunsaturated fatty acids, high oxygen consumption and low antioxidant 
capacity. Hence, the brain is dependent on glutathione defense mechanism as a primary 
endogenous neuroprotectant. GSH helps neurons in detoxification of HNE and other 
reactive alkenals and damage by peroxynitrite (Mark, Lovell et al., 1997; Koppal, Drake 
et al., 1999a). HNE, acrolein and other lipid peroxidation product are known to cause 
damage to proteins and other biomolecules in AD brain (Sayre, Zelasko et al., 1997; 
Lovell, Xie et al., 1998; Lauderback, Hackett et al., 2001). These alkenals form an 
immediate substrate for GSH (Xie, Lovell et al., 1998) consequently, GSH depletion may 
lead to apoptosis initiated by lipid peroxidation products (Mark, Lovell et al., 1997). In 
the current study, reduced level of brain GSH was found in ADR-injected mice when 
compared to saline-injected control (Fig. 5.1). We previously reported an increased 
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protein carbonyls, HNE and 3NT levels in brain isolated from ADR-injected mice (Joshi, 
Sultana et al., 2005b). We hypothesized that a reduced level of GSH play a role in the 
observed brain protein oxidation and increased reactive alkenal in ADR-injected mice.  
Oxygen is the terminal acceptor of electrons in the electron transport chain that 
subsequently produces superoxide radical. Superoxide radicals are formed by action of 
enzyme NADPH oxidase (NOX) on oxygen (Babior, 1999). Superoxide radicals are also 
increased by ADR that enhances production of NO (Vasquez-Vivar, Hogg et al., 1999). 
SOD catalyses the dismutation of superoxide free radicals to form H2O2. GPx and GR 
provide protection to neurons from oxidative stress at the expense of GSH (Sies, 1999; 
Hansen, Go et al., 2006). GPx converts the H2O2 to H2O and O2. The reducing electrons 
are provided by GSH which is converted to its disulfide GSSG. GR converts GSSG back 
to reduced GSH by utilizing NADPH as a cofactor. NADPH also reduces peroxynitrite, 
thereby providing enzymatic defense against peroxynitrite (Sies, Sharov et al., 1997). 
GST play a role in neuroprotection by catalyzing the conjugation of GSH to HNE, a lipid 
peroxidation product, and, formation of other glutathione-S conjugates with various toxic 
electrophiles. These conjugates are then cleared from neurons by the action of the MRP-1 
(Sultana and Butterfield, 2004). Both GST and MRP-1 are oxidatively modified and 
likely dysfunctional in AD brain (Sultana and Butterfield, 2004). We previously reported 
increased expression of brain MRP-1 in ADR-injected mice (Joshi, Sultana et al., 2005b). 
In the present study we found a significantly increased expression of GST, GPx and GR 
(Fig 5.2 and 5.3). Although increased protein expression is not always indicative of the 
activity of these enzymes, the activity of GST, GR and SOD in brain isolated from ADR-
injected mice is significantly decreased whereas a significant elevated activity of GPx is 
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observed. A reduced activity in GR may result in increased GSSG levels, thereby altering 
the GSG/GSSG ratio towards more oxidized form, leading to oxidative stress. A reduced 
GST activity would lead to less clearance of toxic substances, which may contribute to 
the observed increased protein-bound HNE levels in brain from ADR-injected mice.  A 
reduced SOD activity leads to an increase in superoxide radical levels. Superoxide 
radical, H2O2 and NO can react directly or indirectly with each other and produce several 
other toxic ROS and RNS (Halliwell and Gutteridge, 1999), which may contribute to the 
oxidative stress observed. 
In vivo ADR induces TNF-α production, and circulating TNF-α in brain triggers 
apoptotic pathways along with production of ROS/RNS. A neutralizing antibody against 
TNF eliminates these effects (Tangpong, Cole et al., 2006b). Injection of ADR causes 
significant increase in protein oxidation and lipid peroxidation (Joshi, Sultana et al., 
2005b). The observed elevated oxidative stress could be either a cause or consequence of 
glutathione depletion and alteration in various antioxidant enzyme defense systems and 
TNF-mediated processes. Cognitive dysfunction in patients undergoing chemotherapy is 
elevated (Meyers, 2000; Schagen, Hamburger et al., 2001; Freeman and Broshek, 2002). 
We suggest that oxidative stress in brain could contribute to somnolence observed in 
some patients undergoing ADR or other chemotherapy. The current study is the first to 
show the role of GSH in ADR-mediated chemobrain. The results suggest that increment 
in brain GSH levels and the activity of its dependent enzymes (GST, GPx and GR) could 
be a potential therapeutic approach towards eliminating the observed cognitive 
impairment in patients undergoing chemotherapy. Studies to determine if such an 
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approach to prevent chemobrain may be useful, without compromising the 
chemotherapeutic properties of ADR are in progress. 
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Chapter 6 
Proteomic identification of differentially expressed proteins and redox proteomic 
identification of specifically oxidized proteins in brain isolated from adriamycin-
injected mice: Potential targets for therapeutics. 
6.1. Overview of study 
The central nervous system (CNS) toxicity mediated by the anti-cancer drug 
adriamycin (ADR) has gained considerable importance recently. ADR is a 
chemotherapeutic agent used in treatment of solid tumors. Its toxic side effects in heart 
and brain limit successful use of this drug in treating cancer. Many patients report 
symptoms of somnolence (Chemobrain) following ADR therapy. Systemic 
administration of ADR leads to significant protein oxidation, lipid peroxidation and 
glutathione (GSH) depletion along with alteration in GSH dependent enzyme activities in 
brain. The observed protein oxidation and lipid peroxidation was reduced by in vivo 
administration of GSH precursor, γ-glutamyl cysteine ethyl ester (GCEE). Intra-
peritoneal (i.p.) injection of ADR induces production of tumor necrosis factor-α (TNF- α) 
and causes mitochondrial dysfunction, leading to apoptosis in brain. Inducible nitric 
oxide synthase is involved in ADR-mediated CNS injury, since brain mitochondria 
isolated from iNOS knock-out mice previously treated with ADR are not dysfunctional 
when compared to mitochondria isolated from ADR-injected wild type mice. ADR does 
not cross the blood brain barrier (BBB), but ADR-induced cognitive dysfunction by 
cytokine-mediated pathways appear prominent. Free radical-mediated oxidative stress 
caused by ADR damages biomolecules such as proteins and membrane lipids, which 
might lead to neuronal loss followed by cognitive impairment. These damaged 
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biomolecules lead to antioxidant depletion, mitochondrial dysfunction and loss of 
function of important metabolic protein. Although ADR-induced CNS toxicity and 
chemobrain are increasingly recognized, the biochemical basis behind these effects is not 
clear yet. The current study was aimed at using expression proteomics followed by 
parallel redox proteomics for unbiased identification of brain proteins that are 
differentially expressed or specifically oxidized. The results are discussed with reference 
to ADR-mediated CNS toxicity, cognitive dysfunction and chemobrain. 
6.2. Introduction 
Free radical-mediated oxidative stress has been implicated in many 
neurodegenerative conditions. Impaired function of central nervous system (CNS) and its 
toxicity is caused, in part, by free radical-mediated protein oxidation (Stadtman and 
Berlett, 1997; Butterfield and Kanski, 2001), lipid peroxidation (Markesbery and Lovell, 
1998), DNA/RNA oxidation (Wang, Xiong et al., 2005) and neuronal dysfunction or 
death. In most of the neurodegenerative conditions, free radicals react with brain 
biomolecules such as proteins and lipids, resulting in cognitive decline (Butterfield and 
Lauderback, 2002). Mitochondria, in particular, play an important role in free radical 
generation. Mitochondrial dysfunction along with damaged mitochondrial enzymes lead 
to increased free radical generation and increased oxidative stress (Miquel, Economos et 
al., 1980). Although mitochondria are a source of free radicals, they also become 
immediate targets for free radical-mediate oxidative stress thereby, causing energy 
metabolism dysfunction along with triggering apoptotic signals, leading to neuronal death 
(Ventura, Genova et al., 2002; Sastre, Pallardo et al., 2003).  
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Adriamycin (ADR), a cancer chemotherapeutic drug used in treating various solid 
tumors in breast and lung cancer, has shown various side effects in heart and brain. Apart 
from its known mechanism of action of intercalating itself into the grooves of DNA and 
inhibiting DNA replication (Cummings, Anderson et al., 1991), a free radical-mediated 
mechanism of toxicity involving enzymatic electron reduction of ADR by variety of 
oxidases, reductases and dehydrogenases, is widely accepted (Kappus, 1987; Gutierrez, 
2000). The quinone-containing ADR is known to cause cardiomyopathy, a serious side 
effect that limits its successful use in treating cancer (Steinherz, Steinherz et al., 1991). 
Cardiomyocytes treated with ADR show significant protein oxidation and lipid 
peroxidation, and antioxidants are known to prevent these effects (DeAtley, Aksenov et 
al., 1998; DeAtley, Aksenov et al., 1999). Apart from its known side effects in heart, 
ADR also induces cognitive decline (chemobrain) in many patients, often lasting years 
following treatment with this drug (Meyers, 2000; Schagen, Hamburger et al., 2001). 
ADR does not cross the blood brain barrier (BBB) (Bigotte, Arvidson et al., 1982a; 
Bigotte, Arvidson et al., 1982b). In vivo ADR causes significant elevation in markers of 
protein oxidation and lipid peroxidation and increased expression of multidrug resistant 
protein-1 (MRP-1) in brain (Joshi, Sultana et al., 2005b). ADR also causes glutathione 
(GSH) depletion and alteration in expression and activities of various GSH related 
enzymes in brain (Joshi, Sultana et al., 2006). In vivo delivery of GSH precursor, γ-
glutamyl cysteine ethyl ester (GCEE), modulated brain oxidative stress induced by ADR 
(Joshi, Hardas et al., 2006).  
Involvement of mitochondria and mitochondrial enzymes has been reported in 
ADR mediated toxicity in heart and brain (Yen, Oberley et al., 1999; Tangpong, Cole et 
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al., 2006a; Tangpong, Cole et al., 2006b). Manganese superoxide dismutase (MnSOD), a 
key mitochondrial enzyme is involved in catalyzing the dismutation of superoxide 
radicals to hydrogen peroxide. Increased expression of MnSOD protects mitochondrial 
complex 1 against ADR-induced cardiomyopathy (Yen, Oberley et al., 1999). We 
recently showed that systemic administration of ADR caused mitochondrial dysfunction 
in brain by inducing tumor necrosis factor-α (TNF- α), which leads to various apoptotic 
pathways (Tangpong, Cole et al., 2006b). Inducible nitric oxide synthase, leads to NO, 
plays a significant role in ADR-induced CNS toxicity, since iNOS knock-out mice 
treated with ADR show no brain mitochondrial dysfunction (Tangpong, Cole et al., 
2006a). An antibody against TNF prevented the mitochondrial dysfunction and apoptosis 
mediated by ADR in vivo (Tangpong, Cole et al., 2006a; Tangpong, Cole et al., 2006b). 
Based on these previous studies, we hypothesized that in vivo ADR cause oxidative stress 
in brain and ADR-mediated CNS toxicity is involved in chemobrain and subsequent 
cognitive decline in patients treated with this drug. 
6.3. Purpose of the study 
Recently, proteomics along with advances in bioinformatics tools has lead to the 
identification, characterization and sequencing of proteins in various organisms, 
including humans. Using redox proteomics (Dalle-Donne, Scaloni et al., 2006) our 
laboratory has shown many key proteins that are oxidized or differentially expressed in 
various neurodegenerative conditions or models thereof, such as Alzheimer’s disease 
(AD) (Butterfield and Boyd-Kimball, 2004; Tangpong, Cole et al., 2006a), ageing (Poon, 
Calabrese et al., 2006), amylotropic lateral sclerosis (ALS) (Poon, Hensley et al., 2005), 
Parkinson’s disease (PD) (Poon, Frasier et al., 2005), mild cognitive impairment (MCI) 
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(Butterfield, Poon et al., 2006) among others. Although it is clear that in vivo ADR 
increases protein oxidation in brain, it is not clear which specific brain proteins show 
increased oxidative damage. In the current study we used 2-dimensional gel 
electrophoresis (2DE) coupled with mass spectrometric analysis (expression proteomics) 
to identify proteins that are differentially expressed and 2DE followed by western blot 
coupled with mass spectrometric analysis (redox proteomics) to identify proteins that are 
oxidized in brain isolated from mice i.p injected with ADR.  
6.4. Experimentals 
6.4.1. Chemicals 
All the chemicals used were purchased from Sigma-Aldrich (St. Louis, MO), 
unless stated otherwise. Doxorubicin HCl (ADR) was purchased from Bedford 
Laboratories.  All the 2DE gels, stains, buffers and Western blot material were purchased 
from Bio-Rad (Hercules, CA). The protein oxidation detection kit was purchased from 
Intergen (Purchase, NY). Trypsin was purchased from Promega (Madison, WI). 
6.4.2. Animals 
For the studies, male mice (2-3 months of age), approximately 30 g in size, 
housed in the University of Kentucky Central Animal Facility in 12-h light/dark 
conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The 
animal protocols were approved by the University of Kentucky Animal Care and Use 
Committee. The animals were divided into 2 groups. One group received saline and other 
group received ADR (20mg/kg body weight). 72 h post i.p. injection the mice were 
sacrificed, brains were isolated and flash frozen in liquid nitrogen till further studies. The 
dosage and time were chosen based on prior studies (Joshi, Sultana et al., 2005b). 
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6.4.3. Preparation of brain homogenate 
Brains obtained from mice were thawed and placed in lysing buffer containing 
4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml aprotinin, 2mM ethylenediaminetetraacetic 
acid (EDTA), 2mM ethylene glycol-bistetraacetic acid (EGTA) and 10mM 4-(2-
hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), pH 7.4 and homogenized by 
20 passes of a Wheaton tissue homogenizer. The resulting homogenate was centrifuged at 
15,800g for 10 min to remove debris. The supernatant was retained and suspended in 
PBS after washing twice with PBS at 32000g for 10 min. The resulting fractions were 
assayed for protein concentration by the Pierce BCA method (Bradford, 1976).  
6.4.4. 2-dimentional gel electrophoresis 
Samples of the proteins from homogenate were prepared as previously described 
(Poon, Castegna et al., 2004). Briefly, for isoelectric focusing, 200μg of protein were 
applied to a pH 3–10 ReadyStrip™ IPG strip (Bio-Rad), and Linear Gradient (8– 16%) 
Precast criterion Tris-HCl gels (Bio-Rad) were used to separate proteins according to 
their molecular migration rate (MrW). Sypro ruby stain was used to stain the gel for ~ 1 
h, after which the gels were placed overnight in deionized water for destaining.  
6.4.5. Western blotting 
Western blotting for 2DE gels was performed as previously described (Poon, 
Castegna et al., 2004). Briefly, 200μg of the brain protein were incubated with 10 mM 
DNPH solution in 2 N HCl at room temperature (37°C) for 20 min. The gels were 
prepared in the same manner as for 2DE. The proteins from gels following the second 
dimension electrophoresis were transferred onto nitrocellulose paper (Bio-Rad) using a 
Transblot-Blot® SD semi-dry Transfer Cell (Bio-Rad) at 15V for 2 h. The derivatized 
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carbonyl adduct of the brain proteins were detected immunochemically (Butterfield, 
2004). 
6.4.6. Image analysis 
The gels and blots were scanned and saved in TIF format using a Storm 860 
Scanner (Molecular Dynamics, Sunnyvale, CA) and Scanjet 3300C (Hewlett Packard, 
Palo Alto, CA), respectively. PDQuest (Bio-Rad) software was used for matching and 
analyzing visualized protein spots among different gels and oxyblots. After matching all 
the spots, the normalized intensity of each protein spot from individual gels (or oxyblots) 
was compared between groups using statistical analysis. 
6.4.7. Trypsin digestion 
Statistically significant spots were excised from the gel and were digested as 
described previously (Poon, Castegna et al., 2004). Briefly, the excised protein spots 
were washed with ammonium bicarbonate (NH4HCO3) followed by acetonitrile at room 
temperature. The gel pieces were digested with 20ng/μl modified trypsin and incubated at 
37°C overnight in a shaking incubator. 
6.4.8. Mass spectrometry 
1 μl of α-cyano-4-hydroxy trans-cinnamic acid (10 mg/ml in 0.1% TFA: ACN, 
1:1, v/v) was mixed with tryptic digests (1 μl). The mixture (1 μl) was deposited onto the 
surface of a fast evaporation nitrocellulose matrix and analyzed in reflectron mode with a 
TofSpec 2E (Micromass, UK) matrix-assisted laser desorption ionization-time of flight 
(MALDI-TOF) mass spectrometer. The mass axis was adjusted with trypsin 
autohydrolysis peaks (m/z 2239.14, 2211.10, or 842.51) as lock masses. The MALDI 
spectra used for protein identification from tryptic fragments were searched against the 
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Swissprot protein databases using the MASCOT search engine. Peptide mass 
fingerprinting used the assumption that peptides are oxidized at methionine residues, are 
monoisotopic and cysteine residues in peptide is carbamidomethylated (Butterfield and 
Castegna, 2003; Tangpong, Cole et al., 2006a). Up to 1 missed trypsin cleavage was 
allowed. Window of error allowed for matching the peptide mass values was set at mass 
tolerance of 150 ppm. We used the probability-based Mowse score, which indicates the 
probability that the match between the database and a spectrum is a random event to 
assign a level of confidence to the identification of specific proteins from the mass 
spectra. This probability equals 10(−Mowse score/10). Mowse scores greater than 53 were 
considered significant. 
6.5. Statistics 
The expression level of specific proteins and carbonyl levels in specific proteins, 
measured by the intensity of the carbonyl level divided by the intensity of protein level of 
an individual spot, were obtained from five individual 2D gels or blot, one each from 
each animal. The data were analyzed by two-tailed Student’s t tests. A value of p < 0.05 
was considered statistically significant. In proteomics for identification of a smaller 
member of protein, large-scale statistical analysis such as that used in DNA microarray 
studies, is not appropriate. 
6.6.  Results 
Previously we reported (Chapter 4) an increased total protein carbonyl levels in 
brain isolated from ADR-injected mice when compared to brain isolated from saline-
injected controls (Joshi, Sultana et al., 2005b). Here we performed expression proteomics 
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analysis and redox proteomics analysis unbaisly identify for differentially expressed brain 
proteins and specifically oxidized proteins respectively, following treatment with ADR.  
6.6.1. Expression proteomics 
From Figure 6.1a and b, it is evident that there are proteins that are less expressed 
in 2D gels of brain proteins of ADR-injected mice when compared to control. Upon 
image analysis by using PDQest software we identified 6 proteins that showed 
significantly decreased expression in brain from ADR-injected mice. These proteins were 
dynamin 1 (DNM1), triose phosphate isomerase (TPI), NADH ubiqinone oxidoreductase, 
vacoular ATP synthase (V-ATPase), visinin like protein 1 (VLP 1) and syntaxin 1B2.  
These proteins are shown on representative gels in Figures 1a and b. Table 6.1 presents 
the Mowse scores and p values along with molecular migration rate (MrW) and 
isoelectric point (PI) of the respective proteins. The identification of the proteins was 
performed by matching the obtained mass spectrum to the spectrum in the Swissprot 
database. The probability of the match being a random event is indicated by the Mowse 
score. A higher Mowse score indicates that the match is unlikely to be a random event. 
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Figure 6.1a and b: representative 2DE gels of brain proteins from saline-injected 
and ADR-injected mice, respectively. The labeled proteins on respective gels showed 
significantly lower expression in brain isolated from ADR-injected mice when compared 
to saline-injected control. (p < 0.05, n = 5). 
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Figure 6.2a and b: representative Western blot obtained from 2DE gels of brain 
proteins from saline-injected and ADR-injected mice, respectively. The labeled proteins 
on respective blots showed significantly increased oxidation in brain isolated from ADR-
injected mice when compared to saline-injected control. (p < 0.05, n = 5). 
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6.6.2. Redox proteomics 
From Figure 6.2a and b, there are proteins that are more oxidized in 2D Western 
blots of brain proteins from ADR-injected mice when compared to control. Upon image 
analysis by using PDQest software we identified 6 proteins that showed significantly 
increased oxidation in brain from ADR-injected mice. These proteins were α-enolase 
(ENO1), DNM1, TPI, peroxiredoxin-1 (Prdx1), β-tubulin and prohibitin.  These proteins 
are shown on representative Western blots in figures 2a and b. Table 6.2 shows the 
Mowse scores and p values along with MrW and PI of respective proteins. The 
identification of the proteins was performed by matching the obtained mass spectra of 
tryptic peptides to the spectra in the Swissprot database. The initial results suggest that 
the accuracy of protein identification by mass spectrometry is equivalent to 
immunochemical identification (Castegna, Aksenov et al., 2002a). 
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Protein 
Number of 
peptides 
matched 
% Sequence 
coverage 
Mowse 
score p value pI MrW 
gi accession 
number 
Dynamin 1 25 26% 156 0.01 7.6 98.14 gi|32172431 
TPI 8 39% 77 0.04 7.0 26.90 gi|2851390 
NADH 
ubiquinone 
oxidoreductase 
7 37% 75 0.05 7.0 27.64 gi|20178012 
Vacoular ATP 
synthase 15 40% 145 0.07 5.5 56.8 gi|51338706 
Visinin like 
protein 1 9 45% 107 0.009 5.0 22.7 gi|51338697 
Syntaxin 1B2 8 36% 145 0.05 5.2 33.4 gi|47117767 
 
Table 6.1: Proteins showing decreased levels in brain isolated from ADR-injected 
mice when compared to saline-injected control, as determined by PDQuest analysis on 
gels obtained from 2DE. Proteins were trypsinized and analyzed by Mass spectrometry in 
order to ascertain their identities. Proteins with Mowse score > 53 were considered to be 
identified at statistically significant level. 
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Protein 
Number of 
peptides 
matched 
% Sequence 
coverage 
Mowse 
score p value pI MrW 
gi accession 
number 
Alpha 
Enolase 6 19% 61 0.05 6.36 47.322 gi|13637776
Peroxiredoxin 
1 9 45% 134 0.05 8.26 22.39 gi|547923 
Dynamin 1 25 26% 156 0.01 7.61 98.14 gi|32172431
TPI 8 39% 77 0.04 7.08 26.907 gi|2851390 
beta Tubulin 10 24% 95 0.07 4.78 50.095 gi|56754803
Prohibitin 9 48% 133 0.05 5.57 29.859 gi|54038837
 
Table 6.2: Proteins showing increased oxidation levels in brain isolated from 
ADR-injected mice when compared to saline-injected control, as determined by PDQuest 
analysis on the blots obtained from 2DE followed by Western blot. The normalized spots 
were identified and corresponding proteins were trypsinized and analyzed by Mass 
spectrometry in order to ascertain their identities. Protein with Mowse scores > 53 were 
considered to be identified at a statistically significant level. 
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6.7. Discussion 
Previously we reported an increased protein oxidation and lipid peroxidation in 
brain isolated from ADR-injected mice when compared to that of saline-injected mice 
(Joshi, Sultana et al., 2005b). Increased oxidative stress markers may be cause or 
consequence of a compromised antioxidant defense system. Our laboratory also reported 
that ADR injection systemically causes increased TNF-α in brain that leads to increased 
apoptotic bodies and mitochondrial dysfunction (Tangpong, Cole et al., 2006b). We also 
recently reported that iNOS was involved in ADR-induced modulation of MnSOD and 
mitochondrial dysfunction, since iNOS knock-out mice injected previously with ADR 
had no brain mitochondrial dysfunction (Tangpong, Cole et al., 2006a). 
The present study was carried out to identify in an unbiased manner differentially 
expressed and specifically oxidized proteins in the brain isolated form saline- or ADR-
injected mice. Using the proteomics approach previously utilized in our laboratories 
(Castegna, Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; Poon, Castegna et al., 
2004; Poon, Calabrese et al., 2006; Tangpong, Cole et al., 2006a), we  determined that 
the expression levels of DNM 1, TPI, NADH ubiqinone oxidoreductase, V-ATPase, 
VLP1 and syntaxin 1B2 were significantly decreased in the brains isolated from ADR-
injected mice when compared to the brains isolated from saline-injected mice (Figure 
6.1a & b). Further, we showed that the total level of protein oxidation increased in the 
brains isolated from ADR-injected mice when compared to brain from saline-injected 
mice, and that the specific carbonyl levels of ENO 1, DNM 1, TPI, Prdx1, β-tubulin and 
prohibitin were significantly increased in the brains of  ADR-injected mice (Figure 6.2a 
& b). Upon examination of the proteomic data, we observed that the proteins that were 
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differentially expressed in the brain isolated from saline- or ADR-injected mice fell into 
four broadly defined functional groups, with some placed  in more than one of these 
groups: namely, metabolism, antioxidant defense, transport/motility, cell proliferation 
and regulation. Interestingly, these processes are known to affect cognitive function. 
6.7.1. Transport/mobility and cytoskeleton 
Dynamins are members of a subfamily of GTP-binding proteins. DNM1 is a 
GTPase that is involved in clathrin-mediated endocytosis and other vesicular trafficking 
processes (Sontag, Fykse et al., 1994) and is a substrate for protein kinase C (PKC). 
Phosphorylation of DNM1 by PKC enhances the GTPase activity of DNM1 (Sontag, 
Fykse et al., 1994). DNM1 also functions in receptor-mediated endocytosis and vesicle 
formation. DNM1 is believed to assemble around the necks of clathrin-coated pits and 
assist in pinching vesicles from the plasma membrane (van der Bliek, Redelmeier et al., 
1993). It is suggested that DNM1 has a primary role in synaptic vesicle recycling in the 
nerve terminal (Sontag, Fykse et al., 1994). The formation of complexes between the 
actin-binding protein profilin and DNM1 at sites of synaptic vesicle recycling has been 
well-characterized (Witke, Podtelejnikov et al., 1998). An observed significant decrease 
in DNM1 mRNA and protein levels in AD brains was interpreted to reflect its role in 
synaptic vesicle endocytosis (Yao, Zhu et al., 2003). Our laboratory recently reported that 
DNM1 protein is less abundant in the olfactory bulbs of old mice (Poon, Vaishnav et al., 
2005). In the current study we showed a decreased expression of DNM1 in brain isolated 
from ADR-injected mice when compared to brain isolated from saline-injected mice (Fig 
6.1a & b). By redox proteomics we showed that DNM1 is significantly oxidized in brain 
isolated from ADR-injected mice when compared to saline-injected control (Fig 6.2a & 
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b), Consistent with the notion of altered neurotransmitter reuptake by neuronal synapses 
and altered synaptic vesicle recycling with ADR injection. Since synaptic remodeling is 
critical to learning and memory, these alterations could affect neuronal transport/mobility 
considerably leading to decreased synaptic function, which conceivably could contribute 
to chemobrain. 
Tubulin is a heterodimer consisting of alpha and beta-tubulin subunits present 
ubiquitously among eukaryotic cells (Chakraborty, Sarkar et al., 1999). Like DNM1, beta 
tubulin is a GTPase and forms the structural subunit of microtubules (Tian, Bhamidipati 
et al., 1999). α- and β-tubulin polymerize to form microtubules that help in cellular 
trafficking (Pennisi, 1998). Hence, β-tubulin inactivation may not only alter cytoskeleton 
and intracellular transport but also alter cell proliferation. The level of α-tubulin is 
significantly decreased as a function of age (Nishibayashi, Ogawa et al., 1994; Poon, 
Calabrese et al., 2006).  Recently our laboratory showed oxidation of β-tubulin in a 
model of AD by using redox proteomics (Boyd-Kimball, Sultana et al., 2005b). In the 
present study we showed significant oxidation of β-tubulin in brain isolated from ADR-
injected mice when compared to brain isolated from saline-injected mice. Oxidation of β-
tubulin may implicate altered intracellular trafficking and disruption of the cytoskeleton 
that may contribute to chemobrain. 
6.7.2. Energy Metabolism 
NADH ubiquinone oxidoreductase, a component of mitochondrial complex 1, is 
involved in catalyzing the oxidation of NADH, the reduction of ubiquinone, and the 
transfer of 4H+/NADH across the coupling membrane. This protein provides the input to 
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the oxidative phophorylation for ATP production from the NAD-linked dehydrogenases 
of the citric acid cycle (Weiss, Friedrich et al., 1991). Mutation and dysregulation in this 
complex is associated with many neurodegenerative disorders including AD  (Robinson, 
Luo et al., 1998; Karry, Klein et al., 2004). Dysfunctional NADH ubiquinone 
oxidoreductase is linked to altered energy metabolism. Consistent with this notion we 
showed a lower expression of this enzyme in brain isolated from ADR-injected mice 
when compared to brain isolated from saline-injected mice. An altered energy 
metabolism may lead to mitochondrial dysfunction, which was observed in the brain 
isolated from ADR-injected mice when compared to control (Tangpong, Cole et al., 
2006a; Tangpong, Cole et al., 2006b) and may be related to cognitive dysfunction 
following ADR chemotherapy. 
V-ATPase, found in the endomembrane of eukaryotic cells and the plasma 
membrane of some specialized eukaryotic cells, is primarily involved in ATP hydrolysis 
to drive a proton pump. Apart from its ATPase activity V-ATPase also is involved in 
active transport of metabolites, protein trafficking, receptor mediated endocytosis and 
neurotransmitter release (Finbow and Harrison, 1997; Stevens and Forgac, 1997; Nelson 
and Harvey, 1999; Futai, Oka et al., 2000; Nishi and Forgac, 2002; Wilkens, Inoue et al., 
2004). In all cases, V-ATPase carries proton transport from the cytoplasmic compartment 
to the opposite side of the membrane in an ATP dependent manner (Nishi and Forgac, 
2002). The proton gradient generated by V-ATPase is also used to accumulate 
neurotransmitters in synaptic vesicles by specific vesicular transporters in neurons 
(Verdier, Huszar et al., 2005). Any alteration in V-ATPase may have consequences in 
energy production and/or neurotransmitter accumulation in presynaptic vesicles. In the 
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present study we reported a decreased expression of V-ATPase in brain isolated from 
ADR-injected mice when compared to brain isolated from saline injected mice. A 
decreased expression may hence implicate altered functions of V-ATPase that have roles 
in the various cellular processes described above, which conceivably could be involved in 
cognitive dysfunction associated with cancer chemotherapy. 
ENO1 is a key glycolytic enzyme present in the cytosol. The prime function of 
ENO1 is to catalyze the formation of phophoenolpyruvate from 2-phospho-D-glycerate. 
In the subsequent reaction in glycolysis, phophoenolpyruvate is converted to pyruvate 
and ATP by an enzyme, pyruvate kinase. ENO1, also known as α-enolase [brain-specific 
subunit of enolase, (Keller, Berod et al., 1994)], hence becomes a key enzyme in the 
process of ATP synthesis. Previously our lab reported possible post-transcriptional 
regulation of ENO1 in aging by  transcriptional analysis (Poon, Vaishnav et al., 2005), 
which may indicate reduced proteasomal degradation of this protein possibly being 
oxidized/nitrated or as a result of decreased proteasomal activity during aging (Keller, 
Dimayuga et al., 2004). ENO1 is also up-regulated at the protein level in AD brains 
(Schonberger, Edgar et al., 2001). ENO1 is a specific target of oxidation and is both 
oxidized and nitrated in brain that is under oxidative stress in AD patients (Castegna, 
Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; Castegna, Thongboonkerd et al., 
2003; Reverter-Branchat, Cabiscol et al., 2004). In the present study we showed that 
ENO1 is specifically oxidized in brain isolated from ADR-injected mice when compared 
to brain isolated from saline-injected mice. Since oxidatively modified protein are 
generally dysfunctional (Butterfield, Poon et al., 2006; Sultana, Perluigi et al., 2006) the 
possible implications of oxidative modification of ENO1 may relate to altered energy 
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metabolism and directly or indirectly might affect mitochondrial dysfunction. Lower 
ATP production could affect deleteriously the maintenance of ion gradients, the activities 
of pumps and channels, among others processes related to normal cognition. Hence, 
altered ENO1 may contribute to the symptoms of cognitive dysfunction or chemobrain.  
TPI catalyzes the reversible interconversion of dihydroxyacetone phosphate and 
glyceraldehyde 3-phosphate during glycolysis. TPI is ubiquitously expressed in 
cytoplasm. TPI deficiency has been reported in chronic nonspherocytic hemolytic anemia 
that eventually developed into cerebellar dysfunction and spasticity with hyperreflexia 
(Chang, Artymiuk et al., 1993). In another study, decreased neuronal ATP production 
followed by progressive neuronal death was observed upon inhibition of TPI (Sheline and 
Choi, 1998). Previous studies from our laboratory have reported oxidation/nitration of 
TPI in AD (Castegna, Thongboonkerd et al., 2003), however, the activity of TPI is not 
altered in either AD or demented patients (Iwangoff, Armbruster et al., 1980; Meier-
Ruge, Iwangoff et al., 1984). In the current study, we observed an increased oxidation 
and decreased expression of TPI in brain isolated from ADR-injected mice when 
compared to brain isolated from saline-injected control. A lower expression and increased 
oxidation may implicate altered energy metabolism, lower ATP production leading to 
chemobrain as described above. 
6.7.3. Antioxidant proteins 
Prdx1 is an antioxidant protein that contain essential catalytic cysteine residues 
and use thioredoxin as an electron donor (Yim, Chae et al., 1994; Neumann, Krause et 
al., 2003). The primary function of Prdx 1 is to scavenge peroxides and Prdx1 and prdx2 
are thought to be involved in the cellular response to ROS. Prdx1 is ubiquitously 
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expressed predominanlty in cytosol and alternatively in nucleus. In brain Prdx1 is 
localised in astrocytes, whereas Prdx2 is expressed in neurons (Sarafian, Verity et al., 
1999) . Prdx1 expression can be induced by oxidative stress (Ishii, Yamada et al., 1993; 
Prosperi, Ferbus et al., 1998). Transfection studies show that Prdx1 can regulate ROS 
induced by growth factor signalling and can eliminate peroxide in vivo (Kang, Chae et 
al., 1998). Altered expression of various Prdx have been observed in oxidative stress-
mediated neurodegenerative disorders including AD (Krapfenbauer, Engidawork et al., 
2003). A decreased expression of Prdx1 may lead to increased peroxidative stress. In the 
current study we observed an increased oxidative modification of Prdx1 in brain isolated 
from ADR-injected mice when compared to brain isolated from saline-injected control. 
Increased oxidative modification of the antioxidant protein Prdx1 may decrease the 
clearance of various peroxides and increase ROS. This alteration may be related to ADR-
mediated elevated oxidative stress in brain and to cognitive dysfunction in ADR-treated 
pateints. 
6.7.4. Regulation/Homeostasis 
Syntaxin 1B2 is an integral membrane protein belonging to the membrane 
transport proteins. In neurons it forms an integral part of synaptic vesicles. The primary 
function of syntaxin 1B2 is docking/priming of synaptic vesicles at presynaptic active 
zones (Morciano, Burre et al., 2005). It is sometimes also described as a vesicular 
trafficking protein. Although not much research has been done on this protein, its 
expression is known to be decreased in neurons of transgenic mice with altered glial 
fribrillary acidic protein (GFAP), a model of Alexander’s disease, a fatal 
neurodegenerative disorder resulting from missense mutations of the intermediate 
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filament protein, GFAP (Hagemann, Gaeta et al., 2005). In the present study we observed 
a decreased protein expression of this protein in brain isolated from ADR-injected mice 
when compared to brain isolated from saline-injected mice. Lower expression may 
implicate defective vesicle docking to the presynaptic membrane, leading to 
dysfunctional neurotransmitter release, which could be related to cognitive dysfunction or 
chemobrain. 
Prohibitin is ubiquitously expressed predominantly in mitochondria, associated 
with the inner mitochondrial membrane (McClung, Jupe et al., 1995).  Prohibitin is a 
multi-functional protein, ranging from cell proliferation, inhibiting DNA synthesis, 
serving as a chaperone protein in the mitochondria, tumor suppression or progression in 
breast cancer cells and their ability to target to lipid rafts (McClung, Jupe et al., 1995; 
Mishra, Murphy et al., 2006). Prohibitin is also localized in the nucleus and can modulate 
transcriptional activity by interacting with various transcription factors, including steroid 
hormone receptors (Mishra, Murphy et al., 2006). Prohibitin may play role in regulating 
mitochondrial respiration activity and in aging. All these function suggests that altered 
prohibitin may lead to mitochondrial dysfunction and might also have implication in 
various neurodegenerative conditions. In the present study we see an increased 
carbonylation of prohibitin in brain isolated from ADR-injected mice when compared to 
brain isolated from saline-injected mice. Oxidative modification of this protein may alter 
its function, which suggests an altered regulation of mitochondrial respiration activity. 
We previously showed decreased mitochondrial respiration activity in brain upon 
systemic administration of ADR in mice (Tangpong, Cole et al., 2006a; Tangpong, Cole 
et al., 2006b). 
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VLP1 is primarily localized in the plasma membrane, predominantly expressed in 
brain (Bernstein, Baumann et al., 1999). VLP1 belongs to a family of neuronal Ca2+ 
sensor/binding proteins (Braunewell and Gundelfinger, 1999; An, Bowlby et al., 2000). 
VLP1, upon binding to calcium undergoes a conformational change, a mechanism termed 
as Ca2+-myristoyl switch that facilitates its association with lipid bilayers (Ames, Ishima 
et al., 1997). VLP1 is also shown to modulate cGMP signaling pathways in transfected 
neurons, in vitro (Braunewell, Brackmann et al., 2001). Possible involvement of VLP1 in 
pathology and possibly pathophysiology of changed calcium homeostasis in AD has been 
previously studied (Schnurra, Bernstein et al., 2001). VLP1 showed reduced 
immunoreactivity in neurons from temporal cortex of AD patients (Schnurra, Bernstein et 
al., 2001). In the current study we have observed a decreased expression of VLP1 in brain 
isolated from ADR-injected mice when compared to brain isolated from saline-injected 
mice. Lower expression may cause Ca2+ dyshomeostasis that may lead to neuronal 
apoptosis with subsequent effect on cognition.  
The present proteomics identification of differentially expressed brain proteins 
and specifically oxidized proteins are consistent with our previous in vivo (Joshi, Sultana 
et al., 2005b; Tangpong, Cole et al., 2006a; Tangpong, Cole et al., 2006b). The 
previously observed ADR-induced increased oxidative stress, altered glutathione and its 
dependent enzyme expression and activity, TNF-α production, and circulating TNF 
causing mitochondrial dysfunction and appearance of apoptotic bodies in brain may be 
related to the observed differential expression or specific oxidation of key protein in 
brain.  
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The proteins involved in our study are fall under four major categories that have 
implication in neurodegeneration: transport/mobility and cytoskeleton, antioxidant, 
energy metabolism, and regulation/homeostasis. Impairment and alteration in these 
proteins lead to mitochondrial and cellular dysfunction, increased oxidative stress and 
apoptotic cascade, ultimately leading to neuronal death as observed in our previous in 
vivo studies.  All the previous studies and the present study show that mice injected with 
ADR are under oxidative stress. The results presented in this study suggest that a 
therapeutic strategy aimed towards preventing the observed differential expression and 
oxidative modification of specific proteins may modulate the observed cognitive 
impairment in patients undergoing chemotherapy. Studies to test this notion are in 
progress. 
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Chapter 7 
Glutathione elevation by γ-glutamyl cysteine ethyl ester as a potential therapeutic 
strategy towards preventing oxidative stress in brain mediated by in vivo 
administration of adriamycin: Implication for chemobrain. 
7.1. Overview of the study 
Oxidative stress in heart and brain by the cancer chemotherapeutic drug 
adriamycin (ADR), used for treating solid tumors, is well established. Long-term 
treatment of ADR in breast cancer patients has shown symptoms of cardiomyopathy. 
Less well recognized, but increasingly documented, is cognitive dysfunction. Following 
chemotherapy, free radical-mediated oxidative stress has been reported in both heart and 
brain. We recently showed a significant increase in protein oxidation and lipid 
peroxidation in brain isolated from mice injected intraperitonially (i.p) with ADR. 
Systemic administration of ADR also induces tumor necrosis factor-α (TNF-α), that leads 
to production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in 
brain. Circulating TNF also causes mitochondrial dysfunction leading to apoptotic 
pathways in brain. Inducible nitric oxide synthase also plays a role in ADR-induced TNF-
mediated neurotoxicity. We also previously showed a significant decrease in glutathione 
(GSH) levels in brain isolated from ADR injected mice, along with increased expression 
of multidrug resistant protein-1 (MRP-1), glutathione-S-transferase (GST), glutathione 
peroxidase (GPx), and glutathione reductase (GR). There was a significant decrease in 
activity of brain GST. The present study was designed to test the hypothesis that by 
elevating brain levels of GSH, the brain would be protected against oxidative stress in 
ADR-injected mice. γ-Glutamyl cysteine ethyl ester (GCEE), a precursor of glutathione, 
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injected i.p (150mg/kg body weight) 4 h prior ADR injection (20mg/kg body weight) led 
to significantly decreased protein oxidation and lipid peroxidation in subsequently 
isolated mice brain when compared to brain isolated from ADR-injected mice without 
GCEE. The GSH levels were restored to that of brain isolated from saline-injected mice. 
Further, the enzyme activity of GST was increased in brain isolated from ADR-injected 
mice previously injected with GCEE when compared to the brain isolated from ADR-
injected mice previously injected with saline. These results are discussed with relevance 
to potential pharmacological prevention of brain cognitive dysfunction in patients 
receiving ADR chemotherapy. 
 
7.2. Introduction 
Oxidative stress has been implicated in many neurodegenerative disorder 
conditions including Alzheimer’s disease (AD) (Butterfield, Drake et al., 2001; 
Lauderback, Kanski et al., 2002). In brain, free radical-mediated oxidative stress leads to 
significantly increased protein oxidation (Hensley, Hall et al., 1995; Stadtman and 
Berlett, 1997; Butterfield and Kanski, 2001), lipid peroxidation (Markesbery and Lovell, 
1998; Butterfield and Lauderback, 2002), DNA and RNA oxidation (Wang, Xiong et al., 
2005), neuronal dysfunction and death. Brain is particularly vulnerable to oxidative stress 
because of the relatively large amount of polyunsaturated fatty acids (PUFA), higher 
oxygen consumption and relatively low antioxidant capacity. By using redox proteomics, 
our laboratory has previously identified many key enzymes and proteins that are 
oxidatively modified in AD subjects and models of AD (Tangpong, Cole et al., 2006a), 
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aging (Poon, Calabrese et al., 2006) and in the patients with mild cognitive impairment 
(MCI) (Butterfield, Poon et al., 2006). 
Adriamycin (ADR), a cancer chemotherapeutic drug used to treat solid tumors, is 
known to cause side effects in heart and brain (Steinherz, Steinherz et al., 1991; Joshi, 
Sultana et al., 2005b; Tangpong, Cole et al., 2006a; Tangpong, Cole et al., 2006b). 
Cardiomyocytes treated with ADR have elevated levels of protein oxidation and lipid 
peroxidation (DeAtley, Aksenov et al., 1998). Free radical scavengers are known to 
protect cardiomyocytes from this effect (DeAtley, Aksenov et al., 1999). Brain isolated 
from mice treated peripherally with ADR shows evidence of oxidative damage and 
mitochondrial dysfunction (Joshi, Sultana et al., 2005b; Tangpong, Cole et al., 2006a; 
Tangpong, Cole et al., 2006b). Patients under long-term treatment with ADR for breast 
and lung cancer have shown symptoms of cognitive dysfunction such as lack of 
concentration, forgetfulness and dizziness (Meyers, 2000; Schagen, Hamburger et al., 
2001; Freeman and Broshek, 2002). The side effects in heart limit the use of ADR in 
chemotherapy, while the side effects in brain limit the quality of life of patients 
undergoing chemotherapy.  
ADR intercalates into the major groove of DNA and prevents its replication 
(Cummings, Anderson et al., 1991). ADR is also known to inhibit topoisomerase II to 
form a cleavable complex with DNA thereby preventing tumor growth (Chuang and 
Chuang, 1979; Cheng, Cahill et al., 1992). Apart from these mechanisms of action, the 
quinone containing ADR is also known to generate superoxide radical (O2-.) (Deres, 
Halmosi et al., 2005). A free radical-mediated mechanism of toxicity of ADR is widely 
accepted. The quinone in ADR undergoes one electron reduction to generate 
119 
semiquinone, which is a free radical, and in the presence of oxygen converts back to 
quinone producing O2-., a process known as redox cycling. ADR dependent redox cycling 
is likely activated by nitric oxide synthase and cytochrome P 450 (Gutierrez, 2000; 
Deres, Halmosi et al., 2005). Cardiotoxicity mediated by ADR is known to target 
mitochondria and NADH dehydrogenase, a mitochondrial enzyme, stimulates ADR to 
form semiquinone radical and O2-. (Doroshow and Davies, 1986).  O2-. radicals are 
converted to hydrogen peroxide (H2O2) enzymatically by superoxide dismutase. 
Overexpression of MnSOD is known to protect complex I of mitochondrial electron 
transport chain in ADR-mediated cardiomyopathy (Yen, Oberley et al., 1999). 
Superoxide radical can react with H2O2 and other reactive species to generate various 
other reactive oxygen species/reactive nitrogen species (ROS/RNS) (Halliwell and 
Gutteridge, 1999).  
Apart from SOD, another major antioxidant defense system includes glutathione 
(GSH) and its dependent enzymes such as glutathione peroxidase (GPx), glutathione 
reductase (GR) and glutathione-S-transferase (GST). GSH is a non-protein thiol present 
in millimolar concentrations in brain (Cooper, 1997). GSH provides protection against 
H2O2-mediated toxicity by providing reduced electrons and is oxidized to glutathione 
disulfide (GSSG). This reaction is catalyzed by GPx. GSSG is converted to GSH by 
action of glutathione reductase (GR) with the help of the cofactor NADPH (Cooper, 
1997). GPx is also known to reduce peroxynitrite thereby providing protection against 
peroxynitrite-induced toxicity (Sies, Sharov et al., 1997).  
GSH also forms glutathione-S conjugates with xenobiotics and reactive alkenals 
such as 4-hydroxynonenal (HNE) and acrolein, products of lipid peroxidation, with the 
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help of GST, and these conjugates are removed from cells by the multidrug resistant 
protein-1 (MRP-1), an ATP binding cassette (ABC) family protein (Sultana and 
Butterfield, 2004) MRP-1 is an integral plasma membrane protein that exports 
glutathione-S conjugates out of the cell in an ATP-dependent manner (Nies, Jedlitschky 
et al., 2004; Conseil, Deeley et al., 2005). GSH, apart from its endogenous antioxidant 
properties, is also involved in biosynthetic processes, DNA repair, enzyme activity 
regulation and activation of transcription factors (Meister and Anderson, 1983). GSH 
levels are decreased in certain regions of central nervous system (CNS) in various 
neurodegenerative disorders (Benzi and Moretti, 1995a). An imbalance in the ratio of 
reduced to oxidized GSH level indexes oxidative stress. Studies also have shown reduced 
GST activity in brain and ventricular fluids in AD (Lovell, Xie et al., 1998). Increased 
expression of GST increased resistance towards oxidative stress in neuroblastoma cells 
and provides protection against HNE mediated toxicity in neuronal cell culture (Lovell, 
Xie et al., 1998).   
7.3. Purpose of the study 
Involvement of oxidative stress-mediated toxicity in neurodegenerative events 
and neuronal cell death has been extensively studied (Good, Werner et al., 1996; Moreira, 
Smith et al., 2005). Hence, various experimental approaches for effective protection by 
antioxidants have emerged. In different models of oxidative stress-induced cell death, a 
number of potential free-radical scavengers and antioxidant have been tested, such as 
Vitamin E (Behl, Davis et al., 1992), Vitamin C, melatonin (Pappolla, Sos et al., 1997), 
ginko biloba (Smith and Luo, 2003), steroid hormones (Goodman, Bruce et al., 1996; 
Behl, Skutella et al., 1997), N-acetylcysteine (Adair, Knoefel et al., 2001), etc. Due to 
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poor blood brain barrier (BBB) permeability of many of these antioxidants, clinical trials 
largely have been unsuccessful. 
Studies have shown that an increase in endogenous GSH levels by dietary or 
pharmacological intake of GSH precursors or GSH mimetic or substrates for GSH 
synthesis protects brain against oxidative stress (Anderson and Luo, 1998; Halliwell, 
2001; Pocernich, Cardin et al., 2001; Butterfield, Castegna et al., 2002a; Joshi, Sultana et 
al., 2005a; Pocernich, Sultana et al., 2005). Considering the importance of developing 
new antioxidant compounds and their relevance in the treatment of neurodegenerative 
conditions, we examined γ-glutamyl cysteine ethyl ester (GCEE), a GSH precursor.  
Cysteine is the limiting substrate in the synthesis of GSH (Anderson and Luo, 1998). 
Additionally, γ -glutamylcysteine ligase (GCL) is the rate-limiting enzyme for GSH 
synthesis, the enzyme that catalyzes the ligation of the substrate glutamate to cysteine. 
GCL is feedback inhibited by the excess production of GSH. Based on this concept, we 
hypothesized that GCEE administered to the cell would avoid feedback inhibition and the 
limiting substrate for GSH synthesis would be provided to the process (Drake, Kanski et 
al., 2002). The ethyl ester moiety on γ - glutamylcysteine would further increase the 
efficacy of γ - glutamylcysteine to cross the plasma membrane and upregulate GSH 
biosynthesis.  
Previous studies from our laboratory have shown protection against peroxynitrite-
induced oxidative stress in brain following in vivo administration of GCEE (Drake, 
Kanski et al., 2002). GSH up-regulation by GCEE also protects mitochondria against 
peroxinitrite, in vivo (Drake, Sultana et al., 2003). Furthermore, elevation of GSH by 
GCEE protects neurons against Aβ(1-42)-mediated oxidative stress and neurotoxicity 
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(Boyd-Kimball, Sultana et al., 2005a). The present study was carried out to test the 
hypothesis that in vivo GCEE elevates GSH levels in brain and thereby prevents 
oxidative stress mediated by in vivo ADR. 
7.4. Experimentals 
7.4.1. Animals 
For this study, male B6C3 mice (2-3 months of age), approximately 30 g in size, 
housed in the University of Kentucky Central Animal Facility in 12-h light/dark 
conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The 
animal protocols were approved by the University of Kentucky Animal Care and Use 
Committee. 
7.4.2. Chemicals 
All the chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless 
stated otherwise. Doxorubicin HCl (ADR) was purchased from Bedford Laboratories. 
GCEE was purchased from Bachem (Torrance, CA). The OxyBlot kit used for protein 
carbonyl determination was purchased from Intergen (Purchase, NY). The GSH assay kit 
was purchased from Cayman Chemicals (Ann Arbor, MI). The primary antibody for 4-
hydroxynonenal was purchased from Alpha Diagnostics (San Antonio, TX). 
7.4.3. Treatments 
Mice were divided into 4 groups. Two groups received saline and another two 
groups were given 150 mg/kg bodyweight of GCEE. One of the saline-injected and 
GCEE-injected group received 20 mg/kg bodyweight ADR, i.p., 4 h after saline or GCEE 
injection. The dose and time for GCEE and ADR used were chosen based on prior studies 
(Drake, Kanski et al., 2002; Joshi, Sultana et al., 2005b). Following 72 h post-i.p. 
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injections of ADR, mice were sacrificed and brain was isolated and flash frozen in liquid 
nitrogen. 
7.4.4. Preparation of brain homogenate 
Brains were isolated, thawed and dissected from all the treatment groups and 
placed in ice cold lysing buffer containing 4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml 
aprotinin, 2mM ethylenediaminetetraacetic acid (EDTA), 2mM ethylene glycol-
bistetraacetic acid (EGTA) and 10mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic 
acid (HEPES), pH 7.4. The brain was homogenized by 20 passes of a Wheaton tissue 
homogenizer, and the resulting homogenate was centrifuged at 20000g for 10 minutes. 
The pellet was suspended in 1ml phosphate buffered saline (PBS) containing 0.01% 
(w/v) sodium azide and 0.2% (v/v) Tween 20. The supernatant (cytosolic fraction) was 
retained for fluorescence studies, GSH measurement and enzyme activities. All the 
fractions suspended in PBS were washed twice with PBS at 32000g for 10 min. The 
resulting fractions were assayed for protein concentration by the Pierce BCA method 
(Bradford, 1976). 
 
7.4.5. GSH assay 
A known volume of supernatant obtained from homogenate was deproteinated 
with 10% meta phosphoric acid. The subsequent deproteinated supernatant was treated 
with 4M triethanolamine (TEAM) solution. Following TEAM treatment, the GSH assay 
kit was used according to the manufacturer’s direction to determine GSH levels as 
described in chapter 3. 
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7.4.6. Protein Carbonyls  
Samples (5μl) of brain homogenate, 12% sodium dodecyl sulfate (SDS) (5μl), and 
10μl of 10 times diluted 2,4-dinitrophenylhydrazine (DNPH) from 200mM stock were 
incubated at room temperature for 20 min, followed by neutralization with 7.5μl 
neutralization solution (2M Tris in 30% glycerol). Protein (250ng) was loaded in each 
well on a nitrocellulose membrane under vacuum using a slot blot apparatus. The 
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS 0.01% 
(w/v) sodium azide and 0.2% (v/v) Tween 20 for 1h and incubated with a 1:100 dilution 
of anti-DNP polyclonal antibody in PBS containing 0.01% (w/v) sodium azide and 0.2% 
(v/v) Tween 20 for 1h. The membrane was washed in PBS following primary antibody 
incubation three times at intervals of 5 min each. The membrane was incubated following 
washing with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS 
in a 1:8000 ratio for 1h. The membrane was washed three times in PBS for 5 min and 
developed in Sigma fast tablets, [5-bromo-4-chloro-3-indolyl phosphate/Nitro blue 
tetrazolium substrate (BCIP/NBT substrate)]. Blots were dried, scanned with Adobe 
Photoshop, and quantified with Scion Image (PC version of Macintosh compatible NIH 
image). No non-specific binding of antibody to the membrane was observed. 
7.4.7. 4-Hydroxynonenal (HNE) 
Sample (5μl) of brain homogenate, 12% SDS (5μl), and 5μl of modified Laemmli 
buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) glycerol were 
incubated for 20 min at room temperature and were loaded (250ng) in each well on a 
nitrocellulose membrane in a slot blot apparatus under vacuum. The membrane was 
treated as above and incubated with a 1: 5000 dilution of anti-HNE polyclonal antibody 
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in PBS for 1h 30min. The membranes were further developed and quantified as above. A 
faint background staining due to the antibody alone was observed, but since each sample 
had a control, this minor effect was controlled. 
7.4.8. 3-Nitrotyrosine (3-NT) 
Samples (5μl) of brain homogenate, 12% SDS (5μl), and 5μl of modified 
Laemmli buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) 
glycerol were incubated for 20 min at room temperature and were loaded (250ng) in each 
well on a nitrocellulose membrane in slot blot apparatus under vacuum. The membrane 
was treated as above and incubated with a 1: 2000 dilution of anti-3-nitrotyrosine (3NT) 
polyclonal antibody in PBS for 1h 30min. The membranes were developed further and 
quantified as described above. No non-specific binding of antibody to the membrane was 
observed. 
7.4.9. Enzyme activity assays 
Estimation of glutathione-S-transferase activity 
GST (EC 2.5.1.18) activity was measured using a reaction mixture consisting of 
0.1 M phosphate buffer (pH 6.5), 1.0 mM reduced glutathione, 1.0 mM CDNB and 
1mg/ml of supernatant protein (Habig, Pabst et al., 1974). The changes in absorbance 
were recorded at 340 nm in a 96 well microtiter plate, and the enzymatic activity was 
calculated as nmol of CDNB conjugate formed min− 1 mg− 1 protein. 
7.5. Statistical analysis 
Two-way ANOVA followed by a multiple comparisons test (Turkey HSD) was 
used to assess statistical significance. P values <0.05 were considered significant for 
comparison between control and experimental data sets. 
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7.6. Results  
7.6.1. GSH assay 
As shown in Figure 7.1, there were significant reductions in GSH levels in brain 
isolated from ADR-injected mice when compared to the levels in brain isolated from 
saline or GCEE-injected mice. Administration of GCEE elevated the levels of GSH 
significantly (p < 0.05, n = 5) in brain isolated from mice injected with GCEE followed 
by saline or ADR, although the GSH level in the latter case did not reach the level of the 
saline control. 
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Figure 7.1: Levels of GSH in all the treatment groups. There is a significant 
decrease in GSH level in brain isolated from ADR-injected mice when compared to 
control (* p < 0.05, n = 5). I.p injection of GCEE increases GSH level significantly in 
brain. The brain isolated from GCEE-injected mice followed by ADR injection shows a 
significant increase in GSH levels when compared to the levels in brain isolated from 
ADR injected mice that were previously injected with saline ( * p < 0.05, n = 5). The data 
are presented as mean ± SEM expressed as percentage of control. 
7.6.2. Protein carbonyl, 3 nitrotyrosine and 4-hydroxynonenal 
Figures 7.2, 7.3 and 7.4 show the levels of protein carbonyls, 3-NT (markers of 
protein oxidation) and protein bound HNE (a lipid peroxidation product) levels, 
respectively, in all the treatment groups. There was significant elevation in protein 
carbonyl, 3-NT and protein bound HNE levels in brain isolated from ADR-injected mice 
when compared to the levels in brain isolated from saline or GCEE-injected mice (p < 
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0.05, n = 5), confirming our previous findings (Joshi, Sultana et al., 2005b). 
Administration of GCEE reduced the levels of protein carbonyls, 3-NT and protein-
bound HNE significantly (p < 0.05, n = 5) in brain isolated from mice injected with 
GCEE followed by saline or ADR. 
 
 
 
 
 
 
 
 
 
 
Figure 7.2: Levels of protein carbonyl in all the treatment groups. There is a 
significant increase in protein carbonyl level in brain isolated from ADR-injected mice 
when compared to control (* p < 0.05, n = 5). I.p injection of GCEE decreases protein 
carbonyl level significantly in brain. The brain isolated from GCEE-injected mice 
followed by ADR injection shows a significant decrease in protein carbonyl levels when 
compared to the levels in brain isolated from ADR injected mice that were previously 
injected with saline (* p < 0.05, n = 5). The data are presented as mean ± SEM expressed 
as percentage of control. 
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Figure 7.3: Levels of 3NT in all the treatment groups. There is a significant 
increase in 3NT level in brain isolated from ADR-injected mice when compared to 
control (* p < 0.05, n = 5). I.p injection of GCEE decreases 3NT level significantly in 
brain. The brain isolated from GCEE-injected mice followed by ADR injection shows a 
significant decrease in 3NT levels when compared to the levels in brain isolated from 
ADR injected mice that were previously injected with saline (* p < 0.05, n = 5). The data 
are presented as mean ± SEM expressed as percentage of control. 
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Figure 7.4: Levels of HNE in all the treatment groups. There is a significant 
increase in HNE level in brain isolated from ADR-injected mice when compared to 
control (* p < 0.05, n = 5). I.p injection of GCEE decreases HNE level significantly in 
brain. The brain isolated from GCEE-injected mice followed by ADR injection shows a 
significant decrease in HNE levels when compared to the levels in brain isolated from 
ADR injected mice that were previously injected with saline (* p < 0.05, n = 5). The data 
are presented as mean ± SEM expressed as percentage of control. 
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7.6.3. GST activity 
Figure 7.5 shows the activity of GST in all the treatment groups. There was 
significant reduction in GST activity in brain isolated from ADR-injected mice when 
compared to the activities in brain isolated from saline or GCEE-injected mice (p < 0.05, 
n = 5). Administration of GCEE elevated the GST activity significantly (p < 0.05, n = 5) 
in brain isolated from mice injected with GCEE followed by ADR. Injection of GCEE 
alone significantly increased GST activity when compared to saline-injected control. 
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Figure 7.5: Plot of activity of GST in all the treatment groups. There is a 
significant decrease in GST activity in brain isolated from ADR-injected mice when 
compared to control (* p < 0.05, n = 5). I.p injection of GCEE increases GST activity 
significantly in brain. The brain isolated from GCEE-injected mice followed by ADR 
injection shows a significant increase in GST activity when compared to the activity in 
brain isolated from ADR injected mice that were previously injected with saline (** p < 
0.01, n = 5). The data are presented as mean ± SEM expressed as percentage of control. 
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7.7. Discussion 
ADR-mediated oxidative stress in brain has gained increasing importance recently 
(Joshi, Sultana et al., 2005b; Joshi, Sultana et al., 2006; Tangpong, Cole et al., 2006a; 
Tangpong, Cole et al., 2006b). Free radical-mediated protein oxidation and lipid 
peroxidation in cardiomyocytes and involvement of ADR in cardiomyopathy has been 
extensively studied by various groups (Doroshow and Davies, 1986; Sarvazyan, 1996; 
Vasquez-Vivar, Martasek et al., 1997; Yen, Oberley et al., 1999). We previously showed 
increased protein oxidation and lipid peroxidation in brain isolated from ADR-injected 
mice that conceivably could be involved in the symptoms of chemobrain observed in 
patients treated with ADR (Joshi, Sultana et al., 2005b). ADR does not cross the BBB 
(Bigotte, Arvidson et al., 1982a; Bigotte, Arvidson et al., 1982b; Tangpong, Cole et al., 
2006b). The first investigation of potential biochemical pathways for ADR-mediated 
CNS toxicity was recently reported by our group (Tangpong, Cole et al., 2006b). 
Systemic administration of ADR significantly elevated the level of circulating TNF-α, 
which crossed the blood brain barrier to reside in neurons. Neuronal-resident TNF-α 
caused brain mitochondrial dysfunction leading to activation of apoptotic pathways. Pro-
apoptotic p53 migrates to brain mitochondria to interact with anti-apoptotic Bcl-xL. The 
evidence of apoptosis in brain following ADR suggest p53 interacts with Bcl-xL 
inhibited the function of the latter protein. A neutralizing antibody against TNF abrogated 
these effects in brain (Tangpong, Cole et al., 2006b). More recently, we showed a role of 
iNOS in these effects. ADR given to mice lacking iNOS did not demonstrate a brain 
mitochondrial dysfunction (Tangpong, Cole et al., 2006a). ADR was shown to lead to 
nitrated and dysfunctional MnSOD, a mitochondrial-resident protective enzyme. 
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We recently showed a role for GSH, a major endogenous cellular thiol 
antioxidant, and its related enzyme expression and activity, in ADR-mediated oxidative 
stress in brain (Joshi, Sultana et al., 2006). There was a significant depletion in GSH 
levels in brain isolated from ADR-injected mice (Joshi, Sultana et al., 2006). GCEE, a 
precursor of GSH, is known to elevate GSH levels in brain by providing the rate limiting 
substrate, γ –glutamylcysteine (Drake, Kanski et al., 2002). In vivo administration of 
GCEE elevated the GSH level significantly in brain isolated from saline- or ADR-
injected mice (Fig 1). The increase in GSH levels in GCEE followed by ADR injection in 
mice was almost that of control mice. GCEE alone showed a significantly increased GSH 
levels when compared to all the treatment groups. Moreover, the protection of brain 
against peroxynitrite by prior GCEE administration (Drake, Sultana et al., 2003) is 
concomitant with GSH scavenging of NO to form nitrosothiol functionality on GSH.  
Increasing GSH levels by pharmacological or dietary intervention has been shown 
to reduce oxidative stress in models of various neurodegenerative conditions (Pocernich, 
Cardin et al., 2001; Boyd-Kimball, Sultana et al., 2005a). In vivo GCEE administration 
followed by ADR injection to mice reduced the protein oxidation (Figs. 7.2 and 7.3) and 
lipid peroxidation (Fig 4) in brain when compared to brain isolated from ADR-injected 
mice previously injected i.p. with saline.  Increasing GSH by GCEE suggests increased 
antioxidant capacity of brain, hence improved protection against free radical-mediated 
oxidative stress caused by ADR. 
GST is a major detoxification enzyme that works with MRP-1 to remove 
toxicants from the cell (Sultana and Butterfield, 2004). We showed ADR caused 
elevation of expression of MRP-1 (Joshi, Sultana et al., 2005b), an ATP binding cassette 
135 
(ABC) family protein in brain. MRP-1 in conjugation with GST is known to transport 
glutathione-S conjugates of electrophiles, anions and other xenobiotics out of the cell. We 
previously showed a significant elevation in expression of GST in brain isolated from 
ADR-injected mice (Joshi, Sultana et al., 2006). Although the expression of GST was 
increased, there was a significant decrease in its activity of  brain GST in ADR-injected 
mice (Joshi, Sultana et al., 2006). In vivo GCEE elevated the activity of GST in brain 
isolated from ADR-injected mice previously injected with GCEE when compared to 
brain isolated from saline- or ADR-injected mice (Fig 5). Increased activity of GST may 
result in improved formation of glutathione-S- conjugates and these conjugates including 
GS-HNE conjugate are cleared from cell by action of MRP1 from the cell, putatively 
leading to less toxicity and reduced oxidative stress. As noted above, elevated GSH could 
serve as a substrate for NO, produced in response to oxidative stress to form nitrosothiol 
adduct. This would have the effect of decreasing peroxynitrite and therefore 3-NT 
formation as observed in Fig 3. These results are consistent with the notion that brain 
accessible GCEE may protects brain from oxidative stress induced by ADR via TNF- or 
iNOS-mediated processes. 
In conclusion, the protection of brain against the oxidative damage caused by in 
vivo ADR by GCEE is consistent with previous other studies in which GCEE protected 
neurons against AD-related amyloid beta-peptide (Boyd-Kimball, Sultana et al., 2005c). 
Further studies on an animal model could form the basis for eventual treatment strategy 
for preventing oxidative stress mediated by ADR. The current results suggest that GCEE-
mediated increment in brain GSH levels and the activity of GST could be a potential 
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therapeutic approach towards modulating cognitive impairment in patients undergoing 
chemotherapy.  
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Chapter 8 
In Vivo Protection of Synaptosomes from Oxidative Stress Mediated by 
Fe2+/H2O2 or 2,2-Azobis (2-amidino-propane) dihydrochloride (AAPH) by the 
Glutathione Mimetic Tricyclodecan-9-yl-xanthogenate (D609) 
8.1. Overview of the study 
D609 (tricyclodecan-9-yl-xanthogenate) is a phosphatidylcholine- specific 
phospholipase C inhibitor that also has been reported to protect rodents against oxidative 
damage caused by lethal doses of ionizing radiation. We previously showed that D609 
mimics glutathione. D609 has a free thiol group, which upon oxidation forms a disulfide. 
The resulting dixanthate is a substrate for glutathione reductase, regenerating D609. 
Recent studies from our laboratory have also shown that D609 reduces the Alzheimer’s 
amyloid β peptide [Aβ (1-42)]-induced oxidative stress and cytotoxicity in neuronal cell 
culture. The present study was undertaken to test the hypothesis that D609 would provide 
neuroprotection against free radical oxidative stress in vivo. Synaptosomes isolated from 
gerbils, previously injected intraperitoneally (i.p.) with D609, were treated with the 
oxidants, Fe2+/H2O2 or 2,2- Azobis (2-amidino-propane) dihydrochloride (AAPH), which 
produce free radicals. Synaptosomes isolated from the gerbils i.p. injected with D609 and 
treated with Fe2+/H2O2 and AAPH showed significant reduction in reactive oxygen 
species (ROS), levels of protein carbonyl, protein bound hydroxynonenal (HNE, a lipid 
peroxidation product) and 3-nitrotyrosine (3NT, another marker of protein oxidation 
formed by reaction of tyrosine residues with peroxynitrite) when compared to oxidative 
stress in synaptosomes isolated from gerbils that were injected with saline, but treated 
with Fe2+/H2O2 and AAPH. These results are discussed with reference to potential use of 
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this brain accessible glutathione mimetic in the treatment of oxidative stress related 
neurodegenerative disorders. 
8.2. Introduction 
Alzheimer’s disease (AD) is an age-associated dementing disorder characterized 
by loss of synapses and the presence of senile plaques and neurofibrillary tangles, 
affecting more than four million Americans (Katzman and Saitoh, 1991). Oxidative stress 
has been implicated in many neurodegenerative disorders including AD (Hensley, Hall et 
al., 1995; Stadtman and Berlett, 1997; Markesbery and Lovell, 1998; Butterfield, Drake 
et al., 2001; Butterfield and Lauderback, 2002). Reactive oxygen species (ROS) leads to 
protein oxidation (Hensley, Hall et al., 1995; Stadtman and Berlett, 1997), lipid 
peroxidation (Markesbery and Lovell, 1998; Butterfield and Lauderback, 2002), DNA 
and RNA oxidation (Butterfield, Drake et al., 2001) and neuronal dysfunction or death. 
ROS generation hence becomes important in understanding oxidative stress and oxidative 
stress related disorders. Many antioxidant therapies for neurological disorder are under 
investigation. 
Glutathione (GSH) is an intracellular antioxidant that maintains redox balance in 
cell. GSH is the major thiol participating in various cellular redox functions and 
biosynthesis (Schulz, Lindenau et al., 2000). Reduced levels of GSH have been observed 
in oxidative stress related disorders (Bains and Shaw, 1997). Reduced levels of GSH in 
specific regions of the central nervous system of AD patients contribute to the oxidative 
stress mediated neuronal cell dysfunction and/or loss (Benzi and Moretti, 1995a). In AD, 
increased levels of oxidized glutathione (GSSG) have been observed (Cooper, 1997). 
Studies have shown that an increase in endogenous GSH levels by dietary or 
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pharmacological intake of GSH precursors or GSH mimetics or substrates for GSH 
synthesis protects brain against oxidative stress (Anderson and Luo, 1998; Halliwell, 
2001; Butterfield, Castegna et al., 2002a). Previously, our lab showed that endogenous 
elevation of GSH by i.p. injection of N-acetyl cysteine (NAC) or gamma- glutamyl-
cysteine ethyl ester (GCEE) reduced oxidative stress markers in synaptosomes treated 
with various oxidants (Pocernich, Cardin et al., 2001; Drake, Kanski et al., 2002; Drake, 
Sultana et al., 2003). Recently, we showed that tricyclodecan-9-yl-xanthogenate  (D609), 
a glutathione mimetic, protects primary neuronal culture against amyloid β-peptide (1-42) 
[Aβ (1-42)]-induced oxidative stress and neurotoxicity (Sultana, Shelley et al., 2004).  
D609 (Figure 8.1) is a phosphatidylcholine-specific phospholipase C inhibitor 
(Monick, Carter et al., 1999) that has been shown to trap hydroxyl free radical and to 
reduce oxidative stress induced by ionizing radiation (Zhou, Lauderback et al., 2001). 
D609 has antiviral and antitumor activity (Amtmann, 1996). Previously we showed that 
D609 mimics glutathione (GSH) function in that it has a free thiol group, which upon 
oxidation forms a disulfide. The resulting dixanthate is a substrate for glutathione 
reductase, regenerating D609 (Lauderback, Drake et al., 2003). D609 has the ability to 
scavenge hydrogen peroxide and hydroxyl free radicals. In addition, D609 can bind to 
reactive alkenals formed due to peroxidation of lipids and detoxifies their effect, thereby 
preventing these alkenals from damaging synaptosomes (Lauderback, Drake et al., 2003). 
Based on these studies we tested the hypothesis that D609 delivered in vivo, modulates 
oxidative stress in brain induced by various oxidants. 
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8.3. Purpose of the study 
Our study was aimed at determining the effects of intraperitoially (i.p). injected 
D609 in gerbils against oxidative stress in subsequently isolated synaptosomes induced 
by Fe2+/H2O2 (hydroxyl radical formation) and AAPH (alkoxyl and peroxyl radical 
formation).  
S 
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Figure 8.1: Tricyclodecan-9-yl-xanthogenate (D609) 
 
8.4. Experimentals 
8.4.1. Animals 
For all the studies male Mongolian gerbils (2-3 months of age), approximately 
100 g in size, housed in the University of Kentucky Central Animal Facility in 12-h 
light/dark conditions and fed standard Purina rodent laboratory chow ad libitum, were 
used. The animal protocols were approved by the University of Kentucky Animal Care 
and Use Committee. 
8.4.2. Chemicals  
D609 was purchased from Biomol (Plymouth Meeting, PA) and all other 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless stated otherwise. 
Fresh 10 mM stock solution of 2,7-dichlorofluoroscin diacetate (DCFH-DA) was 
141 
prepared in ethanol for DCF fluorescence assay. Fresh D609 (50mg/kg bodyweight) was 
prepared in phosphate-buffered saline (PBS). The protein oxidation detection kit was 
purchased from Intergen (Purchase, NY) and primary antibody for HNE and 3NT were 
purchased from Chemicon International. 
8.4.3. Preparation of Synaptosomes 
Synaptosomes were isolated from gerbils injected i.p. with saline (control) or with 
D609 (50mg/kg body weight), 60min after injection. This level was chosen based on 
previous experiments conducted at various concentrations (Figure 2).  The synaptosomal 
isolation procedure has been described elsewhere (Whittaker, 1993). Briefly, the gerbils 
were sacrificed by decapitation and the brain was isolated on a cold plate and placed in 
0.32M sucrose isolation buffer containing 4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml 
aprotinin, 2mM ethylenediaminetetraacetic acid (EDTA), 2mM ethylene glycol-
bistetraacetic acid (EGTA) and 20mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic 
acid (HEPES), 20μg/ml trypsin inhibitor and 0.2mM phenylmethanesulfonyl fluoride 
(PMSF), pH 7.4. The whole brain was homogenized by 20 passes with a Wheaton tissue 
homogenizer. The homogenate was centrifuged at 1500 g for 10 min. The pellet was 
discarded and the supernatant was retained and centrifuged at 20000 g for 10 min. The 
resulting pellet was resuspended in approximately 1ml of 0.32M sucrose isolation buffer 
and layered over discontinuous sucrose gradient (0.85M pH 8.0, 1.0M pH8.0, 1.18M 
pH8.5 sucrose solutions each containing 2mM EDTA, 2mM EGTA and 10mM HEPES) 
and spun at 82500g for 1h at 4o C. The purified synaptosomes were collected from the 
sucrose gradient interface at the 1.0/1.18M interface and washed with phosphate buffered 
saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS), twice and 
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centrifuged at 32000 g. The resulting synaptosomal membranes were assayed for protein 
concentration by Pierce BCA method (Bradford, 1976). The synaptosomes obtained were 
divided in two aliquots. One part was incubated with 30 mM FeSO4 and 10 mM H2O2, 
and the other aliquot was incubated with 1mM AAPH for 1h at 37o C. The synaptosomal 
samples were washed following incubation and suspended in PBS. 
8.4.4. DCF fluorescence 
10 μM DCFH-DA was incubated with synaptosomes (1mg/ml) for 30 minutes at 
37o C. Intracellular esterases convert DCFH-DA into anionic DCFH, which because of its 
negative charge is trapped in the synaptosomes. Upon oxidation with ROS, DCFH is 
converted to 2,7- dichlorofluoroscein (DCF), a fluorescent compound. Synaptosomes 
were spun at 3000 g in a tabletop Eppendorf centrifuge for 5 minutes at 4o C. 
Synaptosomes were resuspended in 500 μl of PBS and loaded in triplicate (100 μl per 
well) in a black microtiter plate and fluorescence was measured in a Spectramax 
microtiter plate reader (λex = 495nm, λem = 530nm) and quantified using softPro max 
software. To verify that ester cleavage and efflux of the dye were not contributing to 
changes in fluorescence, similar studies were done with an oxidation-insensitive dye 
CDCF-DA (C369). 
8.4.5. Protein carbonyls 
Protein carbonyls are the markers of protein oxidation and were assed by 
following the standard protocol described elsewhere (Stadtman and Berlett, 1997). 
Sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS) and 
10μl of 10 times diluted 2,4-dinitrophenylhydrazine (DNPH) from 200mM stock were 
incubated at room temperature for 20 min. Samples were neutralized with 7.5μl 
143 
neutralization solution (2M Tris in 30% glycerol). The resulting solution was solution 
was loaded in each well on nitrocellulose membrane under vacuum using a slot blot 
apparatus. The membrane was blocked in blocking buffer (3% bovine serum albumin) in 
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 
(PBS) for 1 h and incubated with a 1:100 dilution of anti DNP polyclonal antibody in 
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 
(PBS) for 1h. The membrane was washed three times in PBS and was incubated for 1 h 
with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS in a 
1:8000 ratio. The membrane was washed for three times in PBS for 5 min and developed 
in Sigma fast tablets (BCIP/NBT substrate). Blots were dried, scanned with Adobe 
Photoshop, and quantified with Scion Image (PC version of Macintosh compatible NIH 
image). 
8.4.6. 4-Hydroxynonenal (HNE) 
Sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS) 
and 5μl of modified Laemmli buffer containing 0.125 M tris base pH 6.8, 4% (v/v) SDS, 
and 20% (v/v) glycerol were incubated for 20 minutes at room temperature. Sample (250 
ng) was loaded in each well on nitrocellulose membrane in slot blot apparatus under 
vacuum. The membrane was blocked in blocking buffer (3% bovine serum albumin) in 
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 
(PBS) for 1 hr and incubated with a 1: 5000 dilution of anti-HNE polyclonal antibody in 
PBS for 1 h 30 min. The membrane was washed in PBS for 5 min three times after 
incubation. The membrane was incubated for 1 h, following washing, with an anti-rabbit 
IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 ratio. The 
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membrane was washed three times in PBS for 5 min and developed in Sigma fast tablets 
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and quantified 
with Scion Image as above. 
8.4.7. 3-Nitrotyrosine (3NT) 
Sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS) 
and 5μl of modified Laemmli buffer containing 0.125 M tris base pH 6.8, 4% (v/v) SDS, 
and 20% (v/v) glycerol were incubated for 20 minutes at room temperature. Sample (250 
ng) was loaded in each well on nitrocellulose membrane in slot blot apparatus under 
vacuum. The membrane was blocked in blocking buffer (3% bovine serum albumin) in 
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 
(PBS) for 1 hr and incubated with a 1: 2000 dilution of anti-3-nitrotyrosine (3NT) 
polyclonal antibody in PBS for 1 h 30 min. The membrane was washed in PBS for 5 min 
three times after incubation. The membrane was incubated for 1 h, following washing, 
with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 
ratio. The membrane was washed for three times in PBS for 5 minutes and developed in 
Sigma fast tablets. Blots were dried, scanned with Adobe Photoshop, and quantified with 
Scion Image as above. 
8.4.8. Western blot for Protein oxidation 
Samples (100 μg) were incubated with DNPH at room temperature for 30 min and 
then precipitated with tricholro acetic acid (TCA) following incubation. The pellet was 
washed with 1:1 Ethanol: Ethyl acetate for three times. After addition of sample loading 
buffer, protein sample were denatured and electrophoresed on a 10% SDS-
polyacrylamide gel. Proteins were transferred to nitrocellulose at 90 mA/gel for 2 h. The 
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blots were blocked for 1h in fresh wash buffer (10 mM tris-HCl 9pH7.5), 150 mM NaCl, 
0.05% Tween 20, pH 7.4, containing 3% bovine serum albumin) and incubated with a 
1:100 dilution of anti DNP polyclonal antibody in phosphate buffered saline containing 
0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) for 1h. The membrane was 
washed three times in PBS and was incubated for 1 h with an anti-rabbit IgG alkaline 
phosphatase secondary antibody diluted in PBS in a 1:8000 ratio. The membrane was 
washed for three times in PBS for 5 min and developed in Sigma fast tablets (BCIP/NBT 
substrate). The blot was stripped and reprobed for GAPDH to show equal loading of 
protein. 
8.5. Statistical analysis 
Analysis of variance (ANOVA) was used for comparison among the groups and 
statistical evaluation. Results are presented as means ± SEM. P values < 0.05 were 
considered significant. 
8.6. Results 
8.6.1. DCF fluorescence 
The DCF assay is useful to monitor ROS generation. DCF is sensitive to many 
oxidative stress-inducing compounds including hydroxyl radical, ONOO-, AAPH and Aβ 
(Wang and Joseph, 1999; Keller, Lauderback et al., 2000; Lauderback, Kanski et al., 
2002). Figure 8.2 shows the ROS levels in synaptosomes isolated from saline-injected 
gerbils (control), synaptosomes isolated from saline-injected gerbils treated with 
Fe2+/H2O2 or AAPH and Fe2+/H2O2 or AAPH treated synaptosomes isolated from gerbils 
previously injected i.p. with D609, respectively. There was a significant increase in ROS 
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generation in synaptosomes isolated from control gerbils treated with Fe2+/H2O2 or 
AAPH (p < 0.0001) when compared to control. Synaptosomes isolated form D609 
injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH showed significant 
decrease in ROS levels when compared to synaptosomes treated with Fe2+/H2O2 or 
AAPH, isolated from gerbils injected i.p. with saline (p < 0.005). 
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Figure 8.2: Significant increase in ROS in synaptosomes isolated from saline injected 
gerbils and subsequently treated with Fe2+/H2O2 or AAPH compared to ROS in 
synaptosomes isolated from saline-injected gerbils,  * p < 0.005. Decreased ROS in 
synaptosomes isolated from gerbils injected i.p. with D609 subsequently treated with 
Fe2+/H2O2 or AAPH relative to ROS in synaptosomes isolated from gerbils injected with 
saline and subsequently treated with Fe2+/H2O2 or AAPH, ** p < 0. 005; the data are the 
mean ± SEM expressed as percentage of control values, (n = 6). 
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To ensure that ester cleavage or efflux of the DCFH, prior to the reaction with 
ROS, was not contributing to changes in fluorescence, the oxidation-insensitive dye 
(C369) was used in similar studies and was used as control. No difference in fluorescence 
was found in all the studies, confirming that a change in fluorescence shown in Figure 8.3 
was due to oxidation of the dye and not because of some other parameter.   
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Figure 8.3: Measurement of ROS generation using the oxidation-insensitive 
probe C369. The oxidation-insensitive fluorescence probe C369 was used as control to 
show esterase activity and drug efflux changes of DCFH-DA. 
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8.6.2. Protein carbonyl 
Figure 8.4 shows the protein carbonyl levels in synaptosomes isolated from saline 
injected gerbils (control), synaptosomes isolated from control gerbils subsequently 
treated with Fe2+/H2O2 or AAPH and Fe2+/H2O2 - or AAPH-treated synaptosomes 
isolated from gerbils previously injected i.p. with D609. There was a significant increase 
in protein carbonyl levels in synaptosomes isolated from control gerbils treated with 
Fe2+/H2O2 or AAPH (p < 0.000001) when compared to control. Synaptosomes isolated 
from D609 injected gerbils subsequently treated with Fe2+/H2O2 and AAPH showed 
significantly decreased protein carbonyl levels when compared to synaptosomes isolated 
from saline-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH (p < 
0.00005). 
Figure 8.5 show representative western blots for total protein oxidation. It is clear 
that decreased protein oxidation is found in Fe2+/H2O2 or AAPH treated synaptosomes 
isolated from gerbils previously injected with D609. 
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Figure 8.4: Significant increase in protein carbonyl levels in synaptosomes 
isolated from saline injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH 
compared to protein carbonyls in synaptosomes isolated from saline injected gerbils,  * p 
< 0.005.  Decreased protein carbonyl level in synaptosomes isolated from gerbils injected 
i.p. with D609 subsequently treated with Fe2+/H2O2 or AAPH relative to protein carbonyl 
level in synaptosomes isolated from gerbils injected with saline and subsequently treated 
with Fe2+/H2O2 or AAPH, ** p < 0. 005; the data are the mean ± SEM expressed as 
percentage of control values, (n = 6). 
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Figure 8.5: Representative western blot showing protein carbonyl levels from 
various treatments. 
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8.6.3. HNE 
Arachidonic acid from phospholipids, on attack by free radicals, produces reactive 
alkenals, such as HNE. HNE binds to proteins by Michael addition (Butterfield and 
Stadtman, 1997) and inactivates them by changing their conformation (Subramaniam, 
Roediger et al., 1997; Zhou, Lauderback et al., 2001) Figure 8.6 shows the protein-bound 
HNE levels in synaptosomes isolated from saline-injected gerbils (control), synaptosomes 
isolated from control gerbils treated with Fe2+/H2O2 or AAPH and Fe2+/H2O2- or AAPH- 
treated synaptosomes isolated from gerbils previously injected i.p. with D609. There was 
a significant increase in protein-bound HNE levels in synaptosomes isolated from control 
gerbils treated with Fe2+/H2O2 or AAPH (p < 0.0001) when compared to control. 
Synaptosomes isolated from D609 injected gerbils subsequently treated with Fe2+/H2O2 
or AAPH showed significant decrease in protein bound HNE levels when compared to 
synaptosomes isolated from saline-injected gerbils treated with Fe2+/H2O2 or AAPH (p < 
0.001). 
8.6.4. 3NT 
Figure 8.7 shows levels of 3-NT in synaptosomes isolated from saline injected 
gerbils (control), synaptosomes isolated from control gerbils treated with Fe2+/H2O2 or 
AAPH and Fe2+/H2O2- and AAPH-treated synaptosomes isolated from gerbils previously 
injected i.p. with D609 . There was a significant increase in 3-NT levels in synaptosomes 
isolated from saline-injected gerbils treated with Fe2+/H2O2 or AAPH (p < 0.001) when 
compared to control. Synaptosomes isolated from D609 injected gerbils subsequently 
treated with Fe2+/H2O2 and AAPH showed a significant decrease in 3-NT levels when 
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compared to synaptosomes isolated from saline injected gerbils treated with Fe2+/H2O2 or 
AAPH (p < 0.001).  
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Figure 8.6: Significant increase in protein bound HNE levels in synaptosomes 
isolated from saline injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH 
compared to protein carbonyls in synaptosomes isolated from saline injected gerbils,  * p 
< 0.005.  Decreased protein bound HNE level in synaptosomes isolated from gerbils 
injected i.p. with D609 subsequently treated with Fe2+/H2O2 or AAPH relative to protein 
carbonyl level in synaptosomes isolated from gerbils injected with saline and 
subsequently treated with Fe2+/H2O2 or AAPH, ** p < 0. 005; the data are the mean ± 
SEM expressed as percentage of control values, (n = 6). 
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Figure 8.7: Significant increase in 3NT levels in synaptosomes isolated from 
saline-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH compared to 3-
NT levels in synaptosomes isolated from saline-injected gerbils,  * p < 0.005.  Decreased 
3NT levels in synaptosomes isolated from gerbils injected i.p. with D609 subsequently 
treated with Fe2+/H2O2 or AAPH relative to protein carbonyl level in synaptosomes 
isolated from gerbils injected with saline and subsequently treated with Fe2+/H2O2 or 
AAPH, ** p < 0. 005; the data are the mean ± SEM expressed as percentage of control 
values, (n = 6). 
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8.7. Discussion 
Oxidative stress has been implicated in many neurodegenerative disorders 
including AD (Butterfield, Drake et al., 2001). Oxidative stress arises due to an 
imbalance in the antioxidant system and generation of oxidants such as free radicals (Yu, 
1994). In AD, synaptic membranes are known to show increased oxidative stress 
(Hensley, Carney et al., 1994; Hensley, Hall et al., 1995). Synaptosomes were selected 
for our studies for the following reasons. Synaptic membranes have receptors for 
glutamate which mediate increase in intracellular Ca2+ and exitotoxicity and cause 
production of ROS and RNS including peroxynitrite and lead to subsequent protein 
oxidation (Hensley, Carney et al., 1994; Mattson, 1996). Elevation in Ca2+ level also 
causes change in mitochondrial potential and lead to production of superoxide ion 
radicals. Due to more energy usage in the synaptic region of neuron, mitochondria are 
concentrated in these areas of cell. Hence, the synaptic region of neurons becomes more 
vulnerable to oxidative stress.  
There are increasing evidence to demonstrate that AD brain is under oxidative 
stress (Butterfield, Drake et al., 2001). Oxidative damage to protein, lipids and DNA lead 
to cellular dysfunction and also cell death (Yu, 1994; Butterfield, 2002; Butterfield and 
Lauderback, 2002; Castegna, Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; 
Castegna, Thongboonkerd et al., 2003).  Due to relatively poor antioxidant defense 
available in brain, the high content of polyunsaturated fatty acids and the high oxygen 
utilization in brain, vulnerability of neurons towards oxidative stress is increased. Among 
the antioxidants present in brain, glutathione (GSH) is the most abundant and is present 
ubiquitously (Cooper, 1997).     
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A well known antioxidant and is a free radical scavenger, GSH is also involved in 
maintenance of cellular redox status, DNA synthesis and repair, protein synthesis, amino 
acid transport, binding of heavy metals and other functions (Cooper, 1997). Normally, in 
most cells the GSH/GSSG ratio is vastly shifted to the reduced form of GSH except 
under oxidative stress conditions. These two forms are interconvertible by the action of 
glutathione peroxidase and glutathione reductase (Hayes and McLellan, 1999).  
Many studies have shown that GSH protects the brain against various oxidants 
found in AD (Bains and Shaw, 1997). GSH is known to detoxify HNE, a lipid 
peroxidation product found to be elevated in AD brain (Sayre, Zelasko et al., 1997; 
Lovell, Xie et al., 1998; Xie, Lovell et al., 1998). It has also been shown that GSH 
protects cultured neurons against oxidative damage resulting from amyloid β-peptide, 
iron and HNE (Mark, Lovell et al., 1997; Mark, Pang et al., 1997). In addition, GSH can 
also protect brain from damage by peroxinitrite, hydroxyl free radicals or reactive 
alkenals (Koppal, Drake et al., 1999a; Koppal, Drake et al., 1999b; Pocernich, La 
Fontaine et al., 2000; Pocernich, Cardin et al., 2001; Drake, Kanski et al., 2002; Drake, 
Sultana et al., 2003). Low levels of GSH are associated with aging and many diseased 
conditions including AIDS, amyotrophic lateral sclerosis, AD (Bains and Shaw, 1997). 
The diminution of GSH levels in these conditions could be due to malfunctioning of 
enzymes required for GSH synthesis or due to insufficient supply of substrate involved in 
GSH metabolism.  
Tricyclodecan-9-yl-xanthogenate (D609) is a derivative of xanthic acid (Rao, 
1971) that has been reported as a phosphatidylcholine-specific phospholipase C inhibitor 
(Sauer, Amtmann et al., 1984; Monick, Carter et al., 1999). In performing this function, 
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D609 protects brain from ceramide-induced apoptosis and transcription of inflammatory 
molecules mediated by NF-κB (Schutze, Potthoff et al., 1992; Cifone, Roncaioli et al., 
1995; Li, Maher et al., 1998; Sortino, Condorelli et al., 1999). Since oxidative stress is 
involved in these processes, the antioxidant property of D609 was studied. Our lab 
demonstrated that D609 scavenges H2O2 (Lauderback, Drake et al., 2003). These studies 
suggested that D609 mimics glutathione (GSH) function in that it has a free thiol group, 
which upon oxidation forms a disulfide. The resulting dixanthate formed acts as a 
substrate for glutathione reductase, regenerating D609 (Lauderback, Drake et al., 2003). 
In addition, D609 binds to reactive alkenals formed due to peroxidation of lipids and 
detoxifies their effect, there-by preventing these alkenals from damaging synaptosomes 
(Lauderback, Drake et al., 2003).  
Intracellular elevation of glutathione has been used as therapeutics in many 
diseases (Anderson and Luo, 1998). Previously, our lab showed that i.p. injection of N-
acetyl cysteine (NAC) and gamma- glutamyl-cysteine ethyl ester (GCEE) reduced the 
oxidative stress markers in synaptosomes (Pocernich, Cardin et al., 2001; Drake, Kanski 
et al., 2002) by elevating the endogenous GSH levels. The i.p. injection of NAC protects 
synaptosomes against hydroxyl radical and acrolein and is also shown to protect in vitro 
oxidative stress caused by peroxynitrite (Koppal, Drake et al., 1999a; Pocernich, Cardin 
et al., 2001). Similar results have been shown with GCEE (Drake, Kanski et al., 2002). 
D609 reduces oxidative stress markers in vitro (Lauderback, Drake et al., 2003). Recent 
studies have also shown that D609 reduces the Aβ (1-42) induced oxidative stress and 
cytotoxicity in neuronal cell culture (Sultana, Shelley et al., 2004).  
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Protein oxidation is elevated in AD brain (Butterfield and Lauderback, 2002). 
Oxidation of protein leads to deactivation of enzymes critical for cell functioning, and 
recently our lab showed some of the critical proteins that are oxidized in AD by 
proteomics studies (Castegna, Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; 
Castegna, Thongboonkerd et al., 2003). Fe2+/H2O2 (hydroxyl radical formation) and 
AAPH (alkoxyl and peroxyl radical formation) are known to induce protein oxidation 
(Pocernich, La Fontaine et al., 2000; Kanski, Lauderback et al., 2001). We previously 
demonstrated by using Fenton chemistry (Fe2+/H2O2), D609 inhibits the formation of a 
PBN spin adduct, which shows hydroxyl radical scavenging property (Lauderback, Drake 
et al., 2003). Decreased protein oxidation was observed in neuronal cell culture pretreated 
with D609 on incubation with Aβ (1-42) (Sultana, Shelley et al., 2004). The results 
shown in this in vivo study are in consistent with the in vitro data, showing that D609 acts 
as an antioxidant. There was a significant reduction in protein carbonyl formation and 
3NT levels, both markers of protein oxidation, in synaptosomes isolated from D609 
injected gerbils subsequently treated with Fe2+/H2O2 or AAPH in comparison with 
synaptosomes isolated from saline injected gerbils and subsequently treated with 
Fe2+/H2O2 or AAPH. 
Lipid peroxidation products such as HNE and acrolein are known to be elevated 
in AD brain (Sayre, Zelasko et al., 1997; Lauderback, Hackett et al., 2001). These 
alkenals form the immediate substrate for GSH (Lovell, Xie et al., 1998; Xie, Lovell et 
al., 1998) and these lipid peroxidation products are known to be involved in apoptosis, 
which is seen as a consequence of GSH depletion (Mark, Lovell et al., 1997). Lipid 
peroxidation induced by Fenton chemistry was reduced by D609 in synaptosomes 
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(Lauderback, Drake et al., 2003). Decreased lipid peroxidation was observed in neuronal 
cell culture pretreated with D609 on incubation with Aβ (1-42) (Sultana, Shelley et al., 
2004) . We demonstrated previously that treatment of neuronal cultures with D609 
prevents apoptosis induced by Aβ (1-42) mediated oxidative stress (Sultana, Shelley et 
al., 2004). In the present study, there was a significant reduction in protein bound HNE 
levels in synaptosomes isolated from D609 injected gerbils subsequently treated with 
Fe2+/H2O2 and AAPH in comparison with synaptosomes isolated from saline injected 
gerbils and subsequently treated with Fe2+/H2O2 and AAPH. 
All the in vitro studies and studies on cultures show that D609 acts as an 
antioxidant. Our in vivo data are consistent with previously observed results. There was a 
reduction in ROS levels in synaptosomes isolated from gerbils injected i.p with D609 and 
subsequently treated with Fe2+/H2O2 or AAPH when compared to synaptosomes isolated 
from saline-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH. These 
results are consistent with the notion that D609 or its key metabolites may cross the blood 
brain barrier (BBB) and protect synaptosomes from oxidative stress induced by 
Fe2+/H2O2 or AAPH. In some of the data presented, the level of oxidative stress markers 
are below the control level in synaptosomes isolated from D609-treated rodent. This 
could be due to the presence of D609 in the system that could prevent oxidation of 
synaptosomes due to environmental oxidants, the kind of protection that is lacking in 
controls.  
In conclusion, the protection of synaptosomes, in vivo, by D609 is consistent with 
previous in vitro and cell culture studies. The presence of the thiol group in D609 is the 
basis for its antioxidant property, since the methylated derivative of D609 is inactive 
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(Sultana, Shelley et al., 2004). Xanthates in general are known to be the strong reducing 
agents (Rao, 1971). The thiol group in D609 could react with lipid peroxidation products 
and form Michael adducts and prevent these reactive lipid peroxidation products from 
causing neurotoxicity. These studies on an animal model could form the basis for 
eventual treatment strategies for oxidative stress related disorders, although additional 
studies are required to determine if this notion has merit. Studies on the effect of D609 on 
animal models of oxidative stress-related disorders are on progress.  
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Chapter 9 
In vivo protection by the xanthate D609 against amyloid β-peptide (1-42)-induced 
oxidative stress: Implications for Alzheimer’s disease 
9.1. Overview of the study 
Considerable evidence supports the role of oxidative stress in the pathogenesis of 
Alzheimer’s disease (AD). One hallmark of AD is the accumulation of amyloid β-peptide 
(Aβ), which invokes a cascade of oxidative damage to neurons that can eventually result 
in neuronal death. Aβ is the main component of senile plaques and generates free radicals 
ultimately leading to neuronal damage of membrane lipids, proteins and nucleic acids. 
Therefore, interest in the protective role of different antioxidant compounds has been 
growing for treatment of AD and other oxidative stress-related disorders. Among 
different antioxidant drugs, much interest has been devoted to “thiol-delivering” 
compounds. Tricyclodecan-9-yl-xanthogenate (D609) is an inhibitor of 
phosphatidylcholine specific phospholipase (PC-PLC), and recent studies reported its 
ability to act as a glutathione–mimetic compound. In the present study, we investigate the 
in vivo ability of D609 to protect synaptosomes against Aβ-induced oxidative stress. 
Gerbils were injected intraperitoneally (i.p.) with D609 or with saline solution, and 
synaptosomes were isolated from the brain. Synaptosomal preparations isolated from 
D609 injected gerbils and treated ex vivo with Aβ(1-42) showed a significant decrease of 
oxidative stress parameters: reactive oxygen species (ROS) levels, protein oxidation 
(protein carbonyl and 3-nitrotyrosine levels) and lipid peroxidation (4-hydroxy-2-nonenal 
levels). Our results are consistent with the hypothesis that modulation of free radicals 
generated by amyloid β-peptide might represent an efficient therapeutic strategy for 
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treatment of AD and other oxidative-stress related disorders. Based on the above data, we 
suggest that D609 is a potent antioxidant and could be of importance for the treatment of 
AD and other oxidative stress-related disorders. 
9.2. Introduction 
Alzheimer’s disease (AD) is a progressive neurological disorder characterized by 
loss of memory cognition. Major pathological hallmarks of AD include loss of synapses 
and the presence of senile plaques and neurofibrillary tangles. The major protein 
component of the core of senile plaques is amyloid β-peptide (Aβ). Aβ is formed upon 
proteolytic processing, by β- and γ-secretases (Haass and De Strooper, 1999), of the 
larger amyloid precursor protein (APP), a ubiquitously expressed transmembrane 
glycoprotein (Glenner and Wong, 1984; Glenner, Eanes et al., 1988). The amyloid β-
cascade hypothesis, suitably updated, postulates that Aβ is likely central to the 
pathogenesis of AD (Hardy and Allsop, 1991; Smith, Chen et al., 1999; Selkoe, 2001). 
The mechanisms involved in the Aβ-mediated neurotoxicity are unknown, but there is 
evidence suggesting that oxidative stress plays a key role (Butterfield, Drake et al., 2001; 
Butterfield and Lauderback, 2002; Canevari, Abramov et al., 2004). Growing attention 
has been focused to investigate the oxidative mechanism of Aβ toxicity and as well in the 
search for novel neuroprotective agents. Previous studies from our laboratory and others 
reported that Aβ peptide induces in vitro reactive oxygen species production, protein 
oxidation, DNA and RNA oxidation and lipid peroxidation (Butterfield, 2002). 
Because of the involvement of oxidative stress-mediated toxicity in 
neurodegenerative events and neuronal cell death (Good, Werner et al., 1996; Moreira, 
Smith et al., 2005), various experimental approaches for effective protection by 
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antioxidants have emerged. In addition, antioxidant therapy is being discussed for 
Parkinson’s disease (Ebadi, Srinivasan et al., 1996; Prasad, Cole et al., 1999), ischemia 
(Marczin, El-Habashi et al., 2003) as well as for AD (Grundman and Delaney, 2002; 
Gilgun-Sherki, Melamed et al., 2003) and other age-related disorders (Ames, 2004). 
Numerous potential free-radical scavengers have been tested in different experimental 
paradigms of oxidative stress-induced cell death, such as Vitamin E (Behl, Davis et al., 
1992), Vitamin C, melatonin (Pappolla, Sos et al., 1997), ginko biloba (Smith and Luo, 
2003), steroid hormones (Goodman, Bruce et al., 1996; Behl, Skutella et al., 1997), N-
acetylcysteine (Adair, Knoefel et al., 2001), etc. However, many clinical trials are still 
unsuccessful because all the antioxidants tested are poorly active in crossing the blood 
brain barrier (BBB). 
Glutathione is one of the major intracellular defense systems, and depletion of 
GSH is known to be involved in several neurodegenerative disorders (Benzi and Moretti, 
1995b; Markesbery, 1997; Butterfield, Castegna et al., 2002a). Many attempts have been 
made to develop antioxidant compounds able to “mimic” GSH as scavenger of reactive 
oxygen species (ROS) and to maintain the intracellular redox state. Increase in 
endogenous GSH levels by dietary or pharmacological intake of GSH precursor or GSH 
mimetic protects brain against oxidative stress (Anderson and Luo, 1998; Butterfield, 
Drake et al., 2001; Halliwell, 2001). Considering the importance of developing new 
antioxidant compounds and the relevance of their application in the treatment of 
neurodegenerative diseases, we focused our attention on tricyclodecan-9-yl-xanthogenate 
(D609). D609 is an inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC) 
(Schutze, Potthoff et al., 1992; Wiegmann, Schutze et al., 1994) and sphingomyelinase 
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(Yu, Nikolova-Karakashian et al., 2000; Meng, Luberto et al., 2004). D609 exhibits a 
variety of potent biological properties, including antitumor (Amtmann and Sauer, 1987), 
antiviral (Amtmann, Muller-Decker et al., 1987; Villanueva, Navarro et al., 1991) and 
anti-inflammatory activities (Machleidt, Kramer et al., 1996). The xanthate D609 is a 
reducing agent and it has been reported to protect rodents against UV-induced oxidative 
damage (Zhou, Lauderback et al., 2001). Previous studies from our laboratory have 
shown that D609 exerts its antioxidant properties acting as a glutathione (GSH)-mimetic 
compound (Lauderback, Drake et al., 2003). The free thiol group of the xanthate is 
oxidized to the corresponding disulfide (dixanthate) that is a substrate for GSH-reductase, 
regenerating D609 active form (xanthate). D609 can scavenge hydrogen peroxide and 
hydroxyl free radicals. In addition, D609 can bind directly to reactive alkenals, providing 
detoxification of these lipid peroxidation end-products thereby preventing oxidative 
damage of synaptic membranes (Lauderback, Drake et al., 2003). Recently, Sultana et al. 
demonstrated that D609 is protective against Aβ-induced toxicity in primary neuronal 
cultures (Sultana, Newman et al., 2004). 
9.3. Purpose of the study 
Based upon the mechanisms by which D609 scavenges free radicals, the aim of 
the present study was to investigate the ability of D609 to provide in vivo neuroprotection 
against Aβ-induced oxidative stress. The results are consistent with the hypothesis that 
D609 is a potent antioxidant and could be beneficial in the treatment of AD and other 
oxidative stress-related disorders. 
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9.4. Experimentals 
9.4.1. Chemicals 
D09 was purchased from Biomol Inc (Plymouth Meeting, PA) and most other 
chemicals were purchased from Sigma-Aldrich (St.Loius, MO, USA). The fluorescent 
indicator for ROS measurement, 2,7-dichlorofluorescein diacetate (DCFH-DA), was 
obtained from Molecular Probes (Eugene, OR, U.S.A.), and a fresh 10 mM stock solution 
was prepared in ethanol. Fresh D609 was dissolved in phosphate-buffered saline (PBS). 
The OxyBlot oxidized protein kit was obtained from Intergen, Inc. (Purchase, NY).  
Amyloid-β peptide (1-42) (HPLC and MS certified quality) was purchased from 
Anaspec, Inc. (San Jose, CA). For all experiments, Aβ was incubated for 24 hr in PBS at 
37 °C before application to synaptosomes. Primary antibodies for 4-hydroxynonenal 
(HNE) and 3-nitrotyrosine were obtained from Chemicon.  
9.4.2. Animals 
For the present study, three month-old male Mongolian gerbils, approximately 
100 g in size, were used to isolate synaptosomes. All the following protocols were 
approved by the University of Kentucky Animal Care and Use Committee. All the 
animals were kept under twelve hours light/dark condition at University of Kentucky 
Animal Facility, and fed with standard Purina rodent laboratory chow ad libidum. The 
gerbils (n=12, 12 separate sets of experiments) were injected i.p. with freshly prepared 
D609 (50 mg/Kg body weight) 1 hr before sacrifice. The dose and the time were chosen 
according to previous experiments performed in our laboratory (Joshi, Sultana et al., 
2005a). Control animals were injected with saline solution for the same time (n=12). The 
animals were euthanized with sodium pentobarbital before sacrifice.  
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9.4.3. Synaptosomal preparation 
Synaptosomes were prepared according to the procedure described by Keller et al. 
(Keller, Lauderback et al., 2000). The brain was isolated immediately after decapitation 
and placed in a 0.32M sucrose isolation buffer containing 4 μg/mL leupeptin, 4 μg/mL 
pepstatin, 5 μg/mL aprotinin, 20 μg/mL trypsin inhibitor, 0.2 mM PMSF, 2 mM EDTA, 
2mM EGTA, 20 mM HEPES pH 7.4. Samples were homogenized with a Wheaton tissue 
homogenizer and centrifuged at 1,500 x g for 10 minutes. The supernatant was collected 
and centrifuged at 20,000 x g for 10 min. The pellet was resuspended in 1mL of 0.32 
sucrose isolation buffer and layered onto discontinuous sucrose density gradients of 10 
mL each of 0.85M, pH 8.0; 1.0M, pH 8.0; 1.18M, pH 8.5 sucrose solution each 
containing 10mM Hepes, 2mM EDTA and 2mM EGTA. The gradients were spun in a 
Beckman L7-55 ultracentrifuge at 82,550 x g for 1 hr at 4 C. The synaptosomal layer was 
collected at the 1/1.18M sucrose interface, washed twice with PBS for 10 min at 32000g, 
yielding synaptosomes. Protein concentrations of the purified synaptosomes were 
determined by the BCA assay (Pierce, Rockford, IL). Synaptosomal preparations 
(1mg/mL) were incubated with 10 μM Aβ(1-42) for 6 hr at 37°C.  
9.4.4. Reactive oxygen species (ROS) measurements 
ROS levels were measured by dichlorofluorescein (DCF) assay. After incubation 
with Aβ(1-42), synaptosomes (1mg/mL) were washed with PBS and incubated with 10 
μM of non-fluorescent dichlorofluorescin diacetate (DCFH-DA) for 30 min. Cytosolic 
esterases cleaved DCFH-DA, forming the anion DCFH that is trapped within the 
synaptosomes. The reaction of intracellular ROS with DCFH yields the fluorescent dye 
DCF. Synaptosomes were spun at 3,000 x g in a tabletop Eppendorf centrifuge for 5 min 
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at 4°C. Synaptosomes were resuspended in 500 μL of PBS and run in triplicate (100 μL 
per well) in a black microtiter plate. The measurements were performed on a Molecular 
Devices SpectraMax microtiter plate reader with λex = 495 nm and λem = 530 nm. Data 
are given as percentage of corresponding controls and are the mean of at least six 
independent experiments. 
9.4.5. Protein carbonyl measurement 
Protein carbonyls are an index of protein oxidation and were determined as 
described previously (Berlett and Stadtman, 1997). Briefly, 5 μL of synaptosome 
preparations (4 mg/mL) were incubated at room temperature with 10 mM 2,4-
dinitrophenylhydrazine in the presence of 5 μL of 12% SDS for 20 min at room 
temperature. The samples were neutralized with 7.5 μL of the neutralization solution (2 
M Tris in 30% glycerol). 250 ng of protein sample was loaded into the wells of the slot 
blot apparatus. Proteins were transferred directly to nitrocellulose paper under vacuum 
pressure and standard immunochemical techniques were performed. Membranes were 
blocked in the presence of 3% bovine serum albumin (BSA) in TBS-T (10 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 0.05% Tween 20) for 1 h, followed by incubation with rabbit 
polyclonal antibody anti-DNP (1:100) for 1 h. The membrane were washed three times 
with TBS-T and incubated with alkaline-phosphatase (AP)-conjugated secondary 
antibody for 1 h. The specificity of primary antibodies has been previously demonstrated 
by experiments performed in our laboratory (Aksenov, Aksenova et al., 2001). Samples 
were developed using SigmaFast Tablets (BCIP/NBT) substrate), and blots were scanned 
into Adobe Photoshop (Adobe System, Inc., Mountain View, CA) and quantitated with 
Scion Image (PC version of Macintosh compatible NIH Image). 
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9.4.6. 3NT 
Nitrotyrosine contents were determined by incubating 5 μL of synaptosomes 
preparations with Laemmli buffer (0.125 M Trizma base, pH 6.8, 4% SDS, 20% glycerol) 
for 20 min. 250 ng of protein were blotted onto nitrocellulose membranes and 
immunochemical methods were performed. The rabbit anti–3-NT primary antibody was 
incubated 1:200 in blocking buffer (BSA 3% in TBS-T) for 2 h. The membranes were 
washed three times with TBS-T and incubated with alkaline phosphatase-conjugated goat 
anti-rabbit secondary antibody (1: 10,000). Densitometric analysis of bands in images of 
the blots was used to calculate levels of 3-NT. 
9.4.7. HNE 
Protein-bound HNE levels were measured as markers of lipid peroxidation. The 
samples (5 μL) were incubated with 10 μL Laemmli buffer for 20 min at room 
temperature. 250 ng of protein samples were loaded in each well on nitrocellulose 
membrane in a slot blot apparatus under vacuum. The membranes were incubated with 
anti–HNE rabbit polyclonal antibody (1: 5000) for 2 h, washed three times with TBS-T 
and then incubated with an anti-rabbit IgG alkaline phosphatase-conjugated secondary 
antibody (1:10,000). Controls in which the primary antibody was reacted with free HNE 
resulted in faint and non-specific binding of the antibody (data not shown). In addition, 
the specificity of primary and secondary antibodies was demonstrated by experiments 
previously performed in our laboratory (Sultana, Newman et al., 2004; Perluigi, Fai Poon 
et al., 2005). Samples were developed using SigmaFast Tablets (BCIP/NBT substrate), 
and blots were scanned into Adobe Photoshop (Adobe System, Inc., Mountain View, CA) 
and quantitated with Scion Image (PC version of Macintosh compatible NIH Image). 
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9.4.8. GSH assay 
GSH levels were measured by a GSH Assay Kit (Cayman Chemical Company, 
Ann Harbor, MI). Briefly, the cytosolic fraction isolated from brain homogenates was 
precipitated with 10% (w/v) metaphosphoric acid and then centrifuged for 5 min at 5,000 
X g. The supernatants were neutralized with 4M triethanolamine and then analyzed 
according to manufacturer instructions. GSH concentration in the samples was calculated 
using the kinetic method by measuring the absorbance at 405 nm with a Bio-Tek 
Powerwave X Microtiter Plate Reader (Bio, Inc.). A plot of the corrected absorbance vs 
the concentration of GSH standards (μM) was utilized to calculate the average 
concentration of GSH present in the samples. 
9.4.9. iNOS expression levels 
Synaptosome samples (50 μg) were mixed with sample loading buffer, denatured 
for 5 min at 100 °C and then loaded on 10% SDS-polyacrylamide gels. Proteins were 
transferred to nitrocellulose membrane in 25 mM Tris, 192 mM glycine containing 20% 
(v/v) at 80 mA/gel for 2 h. For iNOS detection, membranes were probed first with 10 ml 
of blocking buffer (3% BSA in TBS-T) containing rabbit anti-iNOS polyclonal antibody 
(Santa Cruz Biotechnology Inc., CA 1:1000) for 2 h at 27 °C, followed by 10 ml of 
blocking buffer containing alkaline phosphatase (AP)-conjugated goat anti-rabbit IgG 
from Sigma Chemical Co. (St. Louis, MO, 1:5000) for 1 h at 27 °C. Membranes were 
washed three times with T-TBS (0.5% tween in TBS) and the bands were visualized 
using SigmaFast Tablets (BCIP/NBT) substrate). iNOS protein levels were normalized 
relative to the β-actin level in each sample. 
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9.5. Statistical analysis 
ANOVA was used for statistical evaluation of data followed by Student’s t-test. P 
values < 0.05 were considered significant for comparison between control and 
experimental data. 
9.6. Results 
9.6.1. D609 prevents in vivo ROS accumulation 
The DCFH-DA method was used to monitor the ROS levels generated by Aβ(1-
42) in our experimental model. Figure 9.1 shows the levels of ROS in synaptosomes 
isolated from saline/D609 injected gerbils (CTR), in synaptosomes isolated from saline 
injected gerbils and treated in vitro with Aβ(1-42) and in synaptosomes isolated from 
D609 injected gerbils and treated in vitro with Aβ(1-42). In the absence of10 μM Aβ(1-
42), levels of ROS in synaptosomes from saline injected gerbils did not show any 
significant difference compared with the levels measured in synaptosomes from D609 
injected gerbils. Hence, both these groups can be referred as CTR. Thus, D609 itself does 
not reduce basal oxidation levels. Synaptosomes isolated from saline injected gerbils and 
treated with 10 μM Aβ(1-42) for 6 hrs displayed an increased fluorescence, about 20% 
compared to control synaptosomes (untreated) (p < 0.005). Synaptosomes isolated from 
D609 injected gerbils were not affected by Aβ(1-42)-induced ROS accumulation (p < 
0.002). Thus, D609 is able to prevent ROS accumulation in synaptosomes. 
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Figure 9.1: D609 prevents Aβ(1-42)-induced ROS production. ROS levels were 
determined by the DCF fluorescence assay. Ctr = synaptosomes isolated from saline 
injected gerbils with no further treatment (n=6, six separate sets of experiments); D609 = 
synaptosomes isolated from D609 injected gerbils with no further treatment (n=6); Aβ(1-
42) = synaptosomes isolated from saline injected gerbils and treated with 10 μM Aβ(1-
42) for 6 hrs (n=6); Aβ(1-42) + D609 = synaptosomes isolated from D609 injected 
gerbils and treated with 10 μM Aβ(1-42) for 6hrs (n=6). The data are the mean ± S.E.M 
of six independent experiments, expressed as percentage of control values. Statistical 
comparison was made using ANOVA test (n=6 for each group). (*) p < 0.005, Aβ(1-42) 
vs Control; (**) p < 0.002, Aβ(1-42) vs Aβ(1-42) + D609. 
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9.6.2. D609 in vivo protects against Aβ(1-42)-induced protein oxidation and 
lipid peroxidation 
Protein carbonyls and 3-NT levels were measured as markers of protein oxidation 
(Stadtman and Berlett, 1997). Collectively, ROS can lead to the oxidation of amino acid 
residue side chains, formation of protein-protein cross-linkages and oxidation of the 
protein backbones resulting in protein fragmentation. The presence of carbonyl groups in 
proteins has therefore been used as a marker of ROS-mediated protein oxidation. Fig. 
9.2a shows the carbonyl levels in synaptosomes isolated from saline injected gerbils and 
from D609 injected gerbils, and then treated in vitro with Aβ(1-42). The level of 
carbonyls was found to be significantly higher (p < 0.001) in synaptosomes obtained 
from saline injected gerbils and treated with Aβ(1-42). D609 treatment protects 
synaptosomes against Aβ(1-42)-induced oxidative protein damage (p < 0.004).  
In order to demonstrate the specificity of D609, two other Aβ peptides, Aβ(1-40) 
and control reverse of Aβ peptide (Aβ (42-1)) were used. Figure 9.2b shows the carbonyl 
levels in Various Aβ peptide treated synaptosomes and in synaptosomes isolated from 
D609 injected gerbils subsequently treated with Aβ(1-42), Aβ(1-40) and Aβ(42-1) 
respectively. As shown in figure, D609 treatment protects synaptosomes against Aβ(1-
42) and Aβ(1-40)-induced oxidative protein damage (p < 0.05). There was no significant 
increase in protein carbonyl levels in synaptosomes isolated from saline injected and 
D609 injected gerbils subsequently treated with Aβ(42-1).  
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Figure 9.2a: Protective effects of D609 on Aβ-induced protein oxidation. 
Synaptosomes isolated from saline injected gerbils and treated with 10μM Aβ(1-42) 
demonstrate a higher level of protein carbonyls than that of untreated controls (Ctr and 
D609). (*) p < 0.001, Aβ(1-42) vs Control. Synaptosomes isolated from D609 injected 
gerbils were completely protected from Aβ-induced oxidative modifications [Aβ(1-42) + 
D609]. (**) p < 0.004, Aβ(1-42) vs Aβ(1-42) + D609. (Data collected in collaboration 
with Dr. Marzia Perluigi) 
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Figure 9.2b: Protective effects of D609 on Aβ-induced protein oxidation. 
Synaptosomes isolated from saline injected gerbils and treated with 10μM Aβ(1-42) and 
10μM Aβ(1-40) demonstrate a higher level of protein carbonyls than that of untreated 
controls, whereas 10μM Aβ(42-1) did not show any significant increase in protein 
carbonyls. Synaptosomes isolated from D609 injected gerbils were completely protected 
from Aβ(1-42) andAβ (1-40) induced oxidative modifications. (*) p < 0.05, n = 5. 
The antioxidant properties of D609 were further confirmed by measuring 3NT 
levels, formed by reaction of reactive nitrogen species (RNS) with proteins (Castegna, 
Thongboonkerd et al., 2003). Figure 9.3 shows the protective effects of D609 on Aβ(1-
42)-induced formation of 3NT. Synaptosomes isolated from saline injected gerbils 
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showed increased levels of 3NT (p < 0.005) when treated in vitro with Aβ(1-42), while 
synaptosomes isolated from D609 injected gerbils were completely protected (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.3: Protective effect of D609 on Aβ-induced 3-NT formation. 3-NT 
levels were determined as described in the “Material and Methods” section. Ctr = 
synaptosomes isolated from saline or D609 injected gerbils with no further treatment; 
D609 = synaptosomes isolated from D609 injected gerbils with no further treatment; 
Aβ(1-42) = synaptosomes isolated from saline injected gerbils and treated with 10 μM 
Aβ(1-42) for 6 hrs; Aβ(1-42) + D609 = synaptosomes isolated from D609 injected 
gerbils and treated with 10 μM Aβ(1-42) for 6 hrs. The data are the mean ± S.E.M 
expressed as percentage of control values (n=6). (*) p < 0.005, Aβ(1-42) vs Control; (**) 
p < 0.05, Aβ(1-42) vs Aβ (1-42) + D609. (Data collected in collaboration with Dr. 
Marzia Perluigi) 
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Free radical attack on phospholipids PUFA leads to the formation of reactive 
aldehydes, among which one of the most neurotoxic is HNE (Esterbauer, Schaur et al., 
1991). This alkenal reacts with proteins forming stable covalent adducts to histidine, 
lysine and cysteine residues via Michael addition. The extent of this reaction can be 
measured immunochemically by quantifying the levels of HNE-bound proteins. Figure 
9.4 shows the HNE-bound protein levels in synaptosomes isolated from gerbils 
previously injected with D609 or with saline solution and incubated in vitro with 10 μM 
Aβ(1-42) for 6 hrs. Consistent with the protein oxidation results showed above, we 
observed in vivo protection by D609 against 10 μM Aβ-induced lipid peroxidation. HNE 
levels were found to be higher in Aβ(1-42)-treated synaptosomes isolated from saline 
injected gerbils, while Aβ(1-42)-treated synaptosomes isolated from D609 injected 
gerbils showed reduced levels of HNE-bound proteins. These results are consistent with 
recent in vitro data obtained on primary neuronal cultures (Sultana, Newman et al., 
2004), indicating that D609 acts as a potent antioxidant thus preventing protein oxidation 
and lipid peroxidation.  
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Figure 9.4: Protective effect of D609 on Aβ-induced lipid peroxidation (HNE 
levels). HNE levels were determined as described in the “Material and Methods” section. 
Ctr = synaptosomes isolated from saline/D609 injected gerbils; D609 = synaptosomes 
isolated from D609 injected gerbils with no further treatment; Aβ(1-42) = synaptosomes 
isolated from saline injected gerbils and treated with 10 μM Aβ(1-42) for 6 hrs; Aβ(1-42) 
+ D609 = synaptosomes isolated from D609 injected gerbils and treated with 10 μM 
Aβ(1-42) for 6 hrs. The data are the mean ± SEM expressed as percentage of control 
values (n=6). (*) p < 0.005, Aβ(1-42) vs Control; (**) p < 0.05, Aβ(1-42) vs Aβ (1-42) + 
D609. (Data collected in collaboration with Dr. Marzia Perluigi) 
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9.6.3. D609 modulates Aβ(1-42)-induced iNOS expression levels 
As shown in Fig. 9.5, iNOS levels were significantly increased (40%) in 
synaptosomes isolated from DMSO-injected gerbils treated with Aβ(1-42) when 
compared with controls (p < 0.01). In contrast, we observed a decrease in expression of 
iNOS in synaptosomes isolated from D609-injected gerbils (p < 0.05) and subsequently 
treated with Aβ(1-42), a result that is consistent with our findings of decreased levels of 
3-NT. Several lines of evidence show that iNOS expression is induced by oxidative stress 
and that antioxidant compounds suppress its expression either at gene level or at protein 
level (Ayasolla, Khan et al., 2004; Calabrese, Stella et al., 2004). In the present study, we 
observed that both iNOS and 3NT levels were increased in Aβ(1-42)-treated 
synaptosomes and that D609 treatment showed protection against the Aβ(1-42)-induced 
increase of iNOS and 3-NT levels. 
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Figure 9.5: Western blot analysis of synaptosomes for iNOS protein expression 
levels. Samples containing 50 μg of protein were loaded onto 10% SDS-PAGE gels, and 
the blots were probed with the polyclonal anti-iNOS antibody (1:1000) for 2 h. 
Immunoblots were scanned by densitometry and all values were normalized to β-actin. A 
representative immunoblot (A) and densitometric values (B) are shown. Densitometric 
values represent the mean ± S.E.M. obtained from three independent experiments. 
Significant differences were assessed by ANOVA. * p < 0.01, control vs Aβ(1-42); ** p 
< 0.05, Aβ(1-42) + D609. (Data collected in collaboration with Dr. Marzia Perluigi) 
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9.7. Discussion 
Oxidative damage is present in the brains of patients with AD, and is observed 
within every class of biomolecules, including nucleic acids, proteins, lipids and 
carbohydrates (Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002; 
Castegna, Thongboonkerd et al., 2003). Our laboratory has suggested a comprehensive 
model for neurodegeneration in AD combining two established notions: i) elevated 
oxidative stress in AD brain; ii) centrality of Aβ in the cause and consequences of this 
dementing disorder (Butterfield and Lauderback, 2002; Castegna, Thongboonkerd et al., 
2003). Many additional studies from different labs have supported the view that oxidative 
stress may be central to the Aβ-driven neurodegeneration. Based on these notions, 
treatment with brain accessible antioxidants may be a promising approach for slowing 
disease progression to the extent that oxidative damage may be responsible for the 
cognitive and functional decline observed in AD.  
Previous studies from our laboratory and others have shown that Aβ(1-42) is 
associated with free radical generation leading to oxidative damage of proteins, lipids, 
DNA and RNA (Varadarajan, Yatin et al., 2000; Butterfield, Drake et al., 2001; 
Butterfield and Lauderback, 2002). The oxidation of proteins by free radicals or free 
radical oxidation products may be responsible for damaging enzymes critical in neuronal 
function (Varadarajan, Yatin et al., 2000; Butterfield, Boyd-Kimball et al., 2003). 
In the present study, we showed the ability of in vivo-injected D609 to provide 
neuroprotection against oxidative stress induced by Aβ(1-42) on subsequently isolated 
synaptosomes. A variety of well established and new potential antioxidant compounds 
are under investigation to prevent Aβ-induced toxic effects (Behl, 2002; Grundman and 
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Delaney, 2002). Among different classes of antioxidant drugs, much interest has been 
devoted to “thiol-delivering” compounds. Because decreased levels of GSH are 
associated with aging and neurodegeneration (Liu and Choi, 2000; Butterfield, Castegna 
et al., 2002a), therapeutic strategies based on elevation of GSH levels have been shown to 
be protective against oxidative stress conditions of the brain (Butterfield, Castegna et al., 
2002a). The age-related decrease of GSH may represent a key factor in the aging process 
and may underlie a number of changes occurring in normal aging and the onset of various 
diseases.  
We have previously shown that the antioxidant properties of D609 are associated 
with the free thiol group of the xanthate (Lauderback, Drake et al., 2003). For example, 
methylated D609 is unable to protect cultured neurons from damage by Aβ(1-42) 
(Sultana et al., 2004).   D609 in its reduced form is oxidized to the corresponding 
disulfide (dixanthate) that is converted back to the xanthate by GSH reductase 
(Lauderback et al., 2003). D609 has been reported to protect against glutamate toxicity 
and ionizing radiation-induced oxidative stress in lymphocytes by maintaining 
intracellular GSH homeostasis (Zhou, Lauderback et al., 2001). The results presented in 
this paper demonstrated that in vivo injection of D609 was effective in reducing protein 
oxidation, lipid peroxidation and ROS production induced by Aβ(1-42) treatment.  
The concept that Aβ induces lipid peroxidation is a key component of the Aβ(1-
42)-associated free radical model for neurodegeneration in AD (Butterfield, 1997; 
Varadarajan, Yatin et al., 2000; Lauderback, Hackett et al., 2001). HNE alters the 
conformation of transmembrane and cytoskeletal synaptosomal proteins (Esterbauer, 
Schaur et al., 1991; Subramaniam, Roediger et al., 1997). GSH blocks the damaging 
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effects of this unsaturated aldehyde on synaptosomal proteins (Pocernich, La Fontaine et 
al., 2000; Pocernich, Cardin et al., 2001). As noted above, D609 binds to α,β-unsaturated 
aldehydes to prevent their toxicity (Lauderback, Drake et al., 2003). Taken together, 
these data support the notion that the ability of D609 to exert its protective effects against 
Aβ-associated lipid peroxidation involves its direct binding to HNE thus providing an 
efficient tool for detoxication. Consistent with the Aβ-associated free radical process, 
Aβ(1-42) induces protein oxidation, indexed by the increase of carbonyl levels and of 
nitrotyrosine residues. Oxidative modification of crucial proteins results in alteration of 
their structural and functional properties, eventually leading to synapse loss and 
neurodegeneration.  
There is compelling evidence supporting that enhanced pro-inflammatory 
activities induced by Aβ are associated with the pathogenesis and/or progression of AD, 
and that some anti-inflammatory agents protect neurons against Aβ-induced neurotoxicity 
(Breitner, 1996). One of the principal enzymes that play a pivotal role in mediating an 
inflammatory response is inducible nitric oxide synthase (iNOS). iNOS is mainly 
localized in astrocytes and microglia, and catalyzes the oxidative deamination of L-
arginine to produce nitric oxide (NO), a potent pro-inflammatory mediator. In 
Alzheimer’s tissue, pro-inflammatory iNOS is notably up-regulated and colocalized in 
Aβ plaques. Several studies have demonstrated that Aβ stimulates microglial and 
astrocytic iNOS induction and subsequent NO production (Akama and Van Eldik, 2000). 
We observed an increase in 3NT levels in synaptosomes isolated from DMSO-injected 
gerbils and treated with Aβ(1-42) that coincides with a parallel increase in iNOS levels. 
Pre-treatment with D609 reduced significantly the levels of iNOS and of nitrated 
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proteins. iNOS induction may reflect the degree of inflammation associated to Aβ(1-42), 
and the ability of D609 to block this effect may represent a further additional protective 
mechanism in addition to the antioxidant potential of this xanthate. 
The levels of oxidized glutathione are consistently elevated in Alzheimer’s 
patients as compared to their age-matched controls and correlate with cognitive 
dysfunction (Vina, Lloret et al., 2004). Recent findings suggested that Aβ could initiate a 
cascade of events resulting in a severe depletion of glutathione (Abramov, Canevari et al., 
2003). Alteration of glutathione homeostasis impairs neuronal viability because GSH 
depletion leaves the neurons vulnerable to damage by oxidative stress. Here, we 
demonstrated that D609 is able to provide neuroprotection against Aβ-induced 
neurotoxicity acting as a glutathione-mimetic compound, thus modulating the effects of 
GSH depletion. Previous studies from our laboratory have shown that i.p. administration 
of N-acetylcysteine and of gamma-glutamyl-cysteine ethyl ester (GCEE) protected 
synaptosomes against oxidative stress (Pocernich, Cardin et al., 2001; Butterfield, 
Castegna et al., 2002a; Boyd-Kimball, Sultana et al., 2005a). These compounds led to an 
increase of brain glutathione by serving as precursor for GSH biosynthesis. Because 
glutathione itself penetrates the blood-brain barrier only poorly and cannot be taken up by 
neurons directly, other treatment options to increase brain concentration of glutathione 
including glutathione analogs, mimetic or precursors have been used in patients or animal 
models. Based on the results presented in the current paper and on our previous studies 
(Sultana, Newman et al., 2004), we hypothesized that D609 is a potential brain-accessible 
GSH-mimetic compound. This hypothesis that D609 is a GSH mimetic that is itself not 
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GSH is further supported by the finding that D609 treatment does not lead to an increase 
of brain GSH levels (Table 9.1). 
Injection GSH (mM) ± S.E.M 
Control 4.27 ± 0.87 
D609 3.98 ± 0.54 
 
Table 9.1: D609 does not influence total brain GSH levels. Results presented are 
the mean ± S.E.M, n=6. Total GSH levels, following i.p D609 injection, were measured 
by a GSH assay kit as described in the Chapter 3. 
The ability of in vivo D609 to prevent Aβ-induced oxidative stress could also be 
related to its property as an inhibitor of PC-PLC and sphingomyelinase. Most of D609 
biological activities (antitumor, antiviral, anti-inflammatory) have been largely attributed 
to the inhibition of PC-PLC and sphingomyelinase. However, the identification of D609 
as a potent antioxidant implies that D609 may exert some of the reported activities by its 
antioxidant properties. The biological activity of PC-PLC and sphingomyelinase involves 
regulation of Ca+2 homeostasis through the production of ceramide. Since Aβ may lead to 
altered Ca+2 homeostasis in neurons (Mattson, Barger et al., 1993), it is reasonable to 
argue that the protective effects of D609 could rely also on its inhibitory activity on PC-
PLC or sphingomyelinase. Thus, we suggest that multiple biological functions of D609 
could potentially contribute to counteract Aβ-driven neurotoxicity in the brain. The 
presence of the free thiol group in the molecule confers to the xanthate a strong reducing 
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property (Rao, 1971; Lauderback, Drake et al., 2003; Sultana, Newman et al., 2004) that 
is undoubtedly responsible for the antioxidant activity of D609.  
Considering that Aβ(1-42) is a potent inducer of oxidative stress and that the 
deposition of this peptide can induce the cascade of pathological changes occurring in 
AD, many attempts to test effective protection by antioxidants are currently under 
investigation.  However, many clinical trials are unsuccessful due to a low brain-
accessible capability of the antioxidant compounds tested. Based on these notions, 
searches for new potential antioxidant compounds could be of relevance for future 
directions of AD treatments.  
In conclusion, the present study demonstrated the ability of D609 to act as a 
potent antioxidant in vivo, thereby providing neuroprotection against Aβ-induced 
oxidative stress. Further studies are required to gain insight into the potential use of D609 
in the treatment of AD and other oxidative stress-related disorders. Investigations of the 
use of D609 on animal models of AD are in progress. 
Note: A part of this study was carried out by Dr. Marzia Perluigi in Prof. Butterfield`s 
laboratory that has been supported by a post-doc grant of the University of Rome “La 
Sapienza”. 
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Chapter 10 
In vivo administration of D609 leads to protection of subsequently isolated gerbil 
brain mitochondria subjected to in vitro oxidative stress inducers: Relevance to 
Alzheimer’s disease and other oxidative stress related neurodegenerative disorders 
10.1. Overview of the study 
Tricyclodecan-9-yl-xanthogenate (D609) has in vivo and in vitro antioxidant 
properties. D609 mimics glutathione (GSH), has a free thiol group, which upon oxidation 
forms a disulfide. The resulting dixanthate is a substrate for glutathione reductase, 
regenerating D609. Recent studies have also shown that D609 protects brain in vivo and 
neuronal cultures in vitro against the potential Alzheimer’s disease  (AD) causative 
factor, Aβ (1-42)-induced oxidative stress and cytotoxicity. Mitochondria are important 
organelles with both pro- and anti-apoptotic factor proteins. The present study was 
undertaken to test the hypothesis that i.p. injection of D609 would provide 
neuroprotection against free radical-induced, mitochondria-mediated apoptosis, in vitro. 
Brain mitochondria were isolated from gerbils 1 h post injection intraperitonially (i.p.) 
with D609 and subsequently treated in vitro with the oxidants Fe2+/H2O2 (hydroxyl free 
radicals), 2,2-azobis-(2-amidinopropane) dihydrochloride (AAPH, alkoxyl and peroxyl 
free radicals) and AD-relevant amyloid β-peptide 1-42 [Aβ (1-42)]. Brain mitochondria 
isolated from the gerbils previously injected i.p. with D609 and subjected to these 
oxidative stress inducers, in vitro, showed significant reduction in levels of protein 
carbonyls, protein-bound hydroxynonenal (HNE) [a lipid peroxidation product], 3-
nitrotyrosine (3-NT), and cytochrome-c release compared to oxidant-treated brain 
mitochondria isolated from saline-injected gerbils. D609 treatment significantly 
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maintains the GSH/GSSG ratio in oxidant-treated mitochondria. Increased activity of 
glutathione-S-transferase (GST), glutathione peroxidase (GPx) and glutathione reductase 
(GR) in brain isolated from D609-injected gerbils is consistent with the notion that D609 
acts like GSH. These anti-apoptotic findings are discussed with reference to the potential 
use of this brain-accessible glutathione mimetic in the treatment of oxidative stress-
related neurodegenerative disorders, including AD. 
10.2. Introduction 
Oxidative stress has been implicated in many neurodegenerative disorders, 
including Alzheimer's disease (AD) (Hensley, Hall et al., 1995; Markesbery and Lovell, 
1998; Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002), AD is 
characterized clinically by progressive dementia and pathologically by extracellular 
amyloid protein deposits, intracellular neurofibrilary tangles (NFTs) (composed mostly of 
hyperphosphorylated tau protein), loss of synapses, mitochondrial dysfunction and 
programmed cell death (PCD) (Katzman and Saitoh, 1991; Bosetti, Brizzi et al., 2002). 
The reduced energy metabolism in AD may be due to oxidative dysfunction of some of 
the key metabolic or mitochondrial enzymes (Castegna, Aksenov et al., 2002a; Castegna, 
Thongboonkerd et al., 2003; Butterfield, 2004; Castegna, Thongboonkerd et al., 2004; 
Sultana, Boyd-Kimball et al., 2006b; Sultana, Poon et al., 2006b), which may lead to 
increased reactive oxygen species (ROS) production.  
It is well known that mitochondria are the major cellular site of energy 
production, and these organelles also play a key role in the ROS generation, resulting in 
oxidative damage to neurons. Amyloid deposition, oxidative stress, mitochondria DNA 
deletion and mitochondrial structural and functional abnormalities are prominent in AD 
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(Bosetti, Brizzi et al., 2002; Huang, Zhang et al., 2004; Aliyev, Chen et al., 2005). Many 
pro-apoptotic signals and anti-apoptotic defenses converge in the mitochondria 
(Antonsson, 2004). Protein factors (cytochrome-C, Apaf1, AIF and SMAC/DIBLO) and 
Ca2+ released from mitochondria during oxidative stress activate caspase dependent 
and/or caspase independent mechanisms that lead to apoptotic cell death (Antonsson, 
2004). The role of mitochondria is not only as ATP producers but also as regulators of 
intracellular Ca2+ homeostasis and endogenous producers of ROS. Increased 
mitochondrial Ca2+ overload has been associated with the generation of superoxide and 
the release of pro-apoptotic mitochondrial proteins leading to cell death (Zamzami, 
Marchetti et al., 1995; Sheehan, Swerdlow et al., 1997).  The alterations in Ca2+ 
homeostasis and ROS generation lead to increased susceptibility to cell death under 
circumstances that are otherwise not ordinarily toxic (Sheehan, Swerdlow et al., 1997).  
In AD brain ROS lead to protein oxidation (Hensley, Hall et al., 1995; Castegna, 
Aksenov et al., 2002a; Castegna, Thongboonkerd et al., 2003; Butterfield, 2004; 
Castegna, Thongboonkerd et al., 2004; Sultana, Boyd-Kimball et al., 2006b; Sultana, 
Poon et al., 2006b), lipid peroxidation (Markesbery and Lovell, 1998; Butterfield and 
Lauderback, 2002), DNA and RNA oxidation (Mecocci, MacGarvey et al., 1993; Lovell, 
Gabbita et al., 1999; Nunomura, Perry et al., 1999), and neuronal dysfunction or death. 
Recent studies indicate that protein oxidation and lipid peroxidation in brain from mild 
cognitive impairment subjects (Butterfield, Poon et al., 2006; Butterfield, Reed et al., 
2006), suggesting oxidative stress is an early event in the pathogenesis of AD. ROS 
generation from mitochondria and its impact on neuronal systems hence becomes 
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important in understanding oxidative stress and oxidative stress-related disorders, 
including AD.  
Mitochondrial electron transport is a potential source of ROS production (Ide, 
Tsutsui et al., 1999). It is now well known that ROS such as superoxide anion (O2-), 
hydroxyl radical (OH), hydrogen peroxide (H2O2), and peroxynitrite (ONOO-) contribute 
to neurodegeneration (Zhang, Dawson et al., 1994; Rego and Oliveira, 2003; Ansari, 
Ahmad et al., 2004; Butterfield, Reed et al., 2006; Tangpong, Cole et al., 2006a). 
Mitochondrial membrane potential depolarization induces cytochrome-c release into the 
cytoplasm and elevates the activity of caspase-3, suggesting a role for mtDNA-derived 
mitochondrial dysfunction in AD degeneration (Bosetti, Brizzi et al., 2002).  
Glutathione is widely recognized as an endogenous nonenzymatic antioxidant, an 
oxyradical scavenger, thereby useful in protecting against oxidative damage by free 
radicals and inhibiting lipid peroxidation and DNA damage (Meister, 1995; Darley-
Usmar and Halliwell, 1996; Sies, 1999; Schulz, Lindenau et al., 2000; Hansen, Go et al., 
2006). Glutathione has been implicated in a wide range of metabolic processes, including 
cell division, DNA repair, regulation of enzyme activity, activation of transcription 
factors, modulation of anion and cation homeostasis and protection against oxidative 
damage (Meister and Anderson, 1983). The nervous system is particularly susceptible to 
oxidative insults, and dependent on its glutathione defense. 
Tricyclodecan-9-yl-xanthogenate (D609) exhibits a variety of potent biological 
functions, including antiviral (Amtmann, 1996) and anti-inflammatory (Amtmann and 
Sauer, 1987; Sauer, Amtmann et al., 1990; Tschaikowsky, Schmidt et al., 1998) 
activities. Most of these activities have been linked to the inhibitory effect of D609 on 
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phosphatidylcholine-specific phospholipase C (PC-PLC) (Schutze, Potthoff et al., 1992; 
Amtmann, 1996). Such inhibition decreases production of the secondary messenger 
diacylglycerol (DAG) that activates protein kinase C (PKC) and acidic sphingomyelinase 
(aSMase) (Cifone, Roncaioli et al., 1995). However, with a free thiol group, D609 may 
also possess strong antioxidant activity (Rao, 1971) with in vitro and in vivo radical 
scavenging properties and inhibition of free radial-induced oxidative stress (Zhou, 
Lauderback et al., 2001; Lauderback, Drake et al., 2003; Sultana, Newman et al., 2004; 
Joshi, Sultana et al., 2005a; Perluigi, Joshi et al., 2006). 
10.3. Purpose of the study 
The particular species of ROS that D609 can effectively scavenge is not clear, but 
this xanthate has ability to scavenge hydroxyl radicals (Zhou, Lauderback et al., 2001; 
Lauderback, Drake et al., 2003; Sultana, Newman et al., 2004; Joshi, Sultana et al., 
2005a; Perluigi, Joshi et al., 2006). The reaction with other ROS is also possible since 
xanthates generally have high reductive potential (Rao, 1971). D609 may protect 
intracellular GSH, which is important intracellular defense molecule against oxidative 
stress in neurons and has been shown to play an important role in radiation protection 
(Anderson and Luo, 1998; Halliwell, 2001; Zhou, Lauderback et al., 2001). Recently, we 
showed that D609, a glutathione mimetic (Lauderback, Drake et al., 2003), protects 
primary neuronal culture against amyloid β-peptide (1-42) [Aβ (1-42)]-induced oxidative 
stress and neurotoxicity in vitro (Sims, 1990) and in synaptosomes in vivo (Perluigi, Joshi 
et al., 2006). 
We performed the current study to test the hypothesis that the D609-mediated in 
vivo protection of brain mitochondria against subsequent in vitro treatment of various 
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oxidants, including Aβ (1-42), is associated with D609-mediated modulation of GSH and 
GSH related enzyme activities. 
10.4. Experimentals 
10.4.1. Animals 
For all studies male Mongolian gerbils (2–3 months of age), approximately 100 g 
in size, housed in the University of Kentucky Central Animal Facility under 12-h 
light/dark conditions and fed standard Purina rodent laboratory chow ad libitum, were 
used. The animal protocols were approved by the University of Kentucky Animal Care 
and Use Committee. 
10.4.2. Chemicals 
D609 was purchased from Biomol (Plymouth Meeting, PA, USA) and all other 
chemicals were purchased from Sigma–Aldrich (St. Louis, MO, USA). Fresh D609 (50 
mg/ kg body wt) was prepared in phosphate-buffered saline (PBS). The primary anti body 
for 4-hydroxy-nonenal (HNE) and 3-nitrotyrosine (3-NT) were purchased from 
Chemicon International. 
10.4.3. Preparation of mitochondria 
Brain mitochondria were isolated from gerbils previously injected i.p. with saline 
(control) or with D609 (50 mg/ kg body wt), 60 min after injection. This time and level of 
D609 were chosen based on previous (Joshi, Sultana et al., 2005a) dose-response 
experiments. The brain mitochondria were isolated according to the procedure of Sims et 
al. (Sims, 1990) with minor modifications. Gerbils were decapitated and the whole brain 
was isolated on ice. Whole brain was homogenized in ice-cold isolation buffer (250 mM 
sucrose, 10 mM HEPES, and 1 mM potassium EDTA, pH 7.2, 4 μg/ml leupeptin, 4 
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μg/ml pepstatin, 5 μg/ml aprotinin 20 μg/ml trypsin inhibitor) with 6 passes of a Wheaton 
tissue homogenizer. The homogenate was centrifuged for 3 min at 1,330× g at 4°C, and 
the resulting pellet was resuspended in isolation buffer and centrifuged at 1,330× g for 3 
min. The supernatants from both spins were combined and spun at 21,200x g for 10 min 
at 4°C. The pellet was resuspended in 15% Percoll solution (v/v in isolation buffer) and 
layered onto discontinuous Percoll gradients of 23 and 40% Percoll (v/v in isolation 
buffer). Gradients were centrifuged at 30,700× g for 5 min at 4°C. At the 23-40% Percoll 
interface, mitochondria were isolated and resuspended in respiration buffer (250 mM 
sucrose, 2 mM magnesium chloride, 20 mM HEPES, and 2.5 mM phosphate buffer, pH 
7.2) and centrifuged at 16,700× g for 10 min at 4°C. The pellet was resuspended in 
respiration buffer, centrifuged at 6,900× g for 10 min at 4°C, and the resulting pellet was 
washed in PBS at 6,900× g for 10 min at 4°C.  
10.4.4. Protein estimation and treatment 
The pellet was resuspended in 250 μl PBS and protein concentration determined 
by the Pierce BCA method (Bradford, 1976), using bovine serum albumin (BSA) as a 
standard. The mitochondrial samples were divided into six aliquots and incubated at 37 
0C. The first sample set was incubated without treatment of any oxidant for 1 h; the 
second set of mitochondria was incubated with 30 μM Fe SO4 and 2.0 mM H2O2, a 
process that induces hydroxyl radical formation (Halliwell and Gutteridge, 1999), the 
third and fourth set of samples were also incubated in same manner with/or without the 
oxidant AAPH (1 mM) for 1 h at 37 0C. The fifth sample set was incubated without 
treatment of any oxidant for 6 h and the sixth sample set was incubated with Aβ(1-42) for 
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6 h. The mitochondrial samples were washed after incubation and resuspended in 
PBS/Tween. 
10.4.5. Protein carbonyls 
Protein carbonyls are markers of protein oxidation and were assessed by 
following the standard protocol described previously (Joshi, Sultana et al., 2005a). 
Samples (5 μl) (normalized to 4 mg/ml), 5 μl of 12% sodium dodecyl sulfate (SDS), and 
10 μl of 10 times diluted 2,4-dinitrophenyl hydrazine (DNPH) from 200 mM stock were 
incubated at room temperature for 20 min. Samples were neutralized with 7.5 μl 
neutralization solution (2 M Tris in 30% glycerol). The resulting solution was loaded into 
each well on nitrocellulose membrane under vacuum using a slot-blot apparatus. The 
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS/Tween for 
1 h and incubated with a 1:100 dilution of anti-DNP polyclonal antibody in PBS/Tween 
for 1 h. The membrane was washed three times in PBS/Tween and was incubated for 1 h 
with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS/ Tween 
in a 1:8000 ratio. The membrane was washed three times in PBS/ Tween for 5 min and 
developed in Sigma Fast tablets (BCIP/ NBT substrate). Blots were dried, scanned with 
Adobe PhotoShop, and quantified with Scion Image (PC version of Macintosh-
compatible NIH Image). No non-specific binding of antibody to the membrane was 
observed. 
10.4.6. 3NT 
Samples (5 μl) (normalized to 4 mg/ml), 5 μl of 12% SDS, and 5 μl of modified 
Laemmli buffer containing 0.125 M Tris base, pH 6.8, 4% (v/v) SDS, and 20% (v/v) 
glycerol were incubated for 20 min at room temperature. Sample (250 ng) was loaded 
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into each well on a nitrocellulose membrane in a slot blot apparatus under vacuum. The 
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS/Tween for 
1 h and incubated with a 1:2000 dilution of anti-3-N T polyclonal antibody in 
PBS/Tween for 1 h 30 min. The membrane was washed in PBS/Tween for 5 min three 
times after incubation. The membrane was incubated for 1 h, after washing, with an anti-
rabbit IgG alkaline phosphatase secondary anti body diluted in PBS/Tween in a 1:8000 
ratio. The membrane was washed three times in PBS/Tween for 5 min and developed in 
Sigma Fast tablets. Blots were dried, scanned with Adobe PhotoShop, and quantified 
with Scion Image as above. No non-specific binding of antibody to the membrane was 
observed. 
10.4.7. HNE 
Sample (5 μl) (normalized to 4 mg/ml), 5 μl of 12% SDS, and 5 μl of modified 
Laemmli buffer containing 0.125 M Tris base, pH 6.8, 4% (v/v) SDS, and 20% (v/v) 
glycerol were incubated for 20 min at room temperature. Sample (250 ng) was loaded 
into each well on a nitrocellulose membrane in a slot blot apparatus under vacuum. The 
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS/Tween for 
1 h and incubated with a 1:5000 dilution of anti-HNE polyclonal antibody in PBS/Tween 
for 1 h 30 min. The membrane was washed in PBS/Tween for 5 min three times after 
incubation. The membrane was incubated for 1 h, after washing, with an anti-rabbit IgG 
alkaline phosphatase secondary antibody diluted in PBS/Tween in a 1:8000 ratio. The 
membrane was washed three times in PBS/Tween for 5 min and developed in Sigma Fast 
tablets. Blots were dried, scanned with Adobe PhotoShop, and quantified with Scion 
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Image as above. A faint background staining due to the antibody alone was observed, but 
since each sample had a control, this minor effect was well controlled. 
10.4.8. Estimation of cytochrome-c release 
Cytochrome c release was detected by the method of Yang et al., (1997) (Yang, 
Liu et al., 1997)with slight modification. After incubation and spun of mitochondrial 
samples, supernatant was used for Western blot analysis to cytochrome c release. The 
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS/Tween for 
1 h and incubated with a 1:2000 dilution of anti-cytochrome-c polyclonal antibody (C-
5723; anti-sheep; Sigma) in PBS/Tween for 1 h 30 min. The membrane was washed in 
PBS/Tween for 5 min three times after incubation. The membrane was incubated for 1 h, 
after washing, with an anti-sheep IgG alkaline phosphatase secondary anti body diluted in 
PBS/Tween in a 1:8000 ratio. The membrane was washed three times in PBS/Tween for 
5 min and developed in Sigma Fast tablets. Blots were dried, scanned with Adobe 
PhotoShop, and quantified with Scion Image as above.  
10.4.9. Estimation of reduced glutathione (GSH) 
Determination of GSH was performed by the method of Hissin and Hilf (Hissin 
and Hilf, 1976). The reaction mixture containing 0.1 M sodium phosphate buffer (pH-
8.0), 5.0 mM EDTA, 10 μl O-phthaldehyde (1.0 mg/ml) and 10 μl of sample. After 
incubation for 15 min at room temperature, fluorescence at emission 420 nm was 
recorded by excitation at 350nm. 
10.4.11. Estimation of oxidized glutathione (GSSG) 
The estimation of GSSG was performed by the method of Hissin and Hilf (Hissin 
and Hilf, 1976). The samples were incubated first with 0.04 M N-ethyleimide (NEM) for 
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30 min to interact with GSH present in sample. The reaction mixture containing 0.1 N 
NaOH, 5.0 mM EDTA, 10 μl O-phthaldehyde (1.0 mg/ml) and 10 μl of sample. After 
incubation for 15 min at room temperature, fluorescence at emission 420 nm was 
recorded by excitation at 350nm. 
10.4.12. Enzyme activities 
10.4.12.1. Estimation of glutathione-S-transferase activity 
GST (EC 2.5.1.18) activity was measured in a 96-well plate reader, with the 
reaction mixture consisting of 0.1 M phosphate buffer (pH 6.5), 1.0 mM reduced 
glutathione, 1.0 mM CDNB and 0.1 μl of PMS in a total volume of 200 μl(Habig, Pabst 
et al., 1974). The changes in absorbance were recorded at 340 nm, and the enzymatic 
activity was calculated as nmol CDNB conjugate formed min− 1 mg− 1 protein. 
10.4.12.2. Estimation of glutathione peroxidase activity 
GPx (EC 1.11.1.9) activity was measured in a 96-well plate reader at 37 °C by a 
coupled assay system (Wheeler, Salzman et al., 1990). The reaction mixture consisted of 
0.2 mM H2O2, 1.0 mM GSH, 0.14 U of GR, 1.5 mM NADPH, 1.0 mM sodium azide and 
0.1M phosphate buffer (pH 7.4) and 10 μl PMS in a total volume of 200 μl. The enzyme 
activity was calculated as nmol NADPH oxidized min− 1 mg− 1 protein.  
10.4.12.3. Estimation of glutathione reductase activity 
The assay system to estimate GR (EC 1.6.4.2) activity consisted of 0.1 M 
phosphate buffer (pH 7.6), 0.5 mM EDTA, 1.0 mM oxidized glutathione, 0.1 mM 
NADPH and 10 μl PMS in a total volume of 200 μl (Carlberg and Mannervik, 1985). The 
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enzyme activity was assayed in a 96-well plate reader by measuring the disappearance of 
NADPH at 340 nm and was calculated as nmol NADPH oxidized min− 1 mg− 1 protein.  
10.5. Statistical analysis 
ANOVA was used for statistical evaluation of data followed by Student's t-test. 
Results are presented as mean ± SEM. P-values less than 0.05 were considered 
significant. 
10.6. Results 
10.6.1. Protein Oxidation and Lipid Peroxidation 
Fig. 10.1, 10.2 and 10.3 show the levels of protein carbonyl, 3NT and HNE 
respectively in mitochondria isolated from brain of gerbils that had been previously 
injected i.p. with  saline or D609. These isolated brain mitochondrial samples were 
subsequently treated with Fe2+/H2O2, AAPH or Aβ (1-42), in vitro. The concentrations of 
these oxidants were chosen based on prior dose-response studies of the agents in in vivo 
investigations (Joshi, Sultana et al., 2005a; Perluigi, Joshi et al., 2006). The levels of 
protein carbonyl, 3NT and HNE were found significantly increased in mitochondria 
isolated from saline-injected gerbils brain and subsequently treated with oxidants, in 
vitro, compared to control (without treatment of oxidants). Brain mitochondria isolated 
from gerbils previously injected i.p. with D609 and subsequent in vitro treatment with 
Fe2+/H2O2, AAPH and Aβ (1-42) showed significantly decreased protein carbonyl, 3NT 
and HNE levels as compared to brain mitochondria isolated from gerbils previously 
injected i.p. with saline and subsequently treated with Fe2+/H2O2, AAPH and Aβ (1-42), 
in vitro. The D609-alone sample had no significant effect on the levels of protein 
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carbonyls, 3NT or HNE in brain mitochondria. It is clear that less protein oxidation and 
lipid peroxidation product, HNE was found in Fe2+/H2O2, AAPH and Aβ (1-42) treated 
mitochondria isolated from gerbils previously injected with D609. 
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Figure 10.1: Shows the increment in protein carbonyl formation in brain 
mitochondria isolated from saline-injected gerbils and treated with various oxidants 
compared to control. The protective effects of D609 against protein carbonyl formation in 
brain mitochondria isolated from gerbils injected i.p. 1h before sacrifice with D609 and 
treated with AAPH, Fe2+/H2O2 and Aβ (1-42) also are shown. *p<0.01 and **p<0.001 
compared to control and # p<0.01 compared to oxidant treatment. The data are presented 
as mean ± SEM expressed as percentage of control (n=6). (Data collected in collbration 
with Dr Mubeen Ansari) 
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Figure 10.2: Shows the increment in 3-NT levels in brain mitochondria isolated 
from saline-injected gerbils and subsequently treated with AAPH, Fe2+/H2O2 or Aβ (1-
42) compared to 3NT levels in brain mitochondria isolated from saline-injected gerbil 
that received no treatment of any oxidant, *p<0.01 and **p<0.001. This figure also 
shows decreased 3NT levels shows in brain mitochondria isolated from gerbils 
previously injected i.p. with D609 1 h before sacrifice and treated with AAPH, Fe2+/H2O2 
or Aβ (1-42) compared to the oxidant treatment but no prior injection of D609, # p<0.01. 
The data are presented as mean ± SEM expressed as percentage of control (n=6). (Data 
collected in collaboration with Dr Mubeen Ansari) 
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Figure 10.3: Shows the significantly elevated protein-bound HNE content in 
brain mitochondria isolated from saline-injected gerbils and treated with different 
oxidants [AAPH, Fe2+/H2O2 or Aβ (1-42)]. The protective effects of D609 against HNE 
formation of protein-bound HNE in brain mitochondria isolated from gerbil injected i.p. 
with D609 1 h before sacrifice and treated with AAPH, Fe2+/H2O2 or Aβ (1-42) also are 
shown. *p<0.01 and **p<0.001 compared to control, # p<0.01 and ## p<0.001 compared 
to oxidant treatment. The data are presented as mean ± SEM expressed as percentage of 
control (n=6). (Data collected in collaboration with Dr Mubeen Ansari) 
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10.6.2. Reduced glutathione (GSH) 
Fig. 10.4a shows the levels of GSH in mitochondria isolated from gerbil brain 
from saline- as well as D609-injected rodents. These brain mitochondrial samples were 
subsequently treated with Fe2+/H2O2, AAPH or Aβ (1-42), in vitro. The levels of GSH 
were found significantly decreased in mitochondria isolated from saline-injected gerbils 
brain and treated in vitro with oxidants compared to control. In contrast, brain 
mitochondria isolated from D609-injected gerbils and subsequently treated in vitro with 
Fe2+/H2O2, AAPH or Aβ (1-42) showed increased levels of GSH.  
10.6.3. Oxidized Glutathione (GSSG) 
Fig. 10.4b shows significantly increased GSSG levels in brain mitochondria 
treated with different oxidants [Fe2+/H2O2, AAPH or Aβ (1-42)] that were isolated from 
saline-injected gerbils (control).  In contrast, there were significantly decreased GSSG 
levels in mitochondria isolated from gerbils previously injected i.p. with D609 and 
treated with Fe2+/H2O2, AAPH or Aβ (1-42), in vitro.  
10.6.4. The Ratio of Reduced and Oxidized Glutathione (GSH/GSSG) 
Fig.10.4c shows the significantly decreased GSH/GSSG ratio in brain 
mitochondria isolated from saline-injected gerbils (control) and treated with different 
oxidants, in vitro.  This GSH/GSSG ratio was significantly increased in brain 
mitochondria isolated from gerbils previously injected i.p. with D609 and treated with 
Fe2+/H2O2, AAPH or Aβ (1-42), in vitro.  
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Figure 10.4a: Shows a significant decrement in GSH levels in brain mitochondria 
isolated from saline-injected gerbils and subsequently treated with AAPH, Fe2+/H2O2 or 
Aβ (1-42) compared to GSH levels in brain mitochondria isolated from saline-injected 
gerbils not subjected to treatment of any oxidant. Also shown is the protection of GSH 
levels in brain mitochondria isolated from gerbils previously injected i.p. with D609 1 h 
before sacrifice and treated with AAPH, Fe2+/H2O2 or Aβ (1-42) compared  to GSH 
levels in brain mitochondria isolated from saline-treated gerbils and then treated with 
oxidants. *p<0.01 and **p<0.001 compared to control, # p<0.01 and ## p<0.01 
compared to oxidant treatment. The data are presented as mean ± SEM expressed as 
percentage of control (n=6). 
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Figure 10.4b: Shows the increased level of GSSG in brain mitochondria isolated 
from saline-injected gerbils and subsequently treated with AAPH, Fe2+/H2O2 or Aβ (1-
42) as compared to GSSG levels in brain mitochondria isolated from saline-injected 
gerbils but not subjected to treatment of any oxidant. The reduction in GSSG level shows 
in brain mitochondria isolated from gerbils previously injected i.p. with D609 1 h before 
sacrifice and treated with AAPH, Fe2+/H2O2 or Aβ (1-42) compared to GSSG levels in 
brain mitochondria isolated from saline-treated gerbil and then treated with oxidants. 
*p<0.01 and **p<0.001 compared to control, # p<0.01 and ## p<0.01 compared to 
oxidant treatment. The data are presented as mean ± SEM expressed as percentage of 
control (n=6). 
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Figure 10.4c: Shows the ratio of GSH/GSSG, decreased in brain mitochondria 
isolated from saline-injected gerbils and subsequently treated with AAPH, Fe2+/H2O2 or 
Aβ (1-42), compared to the GSH/GSSG ratio in brain mitochondria isolated from saline-
injected gerbils but not subjected to treatment of any oxidant. The increment in the ratio 
of GSH/GSSG in brain mitochondria isolated from gerbils previously injected i.p. with 
D609 1 h before sacrifice and then treated with AAPH, Fe2+/H2O2 or Aβ (1-42) compared 
to this ratio determined in brain from mice treated with oxidant but no pre-injection of 
gerbils with D609 is also shown. *p<0.01 and **p<0.001 compared to control, # p<0.01 
and ## p<0.01 compared to oxidant treatment. The data are presented as mean ± SEM 
expressed as percentage of control (n=6). 
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10.6.5. Cytochrome-c Release 
Reactive oxygen species are produced by mitochondria that can cause the release 
of cytochrome-c from the mitochondrial membrane. Figure 11.5 shows the level of 
cytochrome-c released from brain mitochondria isolated from saline- as well as D609-
injected gerbils and subsequently treated with different oxidants, in vitro. There was a 
significant reduction in cytochrome-c release from brain mitochondria by prior i.p. D609 
treatment compared to that in brain mitochondria isolated from saline-injected gerbils. 
Increased cytochrome-c release from brain mitochondria isolated from control gerbils 
with subsequent in vitro treatment of Fe2+/H2O2, AAPH or Aβ (1-42) compared to control 
was discussed. Brain mitochondria isolated from D609-injected gerbils and subsequently 
treated with Fe2+/H2O2, AAPH or Aβ (1-42), in vitro, showed a significant decrease in 
cytochrome-c release compared to mitochondria isolated from saline-injected gerbils 
treated with oxidants (Figure 11.5). 
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Figure 10.5: Shows the increased level of cytochrome-c released from brain 
mitochondria isolated from saline-injected gerbils and treated with various oxidants 
(AAPH, Fe2+/H2O2 or Aβ (1-42) as compared to cytochrome-c released from brain 
mitochondria isolated from saline-injected gerbils but not subjected to treatment of any 
oxidant. Also shown is the decrement of cytochrome-c release from brain mitochondria 
isolated from gerbils previously injected i.p. with D609 1 h before sacrifice and treated 
with AAPH, Fe2+/H2O2 or Aβ (1-42) compared to that released from brain mitochondria 
isolated from gerbils subjected to oxidant treatment. The D609 only treatment shows 
significantly less cytochrome-c release compared control. *p<0.01 as compared to 
control, # p<0.01 compared to oxidant treatment. The data are presented as mean ± SEM 
expressed as percentage of control (n=5). (Data collected in collaboration with Dr 
Mubeen Ansari) 
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10.6.6. The Activity of GSH-relevant Enzymes 
Table 10.1 shows the activity of some GSH-relevant enzymes in gerbil brain from 
which mitochondria were isolated. The activities of glutathione-S-transferase (GST) and 
glutathione peroxidase (GPx) were increased significantly in post mitochondrial 
supernatant from D609-injected gerbils. The activity of glutathione reductase (GR) also 
was increased, but non-significantly. Thus, these results suggest that D609 has a role in 
the redox cycle of GSH (oxidation and reduction of GSH) and in the neuroprotection 
against free radicals.  
 
Enzyme Brain from Control 
Group 
Brain from D609 
Treated Group 
GST (nmol CDNB 
conjugate formed 
min−1 mg−1 protein) 
38.4±3.44 61.5±4.74* 
GPx (nmol NADPH 
oxidized min−1 mg−1 
protein) 
34.5±2.87 43.1±3.41# 
GR (nmol NADPH 
oxidized min−1 mg−1 
protein) 
23.4±2.89 26.6±3.10 
Table 10.1:  Activities of some GSH-related enzymes in post mitochondrial 
supernatant obtained from gerbil brain mitochondria that were previously injected i.p. 
with saline (control) or D609. The data are presented as mean ± SEM expressed as 
percentage of control (n=6).  *p<0.01 and #p<0.05 compared to control. (Data collected 
in collaboration with Dr Mubeen Ansari). 
 
 
208 
10.7. Discussion 
Oxidative stress reflects a marked imbalance between ROS and their removal by 
anti-oxidant systems. This imbalance may originate from an overproduction of ROS or 
from a reduction in antioxidant defenses or both (Butterfield and Stadtman, 1997). An 
inverse relationship between lipid peroxidation and GSH and its dependent enzymes, 
along with the activities of catalase and superoxide dismutase is well known (Sies, 1999; 
Hansen, Go et al., 2006). A reduction in GSH may impair H2O2 clearance and promote 
hydroxyl radical formation, thus increasing the free radical load, which triggers oxidative 
stress. Conversely, GSH is converted to GSSG, a process that in conjunction with the 
cofactor NADPH can reduce lipid peroxides, free radicals and H2O2. NADPH also acts as 
a peroxynitrite reductant, thereby providing enzymatic defense against peroxynitrite 
(Sies, Sharov et al., 1997). Glutathione peroxidase (GPx) and glutathione reductase (GR) 
protect the neurons from oxidative stress by catalyzing the reduction of H2O2 at the 
expense of glutathione (Sies, 1999; Hansen, Go et al., 2006). Glutathione-S-transferase 
(GST) play a role in neuroprotection by catalyzing the formation of the GSH-HNE 
conjugate, which is then removed from neurons by the action of the multidrug resistant 
protein-1 (Sultana and Butterfield, 2004). In AD brain, both GST and MRP-1 are 
oxidatively modified and likely dysfunctional (Sultana and Butterfield, 2004). In our 
results GST (Table I) and GPx have higher activities following in vitro oxidant treatment 
of brain homogenate isolated from previously D609-injected gerbils. GR activity in brain 
(Table I) of D609-injected animals was not significantly elevated following subsequent in 
vitro oxidant treatment to isolated mitochondria relative to control. 
Reduced levels of GSH (Fig. 4A) have been observed in oxidative stress-related 
disorders (Bains and Shaw, 1997) in specific regions of the central nervous system of AD 
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patients, and thus reduced GSH may contribute to the neuronal cell dysfunction and/or 
loss. In AD, increased levels of GSSG (Cooper, 1997) have been observed. Studies have 
shown that an increase in endogenous GSH levels by dietary or pharmacological intake 
of GSH precursors or GSH mimetics or substrates for GSH synthesis protects the brain 
against oxidative stress (Anderson and Luo, 1998; Fontaine, Geddes et al., 2000; 
Pocernich, La Fontaine et al., 2000; Halliwell, 2001; Pocernich, Cardin et al., 2001; 
Drake, Kanski et al., 2002; Drake, Sultana et al., 2003). The increase in the content of 
GSH and decrease in the extent of GSSG in mitochondria isolated from gerbil brain 
previously injected with D609 in our study is in agreement with earlier reports (Perluigi, 
Joshi et al., 2006).  
We earlier showed that D609 could effectively scavenge hydroxyl radicals (Zhou, 
Lauderback et al., 2001). The identification of D609 as a potent antioxidant implies that 
D609 may exert some of the reported activities that have been largely attributed to the 
inhibition of phosphatidyl choline-specific phospholipase C (PC-PLC) by its antioxidant 
properties. Among these activities are inhibition of LPS-and TNF-induced NF-kB 
activation and inflammatory cytokine production (Schutze, Potthoff et al., 1992; 
Amtmann, 1996). ROS activated NF-kB causes a differential change in gene expression 
between neurons and astrocytes in the AD brain (Tanaka, Takehashi et al., 2002; 
Onyango, Bennett et al., 2005). We earlier reported the anticarcinogenic activity of D609 
might be due to its antioxidant property (Zhou, Lauderback et al., 2001). In vitro, D609 
kills a variety of tumor cells but has limited toxic effects on normal cells (Sauer, 
Amtmann et al., 1990). Although D609 might be involved in alternate biochemical 
pathways, its glutathione mimetic property cannot be ignored. The free thiol group in 
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D609 may act as substrate for hydroxyl radicals, or may act as electron acceptor from 
hydrogen peroxide to form a dixanthate, which forms the substrate for glutathione 
reductase to convert it back to xanthate. This property of D609 is yet to be explored. 
Protein carbonyls, 3NT and HNE levels are elevated in AD and MCI brains 
(Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002; Castegna, Aksenov et 
al., 2002a; Castegna, Thongboonkerd et al., 2003; Butterfield, 2004; Castegna, 
Thongboonkerd et al., 2004; Butterfield, Poon et al., 2006; Butterfield, Reed et al., 2006; 
Sultana, Poon et al., 2006a; Sultana, Poon et al., 2006b). HNE is a highly reactive product 
of arachidonic acid metabolism that is believed to interfere with normal cellular functions 
(Butterfield and Lauderback, 2002). During oxidative stress several lipid peroxidation 
products are formed, including HNE, one of the most abundant and toxic lipid-derived 
aldehydes, and which can induce oxidative stress (Esterbauer, Schaur et al., 1991; 
Lauderback, Hackett et al., 2001). Lipid peroxidation products such as HNE and acrolein 
are known to cause damage to biomembranes, proteins and other biomolecules in AD 
brain (Sayre, Zelasko et al., 1997; Lovell, Xie et al., 1998; Lauderback, Hackett et al., 
2001). These alkenals form an immediate substrate for GSH (Xie, Lovell et al., 1998) and 
these lipid peroxidation products are known to be involved in apoptosis, which can be 
initiated as a consequence of GSH depletion (Mark, Lovell et al., 1997). 
GSH is known to detoxify HNE and protect cultured neurons against oxidative 
damage resulting from amyloid β-peptide, iron, and HNE (Mark, Lovell et al., 1997). 
GSH can also protect brain from damage by peroxynitrite, hydroxyl free radicals, or 
reactive alkenals (Koppal, Drake et al., 1999b; Pocernich, La Fontaine et al., 2000; 
Pocernich, Cardin et al., 2001; Drake, Kanski et al., 2002; Drake, Sultana et al., 2003). 
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D609 may binds to reactive alkenals formed due to peroxidation of lipids and detoxifies 
their effects (Lauderback, Drake et al., 2003). 
HNE can alter pyruvate dehydrogenase (PD) (Pocernich and Butterfield, 2003), 
decrease cell survival (decrease MTT reduction) and cause inhibition of Na+K+ ATPase 
(Mark, Lovell et al., 1997). The activity of the adenine nucleotide transporter in 
mitochondria is inhibited by HNE, which directly results in ATP depletion (Chen, 
Bertrand et al., 1995). Aβ increases lipid derived free radical production (Chen, Bertrand 
et al., 1995; Mark, Lovell et al., 1997; Butterfield, Drake et al., 2001; Butterfield and 
Lauderback, 2002; Boyd-Kimball, Mohmmad Abdul et al., 2004). HNE rapidly leads to 
decline in multiple sites of the mitochondrial respiratory chain and modified specific 
mitochondrial target proteins lead to apoptosis and cell death in AD (Picklo, Amarnath et 
al., 1999).  
Recently, we showed that the xanthate D609, a glutathione mimetic (Lauderback, 
Drake et al., 2003), protects primary neuronal culture against Aβ (1-42)-induced 
oxidative stress and neurotoxicity in vitro (Sultana, Newman et al., 2004) and against Aβ 
(1-42) in vivo (Perluigi, Joshi et al., 2006). D609 has the ability to scavenge hydrogen 
peroxide and hydroxyl free radicals (Lauderback, Drake et al., 2003). D609 can bind to 
reactive alkenals and detoxify their effect, thereby preventing these alkenals from 
damaging mitochondria (Lauderback, Drake et al., 2003; Joshi, Sultana et al., 2005a). 
AAPH is known to induce protein carbonylation and nitration (Kanski, Lauderback et al., 
2001) in mitochondria. In the current study, we report that in vivo delivery of D609 
inhibits the damage to brain mitochondria caused by production of hydroxyl free radicals, 
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alkoxyl and peroxyl radicals and Aβ (1-42)-induced in vitro oxidative stress to decrease 
protein oxidation and lipid peroxidation. 
Aβ disrupts Ca2+ homeostasis in neurons (Mattson, Barger et al., 1993), and 
increased intracellular Ca2+ level can increase sphingomylinase activity to produce 
ceramide (Di Paola, Zaccagnino et al., 2004). Activation of the apoptogenic 
sphingomyelin-dependent signaling pathway is mediated by ceramide (Di Paola, 
Zaccagnino et al., 2004) during oxidative stress to play role in the pathogenesis of 
neuronal disease (Michel, Lambeng et al., 1999). Apoptosis induced by the membrane-
permeable second messenger ceramide, followed by the release of cytochrome-c and Ca2+ 
from the mitochondria with the loss of mitochondrial transmembrane potential has been 
observed (Michel, Lambeng et al., 1999). Both cytochrome-c release and rise of 
intracellular Ca2+ cause caspase-3 activation and nuclear condensation (Michel, Lambeng 
et al., 1999). ROS-dependent and independent pathways are initiated by caspase-8 
activation and contribute to ceramide formation via the activation of both neutral and acid 
sphingomyelinases (SMases) in TNF-alpha-induced apoptosis of human glioma cells 
(Michel, Lambeng et al., 1999). In one study, D609 has also been shown to inhibit 
sphingomyelin synthase in SV40-transformed human lung fibroblasts, but ceramide and 
DAG levels evolved in opposite directions (Luberto and Hannun, 1998) and partially 
protected against apoptosis (Denis, Lecomte et al., 2002). 
In conclusion, this study has demonstrated that, similar to the case with elevated 
cytosolic GSH protecting brain mitochondria (Drake, Kanski et al., 2002), i.p. injection 
of D609 protects brain mitochondria (anti-apoptotic) against oxidative stress induced in 
vitro by different oxidants, such as AAPH, Fe2+/H2O2 or Aβ(1–42). In vivo delivery of 
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D609 showed significant protection against protein oxidation, lipid peroxidation and 
cytochrome-c release in gerbil brain mitochondria. While a role for inhibition of PC-PLC 
by D609 in the protection of brain mitochondria cannot be excluded, based on the data 
from the present and previous studies (Joshi, Sultana et al., 2005a; Perluigi, Joshi et al., 
2006), the increment in the GSH level and the activity of its dependent enzymes (GST, 
GPx and GR), are strong indications to suggest that D609 has neuroprotective effects to 
brain mitochondria due in significant part to its antioxidant properties. Thus, in brain 
mitochondria, the antioxidant properties of in vivo delivery of D609 conceivably could be 
beneficial in the treatment of diseases related to oxidative stress that involve 
mitochondria (AD, Huntington disease, Parkinson’s disease, for example). This xanthate 
compound protects against in vitro treatment of Aβ (1-42); consequently, we suggest 
D609 may be part of a promising therapeutic strategy for Alzheimer’s disease. Studies to 
test this notion in rodent models of AD are in progress. 
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Chapter 11 
N-Acetyl cysteine-mediated protection against oxidative stress in APP/PS-1 mouse: 
A pilot study towards therapeutic modulation of mild cognitive impairment (MCI) 
11.1. Overview of the Study 
N-acetyl cysteine (NAC) is a glutathione (GSH) precursor. It provides the limiting 
substrate in GSH synthesis, cysteine. The mechanism by which is does is not very well 
known. NAC is commonly used in treatment of acetaminophen poisoning. NAC is one 
the most widely used in antioxidant therapy. Previously our laboratory showed an 
increase in GSH levels post i.p. injection of NAC. NAC reduces the protein oxidation and 
lipid peroxidation in synaptosomes treated with acrolein. The present study was 
undertaken to test the hypothesis that NAC would provide in vivo neuroprotection against 
free radical oxidative stress-mediated by Aβ (1-42) in APP/PS-1 mice, a model of 
Alzheimer’s disease (AD). In the present study, NAC was administered orally (2mg/kg 
body weight/day) in drinking water for 5 months beginning at 4 months of age for both 
APP/PS-1 mice and wild type aged matched control. Another group of APP/PS-1 and 
wild type mice were given normal drinking water. Brain isolated from APP/PS-1 mice 
given NAC in water at 9 month of age showed significant reduction in the levels of 
protein oxidation and lipid peroxidation when compared to the brain isolated from 
APP/PS-1 mice given normal drinking water. Additionally, increased expression of a key 
antioxidant enzymes expression levels, GPx, was also observed in brain isolated from 
APP/PS-1 given NAC when compared to APP/PS-1 mice given normal drinking water. 
We also observed an increased expression of Pin 1, a key cell cycle protein in brain 
isolated from APP/PS-1 mice that were given NAC when compared to APP/PS-1 mice 
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given normal drinking water. These results are discussed with reference to potential use 
of this brain accessible glutathione precursor in the treatment of oxidative stress-mediated 
AD. 
11.2. Introduction 
Oxidative stress has implication in various neurodegenerative disorders including 
Alzheimer’s disease (AD) (Hensley, Hall et al., 1995; Markesbery and Lovell, 1998; 
Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002). As described in 
Chapter 1, AD affects more that 4 million Americans and is one of the leading causes of 
death in US. There is no efficient therapy towards treatment of this dreaded disorder. 
Pathological characteristics of AD includes the presence of senile plaques comprised of 
aggregated Aβ, neurofibrillary tangles consisting of hyperphosphorylated tau, and 
synapse loss (Katzman and Saitoh, 1991; Bosetti, Brizzi et al., 2002). Etiologically, a free 
radical-mediated oxidative stress hypothesis in AD has gained considerable importance 
(Butterfield, Drake et al., 2001). In AD brain, oxidative stress leads to significant protein 
oxidation (Butterfield and Lauderback, 2002), DNA and RNA oxidation (Mecocci, 
MacGarvey et al., 1993; Lovell, Gabbita et al., 1999; Nunomura, Perry et al., 1999; 
Wang, Xiong et al., 2005), lipid peroxidation (Markesbery and Lovell, 1998; Lauderback, 
Hackett et al., 2001), and neuronal dysfunction or death. Increased production of reactive 
oxygen species (ROS) along with depletion in antioxidant capacity is observed in AD 
(Beckman and Ames, 1998) and consistent with this observation α-tocopherol (vitamin 
E) administration in AD patients delayed its progression when compared to placebo 
treated control (Sano, Ernesto et al., 1997), suggesting that oxidative stress-mediated AD 
progression may possibly be delayed by antioxidant therapy. 
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Mild cognitive impairment (MCI) is generally referred as the transitional zone 
between normal aging and early dementia or clinically probable Alzheimer's disease 
(AD) (Winblad, Palmer et al., 2004). Most individuals with MCI eventually develop AD 
or other forms of dementia, which may suggest that MCI could be the early phase in the 
development of AD (Almkvist, Basun et al., 1998; Morris, Storandt et al., 2001). MCI is 
a general term used to describe a slight but measurable memory disorder. A person with 
MCI has memory problems greater than normally expected with aging, but does not show 
other symptoms of dementia, such as impaired reasoning or judgment. A person with 
MCI is at higher risk for developing AD. Although some of the MCI cases become stable 
or become resolved, most persons with MCI develop AD. A direct relationship between 
MCI and AD is yet to be established.  Recently our laboratory showed an overlap in the 
oxidized proteins in MCI and AD subjects (Butterfield, Poon et al., 2006). Oxidation of 
these proteins may play a significant role in development of MCI to AD (Butterfield, 
Poon et al., 2006). Oxidative stress has been implicated in MCI (Keller, Schmitt et al., 
2005; Butterfield, Reed et al., 2006). Our laboratory recently showed elevated protein-
bound 4-hydroxy-2-nonenal (HNE) levels, a lipid peroxidation product, , in brain from 
persons with mild cognitive impairment (Butterfield, Reed et al., 2006). By using redox 
proteomics, our laboratory showed some key proteins to be oxidized in MCI brain, 
suggesting oxidative stress play an important role in MCI and may be the reason for 
progression of MCI to AD (Butterfield, Poon et al., 2006). Since MCI is potentially 
reversible, and oxidative stress plays a key role in development and progression of this 
disease, it is imperative to look at a potential therapeutic strategy involving antioxidants 
to prevent MCI and eventually stop its progression to AD. 
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Among the genetic risk factors for AD, includes mutations in the presenilin 1 
(PS1) (Sherrington, Rogaev et al., 1995), presenilin 2 (PS2) (Rogaev, Sherrington et al., 
1995), or the APP gene (Chartier-Harlin, Crawford et al., 1991). Approximately 30%  
familial Alzheimer’s disease (FAD) cases have mutations in PS1 (Schellenberg, 1995). 
PS1 is a part of γ-secretase complex that cleaves APP to release Aβ(1-42). Mutation in 
PS1 has been shown to alters APP processing to enhance the generation of Aβ(1–42) 
peptides (Jarrett, Berger et al., 1993). Synaptosomal proteins from PS-1 mutant mice 
showed increased oxidative stress and alteration in synaptosomal protein structure when 
compared to wild type (LaFontaine, Mattson et al., 2002). 
Several line of evidence shows that Aβ(1–42) plays a central role in AD 
pathogenesis and is well documented. Our laboratory was instrumental in hypothesizing 
Aβ(1–42)-mediated oxidative stress in AD brain (Butterfield, Drake et al., 2001). Based 
on these studies a mouse model showing accelerated Aβ(1–42) deposition was used to 
study the oxidative stress parameter and antioxidant therapeutic intervention towards 
MCI or AD. As described in Chapter 2, this mouse model was developed by Borchelt et 
al., which had FAD mutant human PS1-A246E and a chimeric mouse/human (Mo/Hu) 
APP695 harboring a Hu Aβ domain and mutations (K595N, M596L) linked to Swedish 
FAD (APP swe) coexpressed (APP/PS-1 human knock-in mouse) (Borchelt, Ratovitski et 
al., 1997). The APP/PS-1 mice showed increased Aβ production and accelerated amyloid 
deposition in the brain (Borchelt, Ratovitski et al., 1997). Previous studies from our 
laboratory have shown that neurons from APP/PS1 mice have increased basal protein 
oxidation and lipid peroxidation, and are more vulnerable to oxidation by various 
exogenous oxidants when compared to wild type (Mohmmad Abdul, Sultana et al., 
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2006). All these studies suggest that APP/PS1 mice can be used as a model of FAD, 
which is characterized by Aβ(1–42)-mediated oxidative stress. 
Depletion of glutathione (GSH), an intracellular antioxidant, is known to be 
involved in several neurodegenerative disorders (Benzi and Moretti, 1995b; Markesbery, 
1997; Butterfield, Castegna et al., 2002a). Many attempts have been made to develop 
antioxidant compounds that can act as precursor of GSH or mimic GSH as scavenger of 
reactive oxygen species (ROS) and to maintain the intracellular redox state. Increase in 
the endogenous GSH levels by dietary or pharmacological intake of GSH precursor or 
GSH mimetic protects brain against oxidative stress (Anderson and Luo, 1998; 
Butterfield, Drake et al., 2001; Halliwell, 2001). Considering the importance of 
developing new antioxidant compounds and the relevance of their application in the 
treatment of neurodegenerative diseases, we focused our attention on glutathione 
precursor, N-acetyl cysteine (NAC). 
NAC is an FDA-approved drug used in the treatment of acetaminophen-mediated 
liver toxicity (Prescott, Park et al., 1977) or heavy metal poisoning. NAC acts as an 
indirect precursor of GSH. It is thought to provide cysteine, a rate limiting substrate in 
GSH synthesis (Dringen and Hamprecht, 1999). NAC acts as antioxidant by raising 
intracellular levels of cysteine or by the scavenging ROS itself. NAC is also used in 
treatment of HIV infection (Droge, 1993), and cancer chemotherapy (Holoye, Duelge et 
al., 1983). Apart from its antioxidant properties, NAC is known to improve neuron 
survival in the CA1 region of the hippocampus following ischemic-reperfusion injury 
(Zhang, Tian et al., 2003). NAC can acts as transcription factor and can rescue neurons 
from apoptotic death by activation of the Ras-ERK pathway (Yan and Greene, 1998). 
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NAC reduces the inflammatory symptoms in brain by direct inhibition of NF-κB and 
blocking iNOS from producing inflammatory cytokines (Pahan, Sheikh et al., 1998). 
11.3. Purpose of the study 
Previous studies from our laboratory have shown that NAC can partially protect 
brain-derived membrane proteins against peroxynitrite-induced damage (Koppal, Drake 
et al., 1999a). NAC significantly increased endogenous glutathione levels, in vivo, in 
cortical synaptosome cytosol and prevented protein oxidation caused by hydroxyl 
radicals (Pocernich, La Fontaine et al., 2000).  NAC protected mitochondria against 
oxidative damage induced by 3-nitropropionic acid and significantly reduce striatal lesion 
volumes (La Fontaine, Geddes et al., 2000). We also showed that NAC protected 
synaptosomal membranes against acrolein-induced protein damage by elevating GSH 
levels, in vivo (Pocernich, Cardin et al., 2001). We recently showed reversal of memory 
impairment and brain oxidative stress by NAC in aged SAMP8 mice (Farr, Poon et al., 
2003). The current study was designed to determine if in vivo NAC would protect brain 
from APP/PS-1 mice against inherent Aβ(1–42)-mediated oxidative stress-induced 
protein oxidation and lipid peroxidation. 
11.4. Experimentals 
11.4.1. Chemicals 
All the chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless 
stated otherwise. The OxyBlot kit used for protein carbonyl determination was purchased 
from Intergen (Purchase, NY). The primary antibody for HNE was purchased from Alpha 
Diagnostics (San Antonio, TX). The primary antibody for GPx was purchased from 
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Chemicon International (Temecula, CA). Transfer membranes for western blot and slot 
blot were purchased from Biorad (Hercules, CA).  
11.4.2. Animals 
For this study, male Wild type (WT) and APP/PS-1 mice, approximately 30 g in 
size, housed in the University of Kentucky Central Animal Facility in 12-h light/dark 
conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The 
animal protocols were approved by the University of Kentucky Animal Care and Use 
Committee. The APP/PS-1 mice used are the APPNLh/APPNLh × PS-1P264L./PS-1P264L. 
double mutant generated by using the Cre-loc© knock-in technology (Cephalon, Inc., 
Westchester, PA, USA) to humanize the mouse Aβ sequence and to create a PS-1 
mutation identified in human AD (Reaume, Howland et al., 1996; Siman, Reaume et al., 
2000).   
11.4.3. Treatments 
Mice were divided into 4 groups. A group of WT and APP/PS-1 mice received 
normal drinking water and another group of WT and APP/PS-1 mice received water 
containing NAC (2mg/kg/day) for a period of 5 months. A 1% solution of NAC in water 
(pH adjusted to 7.2 by NaOH) was prepared and given to mice. Water was changed every 
alternate day for 5 months. Approximately 4 to 5 ml of water was consumed per mice per 
day, which gives a cumulative dose of 2mg/kg per mice per day, not accounting for spills. 
The NAC treatment was started at 4 month age. The dose of NAC was chosen based on 
prior studies (Andreassen, Dedeoglu et al., 2000). Following 5 months of NAC treatment, 
mice were sacrificed and brains were isolated and flash frozen in liquid nitrogen. 
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11.4.4. Preparation of brain homogenate 
Brains were thawed and placed in ice cold lysing buffer containing 4μg/ml 
leupeptin, 4μg/ml pepstatin, 5 μg/ml aprotinin, 2mM ethylenediaminetetraacetic acid 
(EDTA), 2mM ethylene glycol-bistetraacetic acid (EGTA) and 10mM 4-(2-
hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), pH 7.4. The brains were 
homogenized by 20 passes of a Wheaton tissue homogenizer, and the resulting 
homogenate was centrifuged at 20000g for 10 minutes. The pellet was suspended in 1ml 
phosphate buffered saline (PBS) and the supernatant (cytosolic fraction) was retained for 
fluorescence studies, GSH measurement and enzyme activities. All the fractions 
suspended in PBS were washed twice with PBS at 32000g for 10 min. The resulting 
fractions were assayed for protein concentration by the Pierce BCA method (Bradford, 
1976). 
11.4.5. Protein Carbonyls  
Samples (5μl) of brain homogenate, 12% sodium dodecyl sulfate (SDS) (5μl), and 
10μl of 10 times diluted 2,4-dinitrophenylhydrazine (DNPH) from 200mM stock were 
incubated at room temperature for 20 min, followed by neutralization with 7.5μl 
neutralization solution (2M Tris in 30% glycerol). Protein (250ng) was loaded in each 
well on a nitrocellulose membrane under vacuum using a slot blot apparatus. The 
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS 0.01% 
(w/v) sodium azide and 0.2% (v/v) Tween 20 for 1h and incubated with a 1:100 dilution 
of anti-DNP polyclonal antibody in PBS containing 0.01% (w/v) sodium azide and 0.2% 
(v/v) Tween 20 for 1h. The membrane was washed in PBS following primary antibody 
incubation three times at intervals of 5 min each. The membrane was incubated following 
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washing with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS 
in a 1:8000 ratio for 1h. The membrane was washed three times in PBS for 5 min and 
developed in Sigma fast tablets, [5-bromo-4-chloro-3-indolyl phosphate/Nitro blue 
tetrazolium substrate (BCIP/NBT substrate)]. Blots were dried, scanned with Adobe 
Photoshop, and quantified with Scion Image (PC version of Macintosh compatible NIH 
image). No non-specific binding of antibody to the membrane was observed. 
11.4.6. HNE 
Sample (5μl) of brain homogenate, 12% SDS (5μl), and 5μl of modified Laemmli 
buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) glycerol were 
incubated for 20 min at room temperature and were loaded (250ng) in each well on a 
nitrocellulose membrane in a slot blot apparatus under vacuum. The membrane was 
treated as above and incubated with a 1: 5000 dilution of anti-HNE polyclonal antibody 
in PBS for 1h 30min. The membranes were further developed and quantified as above. A 
faint background staining due to the antibody alone was observed, but since each sample 
had a control, this minor effect was controlled. 
11.4.7. 3NT 
Samples (5μl) of brain homogenate, 12% SDS (5μl), and 5μl of modified 
Laemmli buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) 
glycerol were incubated for 20 min at room temperature and were loaded (250ng) in each 
well on a nitrocellulose membrane in slot blot apparatus under vacuum. The membrane 
was treated as above and incubated with a 1: 2000 dilution of anti-3-nitrotyrosine (3NT) 
polyclonal antibody in PBS for 1h 30min. The membranes were developed further and 
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quantified as described above. No non-specific binding of antibody to the membrane was 
observed. 
11.4.8. Western blots 
Samples (100 μg from cytosolic fraction) were incubated with sample loading 
buffer, and protein samples were denatured and electrophoresed on a 12.5% SDS-
polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane at 90 mA/gel 
for 2 h. The blots were blocked for 1h in fresh wash buffer (10 mM Tris-HCl, pH7.5), 
150 mM NaCl, 0.05% Tween 20, pH 7.4, containing 3% bovine serum albumin) and 
incubated with a 1:1000 dilution of GPx monoclonal antibody in PBS for 1h. The 
membrane was washed three times in PBS and was incubated for 1 h with an anti-rabbit 
IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 ratio. The 
membrane was washed for three times in PBS for 5 min and developed in Sigma fast 
tablets (BCIP/NBT substrate). 
In all cases non-specific background labeling by secondary antibody was 
negligible. 
11.4.9. Enzyme activity assay 
11.4.9.1. Estimation of glutathione peroxidase activity 
GPx (EC 1.11.1.9) was measured using a reaction mixture consisting of 0.2 mM 
H2O2, 1.0 mM GSH, 0.14 U of glutathione reductase (GR), 1.5 mM NADPH, 1.0 mM 
sodium azide and 0.1M phosphate buffer (pH 7.4) and 1mg/ml of supernatant protein 
(Wheeler, Salzman et al., 1990). The changes in absorbance were recorded at 340 nm in a 
96 well microtiter plate and enzyme activity was calculated as nmol of NADPH oxidized 
min− 1 mg− 1 protein.  
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11.5. Statistical analysis 
Two-way ANOVA followed by a multiple comparisons test (Turkey HSD) was 
used to assess statistical significance. P values <0.05 were considered significant for 
comparison between control and experimental data sets. 
11.6. Results 
The reason for starting NAC treatment at the 4 month age was chosen based on 
previous pathological studies. The Aβ(1-42) deposition starts at the age of 5-6 months. 
These mice develop elevated levels of Aβ(1-42) at about 6 months of age (Borchelt, 
Thinakaran et al., 1996; van Groen, Kiliaan et al., 2006). The Aβ(1-42) aggregation as in 
senile plaques is seen at the age of 9 months (van Groen, Liu et al., 2003). The brain 
pathology at 7-9 months age is reminiscent of that of an MCI or early AD brain. Based on 
this observation we hypothesized that administration of NAC at an early age (4-5mo) for 
a period of 5 months (time by which amyloid plaques are formed) can reduce the Aβ(1-
42)-mediated oxidative stress in APP/PS-1 mice at later age (9 mo) and can prevent MCI 
like pathology. 
11.6.1. NAC protects APP/PS-1 mice brains against protein oxidation and 
lipid peroxidation 
Figures 11.1, 11.2 and 11.3 show the levels of protein carbonyls, 3-NT (markers 
of protein oxidation) and protein-bound HNE (a lipid peroxidation product) levels, 
respectively, in all the treatment groups. There was significant elevation in protein 
carbonyl, 3-NT and protein bound HNE levels in brain isolated from 9 month-old 
APP/PS-1 mice that were given normal water when compared to the levels in brain 
isolated from 9 month-old WT mice given normal drinking water or NAC containing 
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water (p < 0.05, n = 6). Administration of water containing NAC to APP/PS-1 mice 
reduced the levels of protein carbonyls, 3-NT and protein-bound HNE significantly 
compared to the levels in brain isolated from APP/PS-1 mice given normal drinking 
water (p < 0.05, n = 6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.1: Levels of protein carbonyl in all the treatment groups. There is a 
significant increase in protein carbonyl level in brain isolated from APP/PS-1 mice that 
were given normal drinking water when compared to WT groups (* p < 0.05, n = 6). 
Administration of NAC in drinking water to APP/PS-1 mice decreases protein carbonyl 
level significantly in brain. The brain isolated from APP/PS-1 mice treated with NAC in 
water shows a significant decrease in protein carbonyl levels when compared to the levels 
in brain isolated from APP/PS-1 mice that were given normal drinking water (* p < 0.05, 
n = 6). The data are presented as mean ± SEM expressed as percentage of control. 
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Figure 11.2: Levels of 3NT in all the treatment groups. There is a significant 
increase in 3NT level in brain isolated from APP/PS-1 mice that were given normal 
drinking water when compared to WT groups (* p < 0.05, n = 6). Administration of NAC 
in drinking water to APP/PS-1 mice decreases 3NT level significantly in brain. The brain 
isolated from APP/PS-1 mice treated with NAC in water shows a significant decrease in 
3NT levels when compared to the levels in brain isolated from APP/PS-1 mice that were 
given normal drinking water (* p < 0.05, n = 6). The data are presented as mean ± SEM 
expressed as percentage of control. 
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Figure 11.3: Levels of protein-bound HNE in all the treatment groups. There is a 
significant increase in protein-bound HNE level in brain isolated from APP/PS-1 mice 
that were given normal drinking water when compared to WT groups (* p < 0.05, n = 6). 
Administration of NAC in drinking water to APP/PS-1 mice decreases protein-bound 
HNE level significantly in brain. The brain isolated from APP/PS-1 mice treated with 
NAC in water shows a significant decrease in protein-bound HNE levels when compared 
to the levels in brain isolated from APP/PS-1 mice that were given normal drinking water 
(* p < 0.05, n = 6). The data are presented as mean ± SEM expressed as percentage of 
control. 
 
 
 
HNE
WT (H
2O)
WT (N
AC)
APP/P
S-1 (H
2O)
APP/P
S-1 (N
AC)
%
 c
on
tro
l (
H
N
E)
40
60
80
100
120
140
*
*
228 
11.6.2. NAC increased GPx expression and activity in APP/PS-1 mice brain 
Figure 11.4a, b and 11.5 shows the expression and activity of GPx in all the 
treatment groups. There was significant reduction in GPx expression and activity in brain 
isolated from 9 month-old APP/PS-1 mice that were given normal water when compared 
to the GPx expression and activity in brain isolated from 9 month-old WT mice given 
normal drinking water or NAC containing water (p < 0.05, n = 6). Administration of 
water containing NAC to APP/PS-1 mice significantly increased the protein expression 
and activity of GPx when compared to the levels in brain isolated from 9 month-old 
APP/PS-1 mice given normal drinking water (p < 0.05, n = 6). 
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Figure 11.4a: Levels of GPx in all the treatment groups. There is a significant 
decrease in GPx level in brain isolated from APP/PS-1 mice that were given normal 
drinking water when compared to WT groups (* p < 0.05, n = 3). Administration of NAC 
in drinking water to APP/PS-1 mice increased GPx level significantly in brain. The brain 
isolated from APP/PS-1 mice treated with NAC in water shows a significant increase in 
GPx levels when compared to the levels in brain isolated from APP/PS-1 mice that were 
given normal drinking water (* p < 0.05, n = 3). The data are presented as mean ± SEM 
expressed as percentage of control. 
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Figure 11.4b: A representative western blot showing levels of GPx in various 
treatment groups. GAPDH was used as loading control. 
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Figure 11.5: Activity of GPx in all the treatment groups. There is a significant 
decrease in GPx activity in brain isolated from APP/PS-1 mice that were given normal 
drinking water when compared to WT groups (* p < 0.05, n = 6). Administration of NAC 
in drinking water to APP/PS-1 mice increased GPx activity significantly in brain. The 
brain isolated from APP/PS-1 mice treated with NAC in water shows a significant 
increase in GPx activity when compared to the activity in brain isolated from APP/PS-1 
mice that were given normal drinking water (* p < 0.05, n = 6). The data are presented as 
mean ± SEM expressed as percentage of control. 
11.7. Discussion 
Oxidative stress has been implicated in MCI and AD (Butterfield, Drake et al., 
2001; Keller, Schmitt et al., 2005; Butterfield, Poon et al., 2006; Butterfield, Reed et al., 
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2006). Previous studies from our laboratory and others have shown that Aβ(1-42) is 
associated with free radical generation leading to proteins and lipids oxidation 
(Varadarajan, Yatin et al., 2000; Butterfield, Drake et al., 2001; Butterfield and 
Lauderback, 2002). A comprehensive model for neurodegeneration in AD combining two 
established notions, viz., elevated oxidative stress in AD brain and centrality of Aβ in the 
cause and consequences of this dementing disorder (Butterfield and Lauderback, 2002; 
Castegna, Thongboonkerd et al., 2003) was developed by our laboratory. Based on these 
and several other well documented notions that support that oxidative stress may be 
central to the Aβ-driven neurodegeneration, treatment with brain accessible antioxidants 
may be a promising approach for slowing disease progression and oxidative damage that 
may be responsible for the cognitive and functional decline observed in MCI or AD. 
The oxidation of proteins by free radicals-mediated protein oxidation may be 
responsible for damaging enzymes critical in neuronal function (Varadarajan, Yatin et al., 
2000; Butterfield, Boyd-Kimball et al., 2003). By using proteomics, our laboratory 
showed some of the critical proteins that are oxidized in AD and MCI (Castegna, 
Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; Castegna, Thongboonkerd et al., 
2003; Butterfield, Poon et al., 2006). One such protein was peptidyl-prolyl cis/trans 
isomerase (Pin 1). Pin 1 is oxidatively dysfunctional in AD (Sultana, Boyd-Kimball et al., 
2006a) and MCI (Butterfield, Poon et al., 2006) and is down-regulated in AD brain 
(Sultana, Boyd-Kimball et al., 2006a). The present results demonstrate elevated levels of 
Pin 1 n 9 month-old APP/PS-1 mice treated with NAC in drinking water compared to the 
levels in 9 month-old APP/PS-1 mice given drinking water. The oxidative modification 
of proteins either by introduction of carbonyl functionality or by nitration of tyrosine 
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residues leads to formation of protein-protein cross-linked aggregates that often changes 
the conformation, including protein unfolding of functional protein, thereby rendering a 
protein inactive (Butterfield and Stadtman, 1997; Stadtman and Berlett, 1997). In the 
present study, we showed the ability of in vivo NAC to provide neuroprotection against 
protein oxidation as indexed by protein carbonyls and 3NT (Stadtman and Berlett, 1997), 
in APP/PS-1 mice on subsequently isolated brain. There was a significant reduction in 
protein oxidation in brain isolated from AAP/PS-1 mice that were given NAC in drinking 
water when compared to the protein oxidation in brain isolated from APP/PS-1 mice that 
were given normal drinking water. This implicate the efficacy of NAC in preventing 
Aβ(1-42)-mediated protein oxidation in he model of MCI or early AD. 
Elevated level of lipid peroxidation products, such as HNE and acrolein are 
observed in AD and MCI brain and in a model of MCI (Sayre, Zelasko et al., 1997; 
Lauderback, Hackett et al., 2001; Butterfield, Reed et al., 2006; Mohmmad Abdul, 
Sultana et al., 2006). These reactive alkenals form the immediate substrate for GSH 
(Lovell, Xie et al., 1998; Xie, Lovell et al., 1998). These lipid peroxidation products are 
also known to be involved in apoptosis, which is seen as a consequence of GSH depletion 
(Mark, Lovell et al., 1997). HNE and other reactive alkenals can bind to the functional 
protein and render them inactive (Lauderback, Hackett et al., 2001). In the present study 
we looked at the levels of protein-bound HNE in all the groups. There was a significant 
reduction in protein-bound HNE levels in brain isolated from AAP/PS-1 mice that were 
given NAC in drinking water when compared to the protein-bound HNE levels in brain 
isolated from APP/PS-1 mice that were given normal drinking water (Figure 11.3). The 
increase in endogenous GSH levels following in vivo administration of NAC (Pocernich, 
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La Fontaine et al., 2000) may be the reason behind decreased HNE levels. Reduce the 
level of lipid peroxidation product implicate less oxidative stress (Butterfield and 
Lauderback, 2002). 
Decreased levels of GSH are associated with aging and neurodegeneration (Liu 
and Choi, 2000; Butterfield, Castegna et al., 2002a) and therapeutic interventions based 
on elevation of GSH levels have been shown to be protective against oxidative stress 
conditions of the brain (Koppal, Drake et al., 1999a; Pocernich, Cardin et al., 2001). A 
variety of well established potential antioxidant compounds are under investigation to 
prevent Aβ-induced toxic effects (Anderson and Luo, 1998; Behl, 2002; Grundman and 
Delaney, 2002; Boyd-Kimball, Sultana et al., 2005c). Previously our laboratory showed 
elevated GSH levels in NAC injected mice and its protective effect on protein and lipid 
oxidation against hydroxyl radical and peroxynitrite-mediated oxidative stress (Koppal, 
Drake et al., 1999a; Pocernich, La Fontaine et al., 2000). In the present study we 
measured the expression and activity of one of the key GSH related enzyme, GPx. GPx 
protects the neurons from oxidative stress by catalyzing the reduction of H2O2 at the 
expense of GSH (Sies, 1999; Hansen, Go et al., 2006). There was a significant elevation 
in protein expression levels of GPx in brain isolated from AAP/PS-1 mice that were 
given NAC in drinking water when compared to the levels in brain isolated from 
APP/PS-1 mice that were given normal drinking water. Consistent with the increased 
GPx expression, we also observed an increased activity of GPx enzyme in brain isolated 
from AAP/PS-1 mice that were given NAC in drinking water when compared to the GPx 
activity in brain isolated from APP/PS-1 mice that were given normal drinking water. A 
lower expression and activity of GPx in APP/PS-1 mice implicate less clearance of H2O2 
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and increased ROS. NAC increases the activity and expression of GPx, in vivo, thereby 
more clearance of H2O2 and less ROS-mediated protein oxidation and lipid peroxidation 
as observed in this study.  
The ability of in vivo NAC to prevent inherent oxidative stress, possibly due to 
increased Aβ(1-42), in this APP/PS-1 mouse model of MCI and AD could also be related 
to its other properties, such as its function as anti-inflammatory and as activator of 
several other protective signaling pathways as discussed earlier. Thus, we suggest that 
multiple biological functions of NAC could potentially contribute to counteract Aβ-
driven neurotoxicity in the APP/PS-1 mice brain. Preliminary result also suggest that 
NAC increases the expression of Pin 1 (data not shown), a cell cycle protein, that is 
known to be oxidatively modified and down-regulated in AD brain (Sultana, Boyd-
Kimball et al., 2006a). However, its potential antioxidant property and role as GSH 
precursor is clear. Consistent with this notion, we showed decreased protein oxidation 
and lipid peroxidation in APP/PS-1 mice administered NAC, in vivo (Figure 11.1-11.3). 
The study also suggests that administration of lower concentration of NAC over a period 
of time could act as a preventive measure towards oxidative stress-mediated 
neurodegenerative disorders, such as MCI. In conclusion, the present study demonstrated 
the ability of NAC to act as a potent antioxidant in vivo, thereby providing 
neuroprotection against Aβ-induced inherent oxidative stress in model of MCI or AD, 
although additional studies are required to determine if this notion has merit. Studies to 
elucidate the mechanistic aspects of neuroprotection by NAC in APP/PS-1 mouse model 
of AD are on progress. 
Copyright © Gururaj Joshi 2006 
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Chapter 12 
Conclusion and future studies 
12.1 Conclusions 
The work in this dissertation examined antioxidant properties of a GSH mimetic 
and GSH precursor against oxidative stress-mediated neurodegenerative disorders. 
Specifically, the role of in vivo D609 protection against Fe2+/H2O2, AAPH and Aβ (1-
42)-mediated oxidative stress in brain synaptosomes or mitochondria, the ability of in 
vivo GCEE to reduce ADR-mediated oxidative stress in brain, and in vivo NAC-mediated 
protection against oxidative stress in APP/PS-1 mouse model of AD were examined. 
The protection of synaptosomes and mitochondria, in vivo, by D609 is arguably 
due to presence of the thiol group in D609 that forms basis for its antioxidant property. 
Our group previously showed that the methylated derivative of D609 is inactive against 
oxidative stress-mediated by Aβ (1-42) in neuronal cultures  (Sultana, Shelley et al., 
2004). The thiol group in D609 could react with lipid peroxidation products and form 
Michael adducts and prevent these reactive lipid peroxidation products from causing 
neurotoxicity. Intraperitoneal (i.p.) injection of D609 (50mg/kg) to gerbils, followed by 
isolation of synaptosomes and mitochondria from brain showed protection against 
oxidative stress-mediated by Fe2+/H2O2, AAPH and Aβ (1-42) when compared to their 
respective control that were injected i.p. with saline. Furthermore, a significant alteration 
of the GSH/GSSG ratio towards more oxidized form was observed in brain mitochondria 
isolated from saline-injected gerbils that were subsequently treated with Fe2+/H2O2, 
AAPH and Aβ (1-42). D609 maintained the GSH/GSSG ratio towards the more reduced 
form in mitochondria isolated from D609-injected gerbils subsequently treated with 
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Fe2+/H2O2, AAPH and Aβ (1-42) when compared to control. These studies on an animal 
model could form the basis for eventual treatment strategies for oxidative stress related 
neurodegenerative disorders. 
GCEE, a GSH precursor, was used to study its antioxidant properties against 
ADR-mediated oxidative stress. We observed that ADR, a cancer chemotherapeutic drug, 
is involved in oxidative stress in brain. Injection (i.p.) of ADR (20 mg/kg) causes 
significant protein oxidation and lipid peroxidation in brain. ADR also increases the 
expression of detoxification enzyme and protein, GST and MRP-1, respectively, in brain 
and alters GSH levels and GSH-dependent enzyme activities. By using redox proteomics 
we identified several important proteins that were oxidized in brain isolated from ADR-
injected mice when compared to control. In vivo GCEE (150 mg/kg) showed protection 
against ADR-mediated alteration in GSH levels and significantly decreased protein 
oxidation and lipid peroxidation in brain isolated from ADR-injected mice that were 
previously injected with GCEE. The protection of brain against the oxidative damage 
caused by in vivo ADR by GCEE is consistent with previous other studies in which 
GCEE protected neurons in vitro AD-related amyloid beta-peptide (Boyd-Kimball, 
Sultana et al., 2005c) or brain in vivo against peroxynitrite-induced oxidative stress 
(Drake, Kanski et al., 2002). Further studies on an animal model could form the basis for 
an eventual treatment strategy for preventing oxidative stress mediated by ADR. The 
results shown in this dissertation research suggest that GCEE-mediated increment in 
brain GSH levels and the activity of GST could be a potential therapeutic approach 
towards modulating cognitive impairment in patients undergoing chemotherapy.  
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Lastly, NAC, a GSH precursor, was examined in the APP/PS-1 mouse model of 
AD. NAC was given to the mice in their drinking water (2mg/kg/day) over a period of 
five months and oxidative stress parameters were studied. The results reported in this 
dissertation research showed that NAC has ability to reduce brain protein oxidation and 
lipid peroxidation in APP/PS-1 mice that our group had shown was due to Aβ (1-42) 
(Mohmmad Abdul, Sultana et al., 2006). APP/PS-1 mice are known to show an 
accelerated Aβ production in brain and have pathology reminiscent of that AD brain. 
Apart from protecting brain from protein oxidation and lipid peroxidation, NAC also 
increased the protein expression levels of several antioxidants and the key modulatory 
protein, Pin 1, in brain isolated from APP/PS-1 mice when compared to wild type. NAC 
is a FDA-approved drug and has been used in several studies involving 
neurodegeneration, such as ALS, AD among others. The findings of this dissertation 
study is particularly relevant to AD brain because of several lines of evidence involving 
Aβ (1-42)-mediated oxidative stress in AD brain. 
12.2 Future studies 
Based on the findings in this dissertation, the following experiments may warrant 
exploration: 
1. Because many neurodegenerative disorders involve mitochondrial 
dysfunction and our study showed that D609 can protect brain mitochondria from various 
oxidative stress inducers, it would be useful to look for its effect in mice models of 
various neurodegenerative disorders, such as AD, PD and ALS. Further, using a redox 
proteomics approach that can identify specifically oxidized protein, one can determine 
the identity of proteins specifically protected by D609 in vivo. 
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2. It is now clear from studies described in this dissertation that ADR causes 
oxidative stress in brain and GCEE protects against ADR-mediated oxidative stress. We 
used proteomics to identify proteins that are specifically oxidized and differentially 
expressed in brain isolated from ADR-injected mice. A similar kind of study can be 
useful to determine if these ADR-mediated oxidized proteins are protected by in vivo 
administration of GCEE. Further, compounds that can elevate the GSH level and have 
similar action as GCEE should be examined in the mice injected with ADR.  
3. Preliminary studies described in this dissertation show that NAC can 
reduce oxidative stress in the APP/PS-1 mouse model of AD. Further studies are required 
to investigate the mechanistic aspects of the mode of action of NAC in its ability to 
protect against oxidative stress. One of the key parameters that will be useful is to 
examine is the levels of GSH and GSSG and their ratio in NAC-treated mice. GSH 
elevation could be the important factor towards NAC’s ability towards protection against 
oxidative stress in APP/PS-1 mice. Proteomics can be used to investigate the proteins that 
are specifically protected from oxidation in these mouse models and should be correlated 
with proteomics studies conducted on human AD samples already reported from our 
laboratory.   
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Appendix I 
In Vivo Protection of Synaptosomes from Oxidative Stress Mediated by 2,2-Azobis 
(2-amidino-propane) Dihydrochloride (AAPH) or Fe2+/H2O2 by Ferulic Acid Ethyl 
Ester (FAEE): Insight into Mechanisms of Neuroprotection and Relevance to 
Oxidative Stress Related neurodegenerative Disorders 
A.1. Overview of the study 
Ferulic acid ethyl ester (FAEE) is an ester derivative of ferulic acid, the latter 
known for its anti-inflammatory and antioxidant properties. Previous studies from our 
laboratory have shown that ferulic acid protects synaptosomal membrane system and 
neuronal cell culture systems against hydroxyl and peroxyl radical oxidation. FAEE is 
lipophilic and is able to penetrate lipid bilayer. Previous studies reported that FAEE 
reduces Alzheimer’s amyloid β peptide Aβ (1-42)-induced oxidative stress and 
cytotoxicity in neuronal cell culture by direct radical scavenging and by inducing certain 
antioxidant proteins. In the present study we tested the hypothesis that FAEE would 
provide neuroprotection against free radical oxidative stress in vivo. Synaptosomes were 
isolated from the gerbils that were previously injected intraperitoneally (i.p.) with FAEE 
or DMSO and were treated with oxidants, Fe2+/H2O2 or 2,2- Azobis (2-amidino-propane) 
dihydrochloride (AAPH). Synaptosomes isolated from the gerbil previously injected i.p. 
with FAEE and treated with Fe2+/H2O2 and AAPH showed significant reduction in 
reactive oxygen species (ROS), levels of protein carbonyl, protein bound 4-
hydroxynonenal (HNE, a lipid peroxidation product), and 3-nitrotyrosine (3NT, another 
marker of protein oxidation formed by reaction of tyrosine residues with peroxynitrite) 
compared to Fe2+/H2O2 or AAPH induced oxidative stress in synaptosomes isolated from 
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the brain of gerbils that were previously injected with DMSO. The synaptosomes isolated 
from gerbil pre-injected with FAEE and subsequently treated with AAPH or Fe2+/H2O2 
showed induction of heme oxygenase (HO-1) and heat shock protein 70 (HSP-70) but 
reduced inducible nitric oxide synthase (iNOS) levels. These results are discussed with 
reference to potential use of this lipophilic antioxidant phenolic compound in the 
treatment of oxidative stress related neurodegenerative disorders. 
A.2. Introduction  
Alzheimer’s disease (AD), an age-associated dementing disorder, and many other 
neurodegenerative disorders, are characterized by free radical mediated oxidative stress 
in brain (Hensley, Hall et al., 1995; Markesbery, 1997; Stadtman and Berlett, 1997; 
Butterfield, Drake et al., 2001; Kanski, Lauderback et al., 2001; Butterfield and 
Lauderback, 2002). AD, characterized by the presence of senile plaques, neurofibrillary 
tangles and loss of synapses, affects more than four million Americans and is one of the 
leading causes of death in United States (Katzman and Saitoh, 1991). The free radical-
mediated reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated 
in brain can lead to protein oxidation (Hensley, Hall et al., 1995; Stadtman and Berlett, 
1997), DNA and RNA oxidation (Gabbita, Lovell et al., 1998; Lovell, Gabbita et al., 
1999; Butterfield, Drake et al., 2001), lipid peroxidation (Sayre, Zelasko et al., 1997; 
Markesbery and Lovell, 1998; Butterfield and Lauderback, 2002) and neuronal 
dysfunction or death. Increased production of ROS and RNS along with depletion in 
antioxidant capacity is observed in AD and other neurodegenerative disorders 
(Butterfield, 1997; McIntosh, Trush et al., 1997; Omar, Chyan et al., 1999; Varadarajan, 
Yatin et al., 2000). Proteomics analysis of protein from AD brain and from models 
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thereof, demonstrates oxidative modification of key proteins that are involved in 
metabolism, exitotoxicity, proteosomal function, lipid asymmetry and redox balance in 
brain (Castegna, Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; Calabrese, 
Stella et al., 2004; Poon, Calabrese et al., 2004). Several lines of evidence show that in 
models of AD, oxidative stress leads to lipid peroxidation, which releases reactive 
alkenals that binds to proteins and cause their dysfunction (Mark, Lovell et al., 1997; 
Sayre, Zelasko et al., 1997; Subramaniam, Roediger et al., 1997; Markesbery and Lovell, 
1998; Butterfield and Lauderback, 2002). It has also been reported that ROS and RNS 
mediated oxidative stress leads to apoptosis in neuronal cell cultures (Butterfield, 
Castegna et al., 2002b; Butterfield and Lauderback, 2002). Hence, ROS and RNS 
generation becomes important in understanding oxidative stress and oxidative stress 
related disorders.   
Antioxidant intervention is gaining significance as a promising therapeutic 
strategy in treating neurological disorders, and many antioxidants and chemicals that 
mimic antioxidants in the free radical scavenging properties are under investigation (Xie, 
Lovell et al., 1998; Halliwell, 2001; Pocernich, Cardin et al., 2001; Drake, Kanski et al., 
2002; Boyd-Kimball, Sultana et al., 2005c; Joshi, Sultana et al., 2005a). Natural plant 
products are been studied in great deal with reference to antioxidant therapy for 
neurodegenerative disorders as they have minimal pathological and toxic side effects 
associated with oxidative stress (Halliwell, 2001; Butterfield, Castegna et al., 2002a) in 
contrast to side effects of a number of synthetic drugs. 
Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a phenolic compound and a 
component of fruits and vegetables, such as tomatoes. Ferulic acid has in vitro free 
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radical scavenging properties toward hydroxyl radical, peroxynitrite and oxidized low-
density lipoprotein (Yu, Hong et al., 1999; Kanski, Aksenova et al., 2002; Kikuzaki, 
Hisamoto et al., 2002; Ogiwara, Satoh et al., 2002). In vivo protection against [Aβ (1-
42)]-induced toxicity in brain and also suppression of [Aβ (1-42)]-mediated 
immunoreactivities of the astrocyte marker glial fibrillary acidic protein (GFAP) and 
interleukin-1 beta (IL-1 beta) in the hippocampus have been reported (Kim, Cho et al., 
2004). Studies from our lab showed protective effects of ferulic acid towards hydroxyl 
and peroxyl free radical-mediated oxidative stress in synaptosomes and neuronal cell 
culture (Kanski, Aksenova et al., 2002). 
Ferulic acid ethyl ester (FAEE) (Ethyl 4-hydroxy-3-methoxycinnamate) (Figure 
A.1) is the ethyl ester, derivative of ferulic acid, the latter known for its anti-
inflammatory and antioxidant properties as noted above (Yan, Cho et al., 2001; Kikuzaki, 
Hisamoto et al., 2002). The ester group of FAEE make the compound more hydrophobic 
and lipophilic when compared to ferulic acid and hence a better potential antioxidant with 
respect to brain (Scapagnini, Butterfield et al., 2004). FAEE induces expression of heme 
oxygenase (HO-1) in astrocytes at both the message and protein levels (Scapagnini, 
Butterfield et al., 2004; Sultana, Ravagna et al., 2005)produces biliverdin and eventually 
bilirubin, both known for their antioxidant activity (Scapagnini, Butterfield et al., 2004; 
Sultana, Ravagna et al., 2005). Recently, our laboratory characterized the protective 
effect of FAEE on the in vitro oxidative stress induced by Aβ (1-42) in rat primary 
neuronal cell culture by inducing HO-1 and heat shock protein 72 (HSP-72) and by 
suppressing inducible nitric oxide synthase (iNOS) (Sultana, Ravagna et al., 2005). 
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A.3. Purpose of the study 
The present study was designed to test the hypothesis that FAEE in vivo would 
protect synaptosomes subsequently isolated from gerbils against oxidative stress induced 
by Fe2+/H2O2 (hydroxyl radical formation) and AAPH (alkoxyl and peroxyl radical 
formation). We examined whether the in vivo protective effect of FAEE on oxidative 
damage in synaptosomes might be mediated by increased expression of HO-1 and HSP-
70 and decreased expression of iNOS, as is the case in vitro (Sultana, Ravagna et al., 
2005). 
 
OH
OCH3
CH3CH2O O
 
Figure A.1: Ethyl 4-hydroxy-3-methoxycinnamate or Ferulic acid ethyl ester 
(FAEE) 
 
A.4. Experimentals 
A.4.1. Animals 
For all the studies male Mongolian gerbils (2-3 months of age), approximately 
80 g in size, housed in the University of Kentucky Central Animal Facility in 12-h 
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light/dark conditions and fed standard Purina rodent laboratory chow ad libitum, were 
used. The University of Kentucky Animal Care and Use Committee approved the animal 
protocols. The animals were divided in three groups. One group was injected i.p. with 
150-mg/kg bodyweight of FAEE (dissolved in dimethyl sulfoxide [DMSO]) one hour 
prior to decapitation and the other groups were given equivalent amount of DMSO at the 
same time. The concentration and time of FAEE were based on dose-dependent and time-
dependent responses (data not shown).  
A.4.2. Chemicals  
All chemicals, including FAEE, were purchased from Sigma-Aldrich (St. Louis, 
MO), unless stated otherwise. Fresh 10 mM stock solution of 2,7-dichlorofluoroscin 
diacetate (DCFH-DA) was prepared in ethanol for the DCF fluorescence assay. Fresh 
FAEE was prepared in DMSO. The protein oxidation detection kit was purchased from 
Intergen (Purchase, NY) and primary antibody for HNE and 3NT were purchased from 
Chemicon International. Anti-HO-1, anti-iNOS, anti-HSP-70 and anti- -actin primary 
antibodies and alkaline phosphatase-conjugated secondary antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). 
A.4.3. Preparation of Synaptosomes 
Synaptosomes were isolated from gerbils injected i.p. with DMSO (control) or 
with FAEE (150mg/kg body weight), 1h after injection. The synaptosomal isolation 
procedure has been described elsewhere (Whittaker, 1993). Briefly, the gerbils were 
sacrificed by decapitation and the brain was isolated on a cold plate and placed in 0.32M 
sucrose isolation buffer containing 4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml aprotinin, 
2mM ethylenediaminetetraacetic acid (EDTA), 2mM ethylene glycol-bistetraacetic acid 
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(EGTA) and 20mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), 
trypsin inhibitor (20μg/ml), and 0.2mM phenylmethanesulfonyl fluoride (PMSF), pH 7.4. 
The whole brain was homogenized by 20 passes with a Wheaton tissue homogenizer. The 
homogenate was centrifuged at 1500 g for 10 min. The pellet was discarded and the 
supernatant was retained and centrifuged at 20000 g for 10 min. The resulting pellet was 
resuspended in approximately 1ml of 0.32M sucrose isolation buffer and layered over a 
discontinuous sucrose gradient (0.85M pH 8.0, 1.0M pH8.0, 1.18M pH8.5 sucrose 
solutions each containing 2mM EDTA, 2mM EGTA and 10mM HEPES) and spun at 
82500 g for 1h at 4o C. The purified synaptosomes were collected from the sucrose 
gradient interface at the 1.0/1.18M interface and twice washed with phosphate buffered 
saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) and 
centrifuged at 32000 g. The resulting synaptosomal membranes were assayed for protein 
concentration by Pierce BCA method (Bradford, 1976). The synaptosomes obtained were 
divided in two aliquots. One aliquot was incubated with 30 μM FeSO4 and 10 mM H2O2, 
and the other aliquot was incubated with 1mM AAPH for 1h at 37o C. Both the 
concentrations were based on prior studies (Joshi, Sultana et al., 2005a). The 
synaptosomes isolated from DMSO-injected gerbils were treated with equal volume of 
buffer. The synaptosomal samples were washed following incubation and suspended in 
PBS for further studies. 
A.4.4. DCF fluorescence 
The DCF fluorescence procedure has been described elsewhere (Wang and 
Joseph, 1999). Briefly, 10 μM DCFH-DA was incubated with synaptosomes (1mg/ml) 
for 30 minutes at 37o C. Intracellular esterases convert DCFH-DA into anionic DCFH, 
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which because of its negative charge is trapped in the synaptosomes. Upon oxidation with 
ROS, the non-fluorescent DCFH is converted to fluorescent 2,7- dichlorofluoroscein 
(DCF). Synaptosomes were spun at 3000 g in a tabletop Eppendorf centrifuge for 5 
minutes at 4o C. Synaptosomes were suspended in 500 μl of PBS and loaded in triplicate 
(100 μl per well) in a black microtiter plate and the fluorescence was measured in a 
Spectramax microtiter plate reader (λex = 495nm, λem = 530nm) and quantified using 
softPro max software. Similar studies were performed with an oxidation-insensitive dye 
CDCF-DA (C369) to determine whether ester cleavage or efflux of the dye might 
contribute to changes in fluorescence. 
A.4.5. Protein carbonyls 
Protein carbonyls are the markers of protein oxidation and were assessed by 
following the standard protocol described elsewhere (Stadtman and Berlett, 1997). 
Samples (5 μl), 12% sodium dodecyl sulfate (SDS) and 10 times diluted 2,4-
dinitrophenylhydrazine (DNPH) (10μl) from a 200 mM stock solutions, were incubated 
at room temperature for 20 min. Samples were neutralized with 7.5μl neutralization 
solution (2M Tris in 30% glycerol). The resulting solution was loaded in each well on a 
nitrocellulose membrane under vacuum using a slot blot apparatus. The membrane was 
blocked in blocking buffer (3% bovine serum albumin) for 1h and incubated with a 1:100 
dilution of anti DNP polyclonal antibody in phosphate buffered saline containing 0.01% 
(w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) for 1h. The membrane was washed 
three times in PBS and was incubated for 1 h with an anti-rabbit IgG alkaline 
phosphatase secondary antibody diluted in PBS in a 1:8000 ratio. The membrane was 
washed for three times in PBS for 5 min and developed in Sigma Fast tablets (BCIP/NBT 
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substrate). Blots were dried, scanned with Adobe Photoshop, and quantified with Scion 
Image (PC version of Macintosh compatible NIH image). 
A.4.6. HNE 
Samples (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS) 
and 5μl of modified Laemmli buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, 
and 20% (v/v) glycerol were incubated for 20 minutes at room temperature. Samples (250 
ng) were loaded in each well on a nitrocellulose membrane in a slot blot apparatus under 
vacuum. The membrane was blocked as above and incubated with a 1: 5000 dilution of 
anti-HNE polyclonal antibody in PBS for 1 h 30 min. The membrane was developed as 
described above. 
A.4.7. 3NT 
Sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS) 
and 5μl of modified Laemmli buffer containing 0.125 M tris base pH 6.8, 4% (v/v) SDS, 
and 20% (v/v) glycerol were incubated for 20 minutes at room temperature, and the 
membranes were developed as described above except a 1:2000 dilution of anti-3-NT 
polyclonal antibody was used.  
A.4.8. Specificity of HNE and 3-NT antibodies 
The specificity for both HNE and 3NT primary antibodies was checked as 
described elsewhere (Scapagnini, Butterfield et al., 2004). For example, the samples were 
treated with either the HNE or 3NT primary antibody reacted with free HNE or free 3-
NT, respectively. Very faint, non-specific binding was seen on the HNE blot (data not 
shown) that was accounted in the background for each blot. No staining was seen on the 
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3-NT blot, suggesting that there was no non-specific binding of the primary 3-NT 
antibody (data not shown). 
A.4.9. Western blots 
Mixtures of loading buffer and synaptosome samples (100 μg) were denatured 
and electrophoresed on a 10% SDS-polyacrylamide gel. Proteins were transferred to 
nitrocellulose at 90 mA/gel for 2 h. The blots were blocked for 1h in fresh wash buffer 
(10 mM tris-HCl [pH7.5], 150 mM NaCl, 0.05% Tween 20, pH 7.4, containing 5% 
nonfat dried milk) and incubated with primary antibodies for 1 h (dilutions (1:1000) of 
primary anti-HSP 70, iNOS, and HO-1 antibodies were made in wash buffer with 3% 
nonfat dry milk). The membrane was washed three times in PBS and was incubated for 1 
h with horse radish peroxidase-conjugated secondary antibodies in wash blot at room 
temperature. The membrane was washed again for three times in PBS for 5 min and the 
bands were visualized using an Amersham chemiluminiscence kit. 
A.5. Statistical analysis 
Analysis of variance (ANOVA) was used for comparison among the groups and 
statistical evaluation. Results are presented as means ± SEM. P values < 0.05 were 
considered significant. 
A.6. Results 
A.6.1. FAEE reduces ROS generation in synaptosomes 
ROS generation was measured by using the DCF assay. DCF is formed by 
reaction of DCFH with ROS (Wang and Joseph, 1999; Keller, Lauderback et al., 2000; 
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Lauderback, Kanski et al., 2002). Figure A.2a shows the ROS levels in synaptosomes 
isolated from DMSO-injected gerbils (control), synaptosomes isolated from DMSO-
injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH and synaptosomes 
isolated from gerbils injected i.p. previously with FAEE and subsequently treated with 
Fe2+/H2O2 or AAPH. As reported previously (Joshi, Sultana et al., 2005a), there was a 
significant increase in ROS generation in synaptosomes isolated from control gerbils that 
were treated with Fe2+/H2O2 or AAPH (p < 0.005) when compared to control. 
Synaptosomes isolated from the FAEE-injected gerbils and subsequently treated with 
Fe2+/H2O2 or AAPH showed a significant decrease in ROS levels when compared to 
synaptosomes treated with Fe2+/H2O2 (p< 0.001) or AAPH (p < 0.005), which were 
isolated from DMSO-injected gerbils.  
The oxidation-insensitive dye, CDCF-DA (C369) was used in similar studies and 
was used as a control experiment to ensure that ester cleavage or efflux of the DCFH was 
not contributing to changes in fluorescence. Figure A.2b shows that there was no change 
observed in the fluorescence in all the groups, confirming that changes in fluorescence 
shown in Figure A.2a were due to oxidation of the dye and not because of drug efflux 
changes or ester cleavage. 
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Figure A.2a: Significant increase in ROS in synaptosomes isolated from DMSO-
injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH compared to ROS in 
synaptosomes isolated from DMSO-injected gerbils. Decreased ROS in synaptosomes 
isolated from gerbils injected i.p. with FAEE subsequently treated with Fe2+/H2O2 or 
AAPH relative to ROS in synaptosomes isolated from gerbils injected with DMSO and 
subsequently treated with Fe2+/H2O2 or AAPH, * p < 0. 005, and ** P < 0.001; the data 
are the mean ± SEM expressed as percentage of control values, (n = 6). 
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Figure A.2b: Measurement of ROS generation using the oxidation-insensitive 
probe C369. The oxidation-insensitive fluorescence probe C369 was used as control to 
demonstrate the results of Figure 2a are due to oxidation of DCFH and not due to drug 
efflux of DCFH-DA with reaction outside the synaptosomes. 
A.6.2. FAEE in vivo inhibits protein oxidation 
Protein carbonylation is one of the markers of protein oxidation (Butterfield and 
Stadtman, 1997). Protein carbonyl levels in synaptosomes isolated from brains of 
DMSO-injected gerbils (control), synaptosomes isolated from control gerbils and 
subsequently treated with Fe2+/H2O2 or AAPH, and Fe2+/H2O2 - or AAPH-treated 
synaptosomes isolated from brains of gerbils previously injected i.p. with FAEE are 
shown in Figure A.3a. A significant increase in protein carbonyl levels is observed in 
synaptosomes isolated from control gerbils and subsequently treated with Fe2+/H2O2 or 
AAPH (p < 0.005) when compared to untreated control. Synaptosomes isolated from 
FAEE-injected gerbils and subsequently treated with Fe2+/H2O2 and AAPH showed 
significantly decreased protein carbonyl levels when compared to synaptosomes isolated 
253 
from DMSO-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH (p < 
0.005). 
A.6.3. FAEE in vivo prevents nitration of tyrosine residues 
3-nitrotyrosine (3-NT) is another marker of protein oxidation (Butterfield and 
Stadtman, 1997; Castegna, Thongboonkerd et al., 2003). Levels of 3-NT in synaptosomes 
isolated from the brains of DMSO-injected gerbils (control), synaptosomes isolated from 
control gerbils and then treated with Fe2+/H2O2 or AAPH and Fe2+/H2O2- and AAPH-
treated synaptosomes isolated from gerbils previously injected i.p. with FAEE is shown 
in Figure A.3b. There was a significant increase in 3-NT levels in synaptosomes isolated 
from DMSO-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH (p < 
0.005) when compared to those of control. Synaptosomes isolated from FAEE-injected 
gerbils and subsequently treated with Fe2+/H2O2 or AAPH showed a significant decrease 
in 3-NT levels when compared to synaptosomes isolated from DMSO-injected gerbils 
and then treated with Fe2+/H2O2 or AAPH (p < 0.005). 
A.6.4. FAEE in vivo inhibits HNE formation 
Free radical attack on arachidonic acid produces reactive alkenals, such as 4-
hydroxynonenal (HNE). HNE binds to proteins by Michael addition (Butterfield and 
Stadtman, 1997), altering their conformation, and thereby reducing there activity 
(Subramaniam, Roediger et al., 1997; Lauderback, Hackett et al., 2001; Zhou, 
Lauderback et al., 2001). Figure A.3c shows the protein-bound HNE levels in 
synaptosomes isolated from DMSO-injected gerbils (control), synaptosomes isolated 
from control gerbils and subsequently treated with Fe2+/H2O2 or AAPH, and Fe2+/H2O2- 
or AAPH- treated synaptosomes isolated from gerbils previously injected i.p. with FAEE. 
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A significant increase in protein-bound HNE levels is observed in synaptosomes isolated 
from control gerbil brains treated with Fe2+/H2O2 or AAPH (p < 0.005) when compared 
to control. Synaptosomes isolated from FAEE-injected gerbils and subsequently treated 
with Fe2+/H2O2 or AAPH showed a significant decrease in protein bound HNE levels 
when compared to synaptosomes isolated from DMSO-injected gerbils subsequently 
treated with Fe2+/H2O2 or AAPH (p < 0.005). 
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Figure A.3a: Significant increase in protein carbonyl levels in synaptosomes 
isolated from DMSO-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH 
compared to protein carbonyls in synaptosomes isolated from DMSO-injected gerbils.  
Decreased protein carbonyl level in synaptosomes isolated from gerbils injected i.p. with 
FAEE and subsequently treated with Fe2+/H2O2 or AAPH relative to protein carbonyl 
level in synaptosomes isolated from gerbils, injected i.p with DMSO and subsequently 
treated with Fe2+/H2O2 or AAPH, * p < 0. 005; the data are the mean ± SEM expressed as 
percentage of control values, (n = 6).  
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Figure A.3b: Significant increase in 3-NT levels in synaptosomes isolated from 
DMSO-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH compared to 
3-NT in synaptosomes isolated from DMSO-injected gerbils.  Decreased 3-NT level in 
synaptosomes isolated from gerbils injected i.p. with FAEE and subsequently treated 
with Fe2+/H2O2 or AAPH relative to 3-NT level in synaptosomes isolated from gerbils, 
injected i.p with DMSO and subsequently treated with Fe2+/H2O2 or AAPH, * p < 0. 005; 
the data are the mean ± SEM expressed as percentage of control values, (n = 6). 
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Figure A.3c: A significant increase in protein bound HNE levels in synaptosomes 
isolated from DMSO-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH 
compared to protein bound HNE in synaptosomes isolated from DMSO-injected gerbils.  
Decreased protein bound HNE level in synaptosomes isolated from gerbils injected i.p. 
with FAEE and subsequently treated with Fe2+/H2O2 or AAPH relative to protein bound 
HNE level in synaptosomes isolated from gerbils, injected i.p with DMSO and 
subsequently treated with Fe2+/H2O2 or AAPH, * p < 0. 005; the data are the mean ± SEM 
expressed as percentage of control values, (n = 6). 
 
Contro
l
Fe2+/H
2O2
Fe2+/H
2O2+F
AEE AAPH
AAPH+
FAEE
%
co
nt
ro
l
40
60
80
100
120
140
* *
* *
258 
A.6.5. FAEE in vivo induces HO-1 and HSP-70 expression 
Previous studies from our laboratory and those of others have shown induction of 
HO-1 and HSP-72 at both the gene and protein levels in cell culture as a protective 
response to oxidative challenge (Calabrese, Stella et al., 2004; Scapagnini, Butterfield et 
al., 2004; Sultana, Ravagna et al., 2005). In the current study we demonstrated an 
increase in expression of HO-1 (Figure A.4a and b) and HSP-70 (Figure A.4c and d) in 
synaptosomes isolated from FAEE-injected gerbils, extending the previous in vitro 
studies. We also observed a significant increase in HO-1 and HSP-70 expression levels in 
synaptosomes isolated from FAEE-injected gerbils and subsequently treated with 
Fe2+/H2O2 or AAPH (p < 0.005) when compared to synaptosomes isolated from control 
gerbils and compared to synaptosomes isolated from DMSO-injected gerbils 
subsequently treated with Fe2+/H2O2 or AAPH, consistent with the observation that both 
oxidative stress and FAEE synergistically increased HO-1 expression. 
A.6.6. FAEE in vivo suppresses iNOS expression 
Several lines of evidence show that iNOS expression increases with oxidative 
stress and several antioxidants suppresses its expression either at gene level or at protein 
level (Luth, Munch et al., 2002; Ayasolla, Khan et al., 2004). We previously showed that 
FAEE suppresses the expression of iNOS in neuronal cell culture exposed to Aβ (1-42)-
induced oxidative stress (Sultana, Ravagna et al., 2005).  Figure A.6 show a decrease in 
expression of iNOS in synaptosomes isolated from FAEE-injected gerbils, extending the 
in vitro studies. There was a significant increase in iNOS expression levels in 
synaptosomes isolated from DMSO-injected gerbils subsequently treated with AAPH (p 
< 0.005) when compared to control. In contrast, synaptosomes isolated from FAEE-
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injected gerbils subsequently treated with AAPH showed a significant decrease in iNOS 
expression levels when compared to synaptosomes isolated from DMSO-injected gerbils 
and then treated with AAPH (p < 0.005). A decreased iNOS expression was observed in 
synaptosomes isolated from FAEE-injected gerbils subsequently treated with Fe2+/H2O2 
when compared to synaptosomes isolated from DMSO-injected gerbils subsequently 
treated with the same oxidant. However the difference was not statistically significant 
(data not shown). This is likely due to a larger scatter of the data. 
 
Figure A.4a                                                                         Figure A.4b 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.4a and b: Representative Western blot and plot showing a significant 
increase in HO-1 expression in synaptosomes isolated from gerbils injected i.p with 
FAEE and then treated with AAPH or Fe2+/H2O2 compared with untreated synaptosomes 
isolated from DMSO-injected gerbils (control) and control synaptosomes treated with 
AAPH or Fe2+/H2O2 respectively, * p < 0.005 Vs Control, (n = 5). 
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Figure A.4c                                                                        Figure A.4d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.4c and d: Representative western blot and plot showing a significant 
increase in HSP-70 expression in synaptosomes isolated from gerbils injected i.p with 
FAEE and then treated with AAPH and Fe2+/H2O2 respectively compared with untreated 
synaptosomes isolated from DMSO-injected gerbils (control) and control synaptosomes 
treated with AAPH or Fe2+/H2O2 respectively * p < 0.005 Vs Control, (n = 5).  
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Figure A.5 
 
 
                                                                                          
 
 
 
 
Figure A.5: Representative Western blot and plot showing a significant decrease 
in iNOS expression in synaptosomes isolated from gerbils injected i.p with FAEE and 
then treated with AAPH compared with control synaptosomes treated with AAPH. There 
was a significant increase in iNOS expression in control synaptosomes treated with 
AAPH when compared with control showing induction of iNOS in response to oxidative 
stress, * p < 0.005 Vs Control, ** p < 0.005 Vs AAPH alone, (n = 5). 
 
                                                                                  
A.7. Discussion 
High content of polyunsaturated fatty acids, significant oxygen utilization, and 
relatively poor antioxidant capacity make the brain particularly vulnerable towards 
oxidative stress (Halliwell, 2001; Butterfield and Lauderback, 2002). Due to an 
imbalance in the antioxidant system and generation of oxidants such as free radical-
mediated ROS and RNS, there is oxidative stress (Yu, 1994; Butterfield, 2002; 
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Butterfield and Lauderback, 2002). In AD brain, synaptic membranes in particular are 
vulnerable to oxidative damage (Lauderback, Kanski et al., 2002). Receptors for 
glutamate are concentrated in synaptic membranes and these receptors mediate increase 
in intracellular Ca2+ and exitotoxicity, both of which cause ROS and RNS generation that 
lead to subsequent protein oxidation (Hensley, Carney et al., 1994; Hensley, Hall et al., 
1995; Mattson, 1996). Mitochondrial potential change due to increased Ca2+ levels lead 
to release of superoxide ion radicals. Since mitochondria are concentrated in the synaptic 
region of neurons because of high-energy usage (Mattson, 1996), the synaptic region of 
neurons becomes particularly more vulnerable to oxidative stress. Therefore, 
synaptosomes were chosen for our studies to evaluate oxidative stress parameters and 
investigate likely mechanisms of action of FAEE in vivo. 
ROS generation and oxidative stress has been implicated in many 
neurodegenerative disorders including AD (Butterfield, Drake et al., 2001). DCF 
fluorescence is a useful and reliable technique in quantifying overall oxidative stress in 
cells. This method can also be used to evaluate the efficacy of antioxidants against 
oxidative stress in cells (Wang and Joseph, 1999). Previously, our lab showed that ferulic 
acid scavenges hydroxyl and peroxyl radical in synaptosomes (Kanski, Aksenova et al., 
2002). Ferulic acid can form a resonance-stabilized phenoxy radical with free radicals, 
which accounts for its potent antioxidant activity. Recently, we also showed that FAEE 
scavenges hydroxyl and peroxyl radical generated in neuronal cultures in response to Aβ 
(1-42)-induced oxidative stress (Sultana, Ravagna et al., 2005).  
The results shown in Figure A.2a suggest that FAEE has radical scavenging 
property. There was a decrease in fluorescence intensity in synaptosomes that were 
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isolated from FAEE-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH 
when compared to synaptosomes that were isolated from DMSO-injected gerbils and 
subsequently treated with Fe2+/H2O2 or AAPH. Use of an oxidation insensitive dye C369 
(Figure A.2b) demonstrated that the fluorescence observed in Figure A.2a is due to ROS 
only. FAEE has conjugated double bonds in its structure, which makes it a good 
electrophile (Figure A.1). In response to a free radical it can form a resonance-stabilized 
phenoxy radical (Lauderback, Kanski et al., 2002). Because of its ester group, FAEE is 
more lipophilic than ferulic acid (Scapagnini, Butterfield et al., 2004) and can hence cross 
the membrane and trap electrons. This could be the reason for low intracellular ROS in 
FAEE-treated rodents, as observed in the DCF assay of this study. 
As noted above, free radical mediated oxidative stress leads to protein oxidation 
in many neurodegenerative disorders (Butterfield and Stadtman, 1997; Butterfield, Drake 
et al., 2001), and protein carbonyls are one of the chief biomarkers for protein oxidation 
(Stadtman and Berlett, 1997). Studies from our lab and those of others have shown that 
oxidative stress leads to oxidative modification of key protein and enzymes that are 
critical for proper biological functions (Castegna, Aksenov et al., 2002a; Castegna, 
Aksenov et al., 2002b; Poon, Calabrese et al., 2004). AAPH or Fe2+/H2O2 induce protein 
oxidation by increasing protein carbonyl levels (Kanski, Lauderback et al., 2001; 
Pocernich, Cardin et al., 2001).  Ferulic acid was shown to reduce protein oxidation by 
reducing protein carbonyl formation in synaptosomes and cultured neurons (Lauderback, 
Kanski et al., 2002). Supporting the hypothesis of the current study, in vivo protection of 
synaptosomes from Fe2+/H2O2 or AAPH- mediated oxidative stress was demonstrated by 
FAEE. There was a significant reduction in protein carbonyl levels (Figure A.3a) in 
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synaptosomes isolated from FAEE-injected gerbils and subsequently treated with 
Fe2+/H2O2 or AAPH when compared to synaptosomes isolated from DMSO-injected 
gerbils and subsequently treated with Fe2+/H2O2 or AAPH. Attack of free radicals on 
some amino acid residues leads to carbonyl formation (Butterfield and Stadtman, 1997). 
Other direct reactions to produce protein carbonyls include cleavage of the protein 
polypeptide chain or reaction with sugars (glycation) or their glyoxidation products 
(Butterfield and Stadtman, 1997). HNE and other lipid peroxidation products such as 
malondialdehyde and acrolein bind to proteins by Michael addition and introduce 
carbonyl groups in proteins, leading to oxidative modification of proteins (Butterfield and 
Stadtman, 1997). As demonstrated in our current study, FAEE in vivo can reduce free 
radical generation by scavenging ROS and RNS and thereby reduce the chance of free 
radical attack on proteins and hence preventing there oxidative modification. 
As in the case of protein oxidation, elevated lipid peroxidation products such as 
HNE and acrolein have been observed in many neurodegenerative disorders (Sayre, 
Zelasko et al., 1997; Markesbery and Lovell, 1998; Butterfield and Lauderback, 2002; 
Zarkovic, 2003; Simpson, Henry et al., 2004). HNE alters the conformation of cortical 
synaptosomal membrane proteins and reduces there activity (Subramaniam, Roediger et 
al., 1997; Lauderback, Hackett et al., 2001) following binding to proteins by Michael 
addition (Butterfield and Stadtman, 1997). Ferulic acid has been shown to modulate the 
lipid peroxidation in neuronal cultures and synaptosomes (Lauderback, Kanski et al., 
2002). As noted, we recently reported that FAEE reduces HNE levels in neuronal cell 
cultures treated with Aβ (1-42) (Sultana, Ravagna et al., 2005). In the present study we 
demonstrated that FAEE in vivo reduces the HNE levels produced by Fe2+/H2O2 or 
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AAPH. HNE and other lipid peroxidation products are involved in apoptosis and protein 
dysregulation (Subramaniam, Roediger et al., 1997; Butterfield and Lauderback, 2002; 
Awasthi, Sharma et al., 2003; Zarkovic, 2003). Several studies have demonstrated that 
reducing HNE levels may reduce cytotoxicity (Butterfield, Castegna et al., 2002a; Joshi, 
Sultana et al., 2005a; Sultana, Ravagna et al., 2005). In biological systems, several 
enzymes are involved in scavenging or removing HNE (Xie, Lovell et al., 1998; Sultana 
and Butterfield, 2004) and the proteasomal systems in neurons are responsible for the 
removal of HNE-bound oxidized cytosolic and nuclear proteins (Grune and Davies, 
2003). The reduced levels of HNE by FAEE in vivo might implicate reduced cytotoxicity 
in synaptosomes caused by hydroxyl or alkoxyl free radicals. 
Nitration of tyrosine residues on peptides by RNS has been studied as a biomarker 
for protein oxidation in many neurodegenerative disorders (Stadtman and Berlett, 1997; 
Castegna, Thongboonkerd et al., 2003). Nitric oxide (NO) is poorly reactive with most 
biomolecules (except Fe) but reacts vigorously with free radicals such as superoxide 
radicals to form peroxynitrite. Peroxynitrite can be protonated to peroxynitrous acid 
(ONOOH) and subsequently reacts with CO2 and decompose to nitrogen dioxide radical 
(*NO2) and hydroxyl radical (*OH), which posses potent free radical characteristic (Hall, 
Detloff et al., 2004). These radicals react with biomolecules resulting in tyrosine nitration 
and DNA damage (Beckman, Beckman et al., 1990). One possible cause of oxidative 
stress is excessive generation of NO from L-arginine and nitric oxide synthase (NOS) 
(Park, Krishna et al., 2000). Synthesis of NO from inducible NOS (iNOS) has been 
correlated with a cytotoxic or inflammatory response in the immune system (Park, 
Krishna et al., 2000). iNOS is specifically expressed as a response to immunological 
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stimulus during certain pathophysiological conditions (Bredt, 1999). Hence, study of 
iNOS expression might provide an insight into the effect of pharmacological agents in 
response to inflammation. We previously showed increased 3NT levels and iNOS 
expression in cultured neurons treated with Aβ (1-42), an expression that was attenuated 
by FAEE treatment (Sultana, Ravagna et al., 2005). Consistent with our in vitro data, 
here we demonstrated in vivo reduction in 3NT levels in synaptosomes isolated from 
FAEE-injected gerbils and subsequently treated with AAPH or Fe2+/H2O2 when 
compared to synaptosomes isolated from DMSO-injected gerbils and subsequently 
treated with AAPH or Fe2+/H2O2 (Figure A.3b). We also demonstrated reduced iNOS 
expression in synaptosomes isolated from FAEE-injected gerbils and subsequently 
treated with AAPH compared to that in synaptosomes isolated from DMSO-injected 
gerbils and subsequently treated with AAPH (Figure A.5). FAEE is known for its anti-
inflammatory properties. The data obtained suggest that FAEE may be able to reduce NO 
production by reducing the expression of iNOS reflecting lower inflammation and 
nitration of tyrosine residues on proteins.  
The involvement of heme oxygenase (HO) or heat shock protein (HSP) responses 
in oxidative stress-related disorders, including AD, has gained considerable importance in 
recent years (Poon, Calabrese et al., 2004). The expression of HO-1, an inducible isoform 
of HO, has been closely related to that of amyloid precursor protein (APP) (Dore, 2002). 
During various pathophysiological conditions, induction of HO-1 (also called HSP-32) 
catabolizes heme and generates carbon monoxide (CO) and biliverdin (and subsequently 
bilirubin), a potent antioxidant and anti-inflammatory agent (Calabrese, Stella et al., 
2004). The expression of HO-1 is also reported to be upregulated during oxidative stress, 
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as well as by GSH depletion (Tyrrell, 1999; Calabrese, Stella et al., 2004). The HO 
pathway has been shown as an important defense system in neurons under oxidative 
stress (Le, Xie et al., 1999; Chen, Gunter et al., 2000) and expression of HO-1 is altered 
at the gene and protein levels in AD and other neurodegenerative disorders seen in some 
neurodegenerative disorders including AD (Pappolla, Chyan et al., 1998; Schipper, 2000; 
Takahashi, Dore et al., 2000; Takeda, Perry et al., 2000). Previously we demonstrated 
that FAEE protects rat neuronal culture against oxidative damage and increases cell 
viability by inducing HO-1 expression both at m-RNA and protein level (Scapagnini, 
Butterfield et al., 2004; Sultana, Ravagna et al., 2005). This protective effect was 
attenuated in the presence of Zinc protoporphyrin IX, an inhibitor of HO activity 
(Scapagnini, Butterfield et al., 2004; Sultana, Ravagna et al., 2005). Similarly, in the 
current in vivo study we demonstrated protection of synaptosomes isolated from FAEE-
injected gerbils against oxidative stress by inducing HO-1 and HSP-70 expression 
(Figure A.4a, b, c, and d, respectively). Although there was an increase in the expression 
of HO-1 and HSP-70 in synaptosomes isolated from DMSO-injected gerbils, 
subsequently subjected to oxidative insult when compared to untreated controls, the 
further increased expression of HO-1 and HSP-70 in synaptosomes isolated from FAEE-
injected gerbils subsequently exposed to oxidative stress is likely due to FAEE in the 
system (Scapagnini, Butterfield et al., 2004; Sultana, Ravagna et al., 2005), suggesting 
FAEE acts in vivo as a neuroprotective agent against oxidative insult by further inducing 
expression of heat shock proteins in brain.  
FAEE has been used previously as an antioxidant agent that has protective effects 
in in vitro models. We extended these results to an in vivo model and validated some of 
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our previous in vitro studies. The probable multifunctional mechanism of action of FAEE 
involves direct scavenging of radicals, up-regulation of HO-1 and HSP 70 and down-
regulation of iNOS (Figure A.6). These in vivo studies on an animal model of oxidative 
stress could form the basis for an eventual therapeutic approach towards oxidative stress-
related disorders, although further studies are required to establish merit in this notion. 
Studies on the effect of FAEE on genetically derived animal models of oxidative stress-
related disorders are in progress.  
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Figure A.6: Schematic representation of proposed mechanisms of 
neuroprotection for FAEE. (+), induction; (-), inhibition; HSP 70, heat shock protein 70; 
HO-1, heme oxygenase-1; iNOS, inducible nitric oxide synthase. 
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Appendix II 
Supporting Data 
Figure 4.1 
Control Adr 
90.44879 176.985 
81.47296 133.2566 
110.2417 174.6835 
100.3452 159.8 
98.73418 168 
99.28058  
97.48201  
103.2374  
  
T value -8.98478 
P value 2.13E-06 
Degrees of 
Freedom 11 
 
Figure 4.2 
Control Adr 
102.4715 126 
100 128 
94.86692 132 
98.85932 138.5932 
102.2814  
101.5209  
96.77419  
95.28536  
93.79653  
113.1514  
104.5161  
  
T value -9.96049 
P value 9.81E-08 
Degrees of 
Freedom 14 
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Figure 4.3 
107.799 147.033 
99.82669 172.7473 
93.58752 139.7802 
110.2253 193.8462 
108.8388 154.9451 
79.7227 188.5714 
  
T value -6.4098 
P value 7.73E-05 
Degrees of 
Freedom 10 
 
Figure 4.4 
 control ADR 
 99.89627 300.3112 
 78.11203 264.5228 
 121.9917 336.0996 
Average 100 300.3112 
Std Dev 21.94002 35.78838 
 
Figure 5.1 
 Control ADR 
1 65.16659 67.74111 
2 108.5701 54.22757 
3 117.864 85.41019 
4 108.3992 69.72808 
5  85.24995 
average 100 72.47138 
std dev 23.63955 13.16665 
 
Figure 5.3 
Glutathione S transferase 
 control ADR 
 64.64498 165.6436 
 81.31929 174.5854 
 124.8557 222.8493 
 129.18 170.7009 
  179.1663 
avg 100 182.5891 
Std Dev 31.98034 23.0496 
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Glutathione peroxidase 
 Control ADR 
 116.8569 131.9281 
 109.1465 158.2046 
 115.6774 155.5398 
 58.31923 167.7934 
  208.726 
avg 100 164.4384 
Std Dev 27.99333 28.0518 
 
Glutathione reductase 
 Control ADR 
 81.82016 147.2937 
 127.2951 146.685 
 132.1064 147.4966 
 58.77835 203.6954 
  284.733 
avg 100 185.9807 
Std Dev 35.61635 60.38976 
 
Figure 7.1 
 Control ADR GCEE ADR+GCEE
1 28.81708 17.98009 38.1673 22.4775
2 18.50748 14.39328 33.15605 20.75295
3 31.2839 22.66988 39.2128 24.7971
4 28.77172 17.29675 40.0967 27.42295
5 28.0154 22.62735 36.62705 26.4817
avg 27.07912 18.99347 37.45198 24.38644
std Dev 4.947606 3.598216 2.726822 2.76701331
 
Figure 7.2 
 control GCEE ADR ADR+GCEE
1 213 271.5 334.5 205.5
2 262 253 319.5 248.5
3 277 189 295.5 260
4 250.5 235.5  272.5
5  253.5 288.5 267
avg 250.625 240.5 309.5 250.7
std Dev 27.3294 31.47817 21.30728 26.81091
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Figure 7.3 
 Control GCEE ADR ADR+GCEE
1 178.5 177 199 202
2 167.5 170 208 173.5
3 181.5 156 178.5 165.5
4 146 165 208 154.5
5 166.5 168 205 177.5
avg 168 167.2 199.7 174.6
Std Dev 13.95529 7.661593 12.40766 17.65786
 
Figure 7.4 
 control GCEE ADR ADR+GCEE
1 313 349 371 339
2 309 322 340 325
3 329 334 381 318
4 322 343 366 349
5 345 270 373 306
6 350 302 329 309
7 359 302 355 349
8 346 305 340 354
9 314 250 345 334
10 318 261 347 365
AVG 330.5 303.8 354.7 334.8
Std Dev 17.99537 34.47962 17.21143 19.932107
 
Figure 7.5 
 control ADR GCEE ADR+GCEE
1 0.010333 0.008667 0.001521 0.001784
2 0.004667 0.004 0.002259 0.001869
3 0.004 0.007 0.001845 0.002372
4 0.011 0.011667 0.001873 0.001586
5  0.011 0.001466 0.002106
avg 0.0075 0.008467 0.001793 0.001943
Std Dev 0.003677 0.003114 0.000319 0.000304
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Figure 8.2 
 Control Fe2+/H2O2 Fe2+/H2O2+D609 AAPH AAPH+D609 
 81.9104 124.26036 122.2316145 150.634 139.4759087 
 99.91547 119.69569 135.4184277 156.9738 137.1935757 
 92.81488 136.93998 83.68554522 167.6247 142.5190194 
 115.131 154.18428 97.12595097 155.7058 135.6720203 
 93.57566 149.11243 113.3558749 117.6669 101.310778 
 116.6526 161.03128 120.7100592 125.0211 89.6880998 
 95.20611 131.54835 126.9891192 101.3284 122.7265765 
 99.86591 141.8284 108.2770096 104.1871 104.7964081 
 102.8043 172.13134 132.5096399 113.3089 94.33281298 
 102.1237 138.39725 136.1234982 107.692 125.5350273 
 96.6319 128.94188 112.7096852 136.483 85.61921822 
 100.4216 176.91266 137.7301231 125.799 84.27943955 
 101.9223 105.59904 90.02759628 163.2685 90.67307928 
 101.0242 112.24294 84.88442788 152.8849 85.19814492 
 95.32536 110.3616 94.09041905 168.9505  
 102.8842 109.61485 87.11653946 166.2484  
 99.54729     
 102.2432     
Avg 100 135.80014 111.4365957 138.3611 109.9300078 
Std Dev 7.721027 22.306731 19.68133688 24.5954 22.75849606 
 
Figure 8.4 
 Control Fe2+/H2O2 Fe2+/H2O2+D609 AAPH 
AAPH + 
D609 
 105.6194 157.096 120.7957342 106.3815 107.2093825 
 102.1329 145.8162 116.8990976 106.7954 86.23663332 
 91.26333 139.2535 107.2600492 214.3791 83.33908244 
 100.4922 148.0722 129.4093519 185.2941 91.2038634 
 100.4922 130.1313 107.9355609 188.8889 48.69281046 
 98.10279 125.8353 109.0095465 174.5098 52.2875817 
 98.37875 122.2554 85.7398568 182.3529 46.73202614 
 96.58503 144.9881 105.2505967 193.7908 44.77124183 
 106.9334 162.5298 77.86396181 150.634 64.37908497 
 101.3072 124.2604 100.9546539 156.9738 62.41830065 
 106.5359 136.94 122.2316145 167.6247 139.4759087 
 90.0358 154.1843 83.68554522 155.7058 137.1935757 
 92.00477 149.1124 97.12595097 117.6669 142.5190194 
 105.6086 161.0313 113.3558749 125.0211 135.6720203 
 99.91547  120.7100592   
avg 99.69385 142.9647 106.548497 159.0014 88.7236094 
Std 
Dev 5.454988 13.58106 15.19950997 34.15375 37.53569008 
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Figure 8.6 
 Control Fe2+/H2O2 Fe2+/H2O2+D609 AAPH 
AAPH + 
D609 
 99.94295 118.68 105.3546 116.9768 96.478 
 101.0839 119.6701 107.9293 112.4834 98.567 
  116.6001 97.20479 116.6001 97.20479 
 94.69481 114.0901 102.56 114.0901 95.6578 
 104.2784 119.3856 100.1711 114.3562 100.1711 
   102.4529  102.4529 
avg 100 117.6852 102.6121 114.9013 98.42194 
Std Dev 3.984453 2.341087 3.76879 1.870497 2.538917 
 
Figure 8.7 
 Control Fe2+/H2O2 Fe2+/H2O2+D609 AAPH AAPH+D609 
 86.11111 117.9487 91.23931624 109.2469 85.60533842 
 102.3504 121.234 101.4957265 115.348 91.70638704 
 101.0684 116.547 101.4957265 110.2002 86.9399428 
 110.4701 125.768 102.1367521 110.4567  
 102.0019 120.768  104.8618  
 98.57007     
 86.11111     
avg 98.09758 120.4531 99.09188034 110.0227 88.08388942 
Std Dev 8.970406 3.552699 5.24375692 3.735478 3.207360122 
 
Figure 9.2b 
 control Abeta 1-
42 
Abeta 1-
40 
Abeta 42-
1 
D609+42 D609+40 D609+42-1
 282 532 314 312 355 317 289
 302 627 316 301 422 385 251
 310 503 350 306 438 375 271
 399 641 543 399 416 420 363
 401 665 592 424 532 438 384
 425 505 487 424 531 456 428
avg 353.1667 578.8333 433.6667 361 449 398.5 331
%control 79.84899 150.6371 88.90986 88.34356 100.5191 89.75932 81.831052
 85.51203 177.5366 89.47617 85.22888 119.4903 109.0137 71.07126
 87.77725 142.4257 99.10335 86.64464 124.0208 106.1822 76.734309
 112.9778 181.5007 153.7518 112.9778 117.7914 118.924 102.78433
 113.5441 188.2964 167.6262 120.0566 150.6371 124.0208 108.73053
 120.3398 142.992 137.8952 120.0566 150.3539 129.1175 121.18924
avg 100 163.8981 122.7938 102.218 127.1354 112.8362 93.723454
std dev 17.49819 20.80923 34.68665 17.18061 19.77531 14.27352 20.024303
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Figure 9.5 
 control A beta 
A 
beta+D609
 100 141.341 99.9549
 100 147.3317 121.5408
 100 128.5565 99.26671
avg 100 139.0764 106.9208
Std Dev  9.590267 12.66599
 
Figure 10.4a 
 Control D609 AAPH AAPH+D609 F2+/H2O2 F2+/H2O2+D609 Abeta Abeta+D609
 90.21581 122.5136 56.62763 83.4349495 46.362786 63.64721443 43.87883 55.9243847
 83.7898 86.87442 71.69909 120.055486 46.053098 74.70563567 50.87261 71.7184425
 92.50621 103.0162 92.55782 94.2998161 44.898223 69.58288977 56.13729 62.5504049
 149.2177 76.78957 63.76335 113.461725 37.478628 87.07377657 65.80212 76.0863254
 95.39017 110.9133 83.40914 102.500081 34.033356 74.48627375 68.38285 95.1772638
 88.88029 94.19014 68.90545 71.0861641 42.898223 59.29868705 44.54982 79.2412658
Ave 100 99.04954 72.82708 97.4730368 41.765218 71.46574621 54.93726 73.4496812
stdev 24.42106 16.5795 13.13398 18.4080449 5.0708098 9.756464506 10.45924 13.7223148
sem 9.969854 6.768553 5.361925 7.51505285 2.0701494 3.983059955 4.269966 5.60211157
 
Figure 10.4b 
 Control D609 AAPH AAPH+D609 F2+/H2O2 F2+/H2O2+D609 Abeta Abeta+D609
 110.4802 78.86197 189.0728 103.683899 199.6163 113.4314346 213.857991 122.89732
 121.636 80.09878 180.9907 110.8476029 215.7438 134.689879 182.937731 217.874564
 82.27851 113.8968 133.8204 142.8699716 209.3149 110.0026532 377.66802 158.99749
 96.01812 121.9177 127.8078 109.9536706 196.9223 117.239831 125.199502 134.371492
 80.66208 96.0916 94.70784 108.7291059 220.4951 151.6745923 145.796681 155.0299
 108.925 96.04261 111.7538 109.3046513 182.636 121.9176684 110.076127 141.106598
Ave 100 97.81823 139.6922 114.2314836 204.1214 124.8260098 192.589342 155.046227
Stdv 16.50134 17.42845 37.74618 14.25282222 13.8845 15.70808137 98.3249719 33.5211061
Sem 6.736643 7.115137 15.40981 5.818690307 5.668324 6.412797365 40.1410017 13.6849342
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Figure 11.1 
 Control 
APP/PS-
1 WT/NAC 
APP/PS-
1/NAC 
 541 660.5 448 476
 439.5 602 436 382
 470 656.5 427.5 419.5
 433 616 433 420
 524.5 497.5 492.5 493
 453  470 583
avg 476.8333 606.5 451.1667 462.25
%control 113.4568 138.518 93.95316 99.82523593
 92.17057 126.2496 91.43656 80.111849
 98.56693 137.6791 89.65397 87.97623209
 90.80741 129.1856 90.80741 88.08109053
 109.9965 104.3341 103.2856 103.3904229
 95.00175  98.56693 122.2649423
avg 100 127.1933 94.61727 96.9416288
STDEV 9.527396 13.83476 5.299935 15.05524034
 
Figure 11.2 
 Wild (H2O) Wild (NAC) APP (H2O) APP (NAC) 
 462 367.5 538 363.5 
 424 366.5 556 429 
 369 299 487 515 
 359.5 348 502 436 
 416 325 494.5 409 
 462 387.5 434.5 406 
ave 415.4166667 348.9166667 502 426.416667 
 111.2136409 88.46539619 129.5085256 87.5025075 
 102.0661986 88.22467402 133.8415246 103.269809 
 88.82647944 71.97592778 117.2316951 123.971916 
 86.53961886 83.77131394 120.8425276 104.954865 
 100.1404213 78.23470411 119.0371113 98.4553661 
 111.2136409 93.27983952 104.5937813 97.7331996 
ave 100 83.99197593 120.8425276 102.647944 
Std Dev 9.676516268 7.091919293 9.348732869 11.0418676 
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Figure 11.3 
 Wild (H2O) Wild (NAC) APP (H2O) APP (NAC) 
 317.5 272.5 401.5 229
 330 259 349 218
 333.5 235 389 243
 309 272.5 341.5 308
 273.5 216 371 286
 316.5 250 353 313
ave 313.3333333 250.833333 367.5 266.166667
% control 101.3297872 86.9680851 128.1383 73.0851064
 105.3191489 82.6595745 111.38298 69.5744681
 106.4361702 75 124.14894 77.5531915
 98.61702128 86.9680851 108.98936 98.2978723
 87.28723404 68.9361702 118.40426 91.2765957
 101.0106383 79.787234 112.65957 99.893617
ave 100 80.0531915 117.28723 84.9468085
     
Std Dev 6.272086371 6.47583173 6.9666638 12.0650915
 
 
Figure 11.4a 
 Wild (H2O) Wild (NAC) 
APP 
(H2O) 
APP 
(NAC) 
 189 209 145 202
 168 201 132 199
 176 213 130 205
Average 177.666667 207.666667 135.66667 202
Std Dev 10.5987421 6.11010093 8.1445278 3
% 
control 106.378987 117.636023 81.613508 113.69606
 94.5590994 113.133208 74.296435 112.0075
 99.0619137 119.88743 73.170732 115.38462
Average 100 116.885553 76.360225 113.69606
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Figure 11.5 
 Wild (H2O) Wild (NAC) APP (H2O) APP (NAC) 
1 0.000952607 0.000665927 0.00077922 0.001600904
2 0.000178838 0.000533885 7.5812E-05 0.000699285
3 0.001284848 0.000801161 0.00026981 0.000712456
4 0.000684366 0.000779661 7.7922E-05 0.000707156
5 0.000613178 0.000505505 0.00030407 0.000521433
6 0.00071829 0.000723445 0.00127916  
avg 0.000738688 0.000668264 0.00046433 0.000848247
std 
Dev 0.00036786 0.000124635 0.00047474 0.000428321
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